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SUMMARY 
 
To be successful a tissue engineered small diameter blood vessel must be non-
immunogenic, non-thrombogenic, have mechanical properties similar to native vessel and 
be vasoactive. The vascular media is responsible for the mechanical properties and the 
vasoactivity of the vessel. The collagen hydrogel approach has been long used and has 
many advantages, but has not yet achieved the mechanical integrity needed for 
implantation. No collagen-based tissue engineered vascular media has been shown to be 
vasoactive using culture techniques required to achieve the cell numbers needed to make 
a vascular graft. To study collagen synthesis, two model systems were used. Cells were 
seeded on top of an adsorbed collagen I or fibrin layer. Alternatively the cells were 
encapsulated in a collagen or fibrin hydrogel. Collagen I, decorin and biglycan synthesis 
was affected by both matrix type and presentation. After two weeks in culture the smooth 
muscle cells produce more type I collagen in the collagen based hydrogels then in the 
fibrin hydrogels and was used for further studies. The collagen based tissue engineered 
vascular media produced a consistent vasoactive response between two and eight weeks 
of culture. The smooth muscle cells have functional endothelin, kinin, adrenergic, 
serotonergic and purinergic receptors. The application of cyclic strain improves both the 
tissue strength and the contractile response. Use of transforming growth factor-β 
improved tissue strength, but reduced the contractile response. Transforming growth 
factor- β actually promoted a more contractile cell phenotype, but a stronger contractile 
force was required to overcome the thick compact collagen hydrogel and elicit a 
measurable contraction. This work adds to what is known about collagen-based tissue 
engineered vascular medias by identifying means of improving not only strength but 
vasoactivity. The trade-offs found between these two important characteristics are 
relevant to all tissue engineered medias.  
1 
CHAPTER 1:  INTRODUCTION 
 
 
Tissue engineering and regenerative medicine aims to repair, replace or enhance 
tissue function. The development of a small diameter blood vessel has long been 
considered the ‘holy grail’ of tissue engineering due to the clinical need for sufficient 
amounts of suitable tissue. Despite medical advances that are less invasive such as 
angioplasty and stents, bypass grafting remains the gold standard and the procedure of 
choice for certain conditions. Small diameter grafts are needed for coronary artery bypass 
grafting as well as for bypass grafts for peripheral vessels such as the femoropopliteal 
artery. Persons needing bypass grafts do not always have sufficient amounts of healthy 
blood vessels that are can be harvested for bypass surgery. Synthetics that have been used 
clinically for large vessel bypass occlude when used for small vessel bypass.  
A successful tissue engineered vascular graft must be non-thrombogenic, non-
immunogenic, and vasoactive, be able to arterialize, and have material properties such to 
withstand arterial pressures. Blood vessel tissue engineering is advancing and there are 
some successful clinical applications, but most of these successes have been in pediatric 
applications on the low pressure side [1-7]. Clinical trials are also being completed for 
use as an arteriovenous shunt [8]. No small diameter grafts have progressed to the clinic. 
All but the most recent trials have used biodegradable polymers, and none of the new 
polymers have been tested in small diameter applications and it is unknown if they will 
remain patent. Natural biopolymers are considered a better choice for small diameter 
application in this regard, but the mechanical properties are often lacking. To this end this 
work focuses on the tissue engineering of the medial layer. This layer imparts the 
mechanical properties of the blood vessel and is responsible for the blood vessel 
contraction and dilation required for regulation of blood flow.   
2 
Mechanical integrity is essential for a vascular graft; vasoactivity, while not as 
important, is still considered a desirable trait. Only a few groups have demonstrated the 
capability of their tissue engineered blood vessels to respond to vasoactive agonists and 
antagonists. While there is work on how different stimulation affects smooth muscle cell 
phenotype there has not been work to show if this change in phenotype results in any 
functional improvement. 
The central hypothesis is that a collagen I as a TEVM scaffold can promote 
collagen production required for strength and a vasoactive response. Further the 
TEVM strength and vasoactive function could be improved through mechanical or 
biochemical stimulation. This hypothesis will be tested by pursuing the following aims: 
 
Specific Aim 1: Investigate the effects of matrix type and 2D/3D presentation on 
synthesis of type I collagen and the associated proteoglycans decorin and biglycan.  
Collagen I synthesis and deposition is important for tissue strength. Decorin and 
biglycan play important roles in collagen fibrillogenesis in different tissues. The 
hypothesis was that both matrix type and method of presentation would affect collagen, 
decorin and biglycan synthesis. The effects of collagen type I and fibrin on smooth 
muscle cell synthesis of these proteins is presented in Chapter 4. 
 
Specific Aim 2: Characterize the contractile response of the tissue engineered 
vascular media.  
A contractile response to vasoactive agonists and antagonists has not yet been 
shown in a collagen-based tissue engineered vascular media. The hypothesis was that 
adult smooth muscle cells in collagen would present multiple classes of vasoactive 
receptors and could exhibit a contractile response. As part of this study the effects of 
tissue culture time and cell passage number were explored. These results are presented in 
Chapter 5. 
3 
Specific Aim 3: Investigate the effects of the application of cyclic strain after 
cessation of gel compaction on tissue strength and vasoactive function.  
Previously the Nerem lab has shown that cyclic strain can improve tissue strength, 
significant gel compaction and not significant increase change in cell phenotype as 
assessed by smooth muscle α-actin. The hypothesis for this specific aim is that by waiting 
until gel compaction ceased before applying strain the gel would better adhere to the 
silicone sleeve, eliminating compaction. Further, the change would produce improved 
strength and improved vasoactive function. The results of this aim are presented in 
Chapter 6.  
 
Specific Aim 4: Investigate the role of TGF-β and the Smad signaling pathway on 
tissue strength and function. 
Transforming growth factor-β (TGF-β) has been shown to promote a more 
contractile cell phenotype and is used by multiple groups to enhance extracellular matrix 
production. It was hypothesized that the contractile response might be influenced by the 
Smad pathway and that TGF-β could improve both tissue strength and vasoactive 
function. To do this tissue engineered vascular media were cultured with either TGF-β or 
tumor necrosis factor-α (TNF- α). The results are shown in Chapter 7. 
An additional study is presented looking at vasoactive function after 
cryopreservation. Cryopreservation may be a way to provide ‘off-the-shelf’ availability 
of tissue engineered organs. Previously our lab had shown that both vitrification and 
freezing resulted in similar viability rates. Both methods resulted in enhanced tissue 
strength. For this study the effects of these cryopreservation methods on vasoactive 
function were investigated. The results are shown in Chapter 8.   
This chapter is followed by a background section, 5 research chapters as indicated 
by the aims discussed above and a discussion and conclusions section. The research 
chapters are divided based on the research questions and methods used. Chapters 4 and 6 
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are similar to manuscripts. Portions of chapters 5, 7 and 8 will be combined with other 
chapters for publication. 
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CHAPTER 2: BACKGROUND 
Cardiovascular Disease 
Cardiovascular disease (CVD) is a major clinical and economic issue as well as a 
leading cause of death in developed nations. CVD affects 80.7 million Americans and is 
attributed to 36.3% of all deaths in the United States in 2004. Direct and indirect costs are 
estimated to reach $448.5 billion in 2008. Atherosclerosis is the most common form of 
CVD and leads to narrowing of the arteries which can lead to reduced function or 
amputation of limbs, stroke, or myocardial infarction depending on location. Coronary 
artery disease is the most prevalent CVD accounting for 52% of all CVD [1, 2]. Coronary 
stenosis can be treated by coronary artery bypass grafting (CABG) or by percutaneous 
coronary intervention (PCI), commonly known as angioplasty; PCI can be completed 
with or without a stent. While PCI has become an alternative, CABG is still considered 
the “gold-standard” of treatment and is the preferred treatment options for patients with 
left main or triple-vessel coronary artery disease with reduced left ventricular function.[3-
5]. Additionally PCI treatment requires significantly more repeated procedures than 
CABG; while drug eluting stents have reduced restenosis they have not eliminated it or 
the need for repeated surgery [3, 6].  
There are several choices of material for bypass graft conduits. Autologous 
venous grafts, most commonly from the saphenous vein were the material of choice at the 
advent of CABG surgery. More recently autologous arterial grafts, especially from the 
internal mammary artery, have gained popularity in CABG procedures due to the lower 
incidence of intimal thickening [7-9]. One issue with the autologous tissue grafts is that 
patients with atherosclerosis do not always have sufficient amounts of healthy tissue. 
There are several non-autologous tissue options such as use of allogeneic umbilical or 
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saphenous vein or xenogeneic bovine internal thoracic artery. Most tissues are made 
nonviable through use of glutaraldehyde fixation. While these are an option the patency 
rates are low ranging from 65% for cryopreserved saphenous vein grafts to less than 16% 
for the xenografts [7]. Synthetic material such as Dacron has been used successfully to 
replace larger diameter vessels (>6 mm); however, these materials have not be successful 
for small diameter (diameter ~3mm) bypass procedures due to occlusion. Much work is 
being done to improve patency of new biomaterials; however, there has been little 
success to date [7, 10-12].  
Artery Anatomy and Physiology 
The arteries are larger vessels (>0.1 mm diameter) that transport blood away from 
the heart and to the tissues. An artery is more than just an inert pipe; it is able to sense 
and respond to hemodynamic changes to regulate blood flow. There are three distinct 
layers to an artery that work together to accomplish this task: the tunica intima, tunica 
media and tunica adventitia, shown in Figure 1. The layers are composed of different cell 
types and matrix components to provide different functions. While all arteries contain 
each of the layers, the thickness and extracellular matrix (ECM) composition can vary 
slightly depending on the distance from the heart. The intimal layer is the innermost 
layer; it is composed of a confluent monolayer of endothelial cells and is separated from 
the other layers by a basal lamina of type VI collagen, laminin, elastin and proteoglycans. 
The endothelial layer creates a non-thrombogenic lining that can act as a selective barrier. 
The endothelial cells also play an important role in sensing hemodynamic changes and 
regulating vascular tone. The middle layer, or medial layer, is composed of smooth 
muscle cells within a matrix of types I and III collagen, elastin and proteoglycans. This is 
usually the thickest of the three layers and provides the strength, compliance and 
vasoactivity of the artery. The collagen is aligned circumferentially and provides the 
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tensile strength required to withstand arterial pressure. The elastin network is the elastic 
component providing compliance and recovery after each pressure pulse. Smooth muscle 
cells synthesize matrix; they are contractile and critical to vasoconstriction. The 
adventitia is the outermost layer of connective tissue; it consists of fibroblasts in a loose 
network of type I collagen. The adventitia stabilized the artery by anchoring it to the 
surrounding connective tissue. In larger blood vessels the nerves and vasa vasorum, the 
small vessels that provide nutrients for the arterial wall, are found in the adventitial layer 
[13, 14]. 
 
 
Figure 1: Cross-section of rat muscular artery.  Sections are stained with Masson's Trichrome. 
Collagen fibers are stained blue, nuclei are stained purple, and the cytoplasm, keratin and muscle 
fibers are stained red. The three layers are shown in the magnified section (B). 
The size, composition, and even presence of the three layers vary in the different 
blood vessels based on functional requirements. Table 1 shows a side by side comparison 
of the composition of arterial and pulmonary blood vessels. All blood vessels have an 
intima layer consisting of a basement membrane and a confluent monolayer of 
endothelial cells. Their function to maintain selective permeability and non-
thrombogenicity are important for every size vessel. The importance of the medial layer 
and its’ components varies by vessel. Elastin’s role in recovery of strain is especially 
necessary in the aorta, closest to the heart. The aorta can expand by approximately 10% 
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and contract to act as a pulse dampener for the system. Large amounts of elastin are 
needed to accomplish this; elastic arteries contain approximately 40% elastin. Muscular 
arteries and the smaller resistance vessels contain a lesser amount of elastin due to the 
smaller strains. Arterioles and veins contain little to no elastin due to the small amount of 
strain that these vessels see. Greater pressures require greater amounts of collagen to 
provide tensile strength. The muscular arteries have the largest amount of collagen. The 
smooth muscle cell content varies based on the need for blood pressure regulation. The 
smooth muscle cells contract and relax to change the diameter of the blood vessel to 
control flow. This is especially important in the muscular arteries. Some smooth muscle 
cells or pericytes are found in and capillaries; the contractile function of the cell is 
important for maintaining blood flow in the small vessels. The anchoring and scaffolding 
for vasa vasorum is most important for the larger vessels [13, 14].  The coronary and 
femoropopliteal arteries are muscular arteries. 
Table 1: Composition of Arteries and Veins 
Arterial Vessels Pulmonary Vessels 
Elastic Artery 
• Endothelial layer 
• Thick medial layer 
• Plentiful elastin  
• Thick adventitia 
Large Vein 
• Endothelial layer 
• Medial layer 
• Little elastin 
• Adventitia 
Muscular Artery 
• Endothelial layer 
• Thick medial layer 
• More collagen then 
elastin 
• Adventitia 
Medium-sized Vein 
• Endothelial layer 
• Medial layer 
• Adventitia 
Arteriole 
• Endothelial layer 
• Medial layer mostly 
smooth muscle cells 
• No adventitia 
Venule 
• Endothelial layer 
• No medial layer 
• Thin adventitia 
Continuous Capillary 
• Endothelial layer 
• Occasional pericytes 
Fenestrated Capillary 
• Endothelial layer 
• Occasional pericytes 
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Arterial Hemodynamics 
Blood vessels are subjected to multiple forces due to the pulsatile nature of blood 
flow. The blood vessels both shear and normal stresses. As blood flows across the 
endothelium, frictional forces cause shear stress on the arterial wall (τw). The τw is 
proportional to the shear rate at the wall and the fluid dynamic viscosity. For many blood 
vessels detailed measurements of the velocity at the wall must be taken to determine wall 
shear stress. For some in vivo and in vitro situations the wall shear stress can be 
approximated as: 
τw=4µQ/πR
3 
where µ is the dynamic viscosity, Q is the volumetric flow rate and R is the tube 
diameter. This approximation assumes steady laminar flow of a Newtonian fluid through 
a rigid pipe. It is not appropriate areas of branching or tapering, non-circular cross-
sections or areas with pulsatile flows. It cannot be used in small diameter vessels where 
blood does not behave as a Newtonian fluid. It is a good approximation for smaller 
arteries. Arteries can adapt to regulate pressure and flow; typically a mean wall shear 
stress of approximately 15 dynes/cm2 is maintained. Wall shear stress provides important 
cues to endothelial cells and can affect endothelial cell alignment. Areas of plaque 
formation often correspond to oscillating or stagnant flow [15-18].  
The blood pressure creates a hoop stress (σh), the circumferential stress in the 
blood vessel walls. For a thin walled tube the hoop stress is approximated as: 
σh = PRt
-1 
where P is pressure, R is the radius and t is the wall thickness. The wall stress increases 
with blood pressure and vessel diameter and decreases with increased wall thickness. The 
mean pressure found in arteries is approximately 100 mmHg; veins see mean pressures of 
approximately 10 mmHg. The blood vessels will adapt to sustained changes in blood 
pressure. Hypertension leads to smooth muscle cell hypertrophy, leading to a thicker 
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medial layer. This increase in wall thickness serves to decrease the pressure seen by the 
smooth muscle cells in the wall [15, 18, 19]. Hoop stress is the best studied stress in 
native and engineered blood vessels; however, work has been done to investigate the 
effects of longitudinal or axial stress and strain [20, 21]. 
Vasoactivity 
Regulation of vascular tone, the smooth muscle tension, is important for 
regulation of blood pressure and flow. In mature blood vessels smooth muscle cells 
contain a number of proteins involved in contraction, many which have smooth muscle 
cell isoforms such as smooth muscle α-actin, myosin heavy chains, myosin light chains, 
α-tropomyosin, calponin, smooth muscle 22α, h-caldesmon, γ-vinculin and α- and β- 
meta-vinculin [22]. The contractile machinery consists of sarcomeric units of actin and 
myosin filaments [14].  
 The smooth muscle cells maintain a partially contracted state at all times; this 
minimum blood vessel tension is called the tonic or basal tone. The increase or decrease 
in tone is regulated via sensitivity to and concentration of Ca2+. The change in 
intracellular free Ca2+ necessary for contraction is on the order of 1 µM [23]. Following 
an increase in cytosolic Ca2+, the calcium ions bind to calmodulin which is associated 
with the enzyme myosin light chain kinase (MLCK). MLCK catalyzes the 
phosphorylation on myosin light-chain (MLC) which is associated with the head of each 
myosin molecule. This phosphorylation increases myosin’s interaction with filamentous 
actin producing contraction. Relaxation is caused by the dephosphorylation of myosin by 
myosin light chain phosphatase [24].  
Vascular tone has complex regulation that requires both intrinsic and extrinsic 
factors. This section is meant to be a review of the most common agonists and 
antagonists but is not all inclusive. The primary mechanisms of intrinsic and extrinsic 
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regulation are listed in Table 2. Intrinsic regulation consists of factors such as the 
endothelial cell secreted nitric oxide and the autacoid histamine that act locally. 
Autoregulation of flow and functional and reactive hyperaemia are mediated exclusively 
by intrinsic regulation. Extrinsic regulation involves mechanisms such as the hormone 
adrenaline and regulation by vasomotor and vasodilator nerves. 
Table 2: Intrinsic and Extrinsic Mechanisms of Vascular Tone Regulation [14] 
Intrinsic 
Regulation 
• Bayliss myogenic response 
• Vasoactive metabolites 
• Endothelial secretions 
• Autacoids – local vasoactive paracrine secretions 
• Temperature 
Extrinsic 
Regulation 
• Vasomotor nerves 
• Circulating hormones 
 
Intrinsic Regulation 
Bayliss Myogenic Response 
Intrinsic regulation is a local regulation designed to meet the needs of the organ. 
The Bayliss myogenic response is the contraction of the smooth muscle cells in response 
to changes in arterial pressure. This response contributes to basal tone and stabilizes local 
blood flow. The Bayliss myogenic response is mediated by depolarization which 
increases the number of open Ca2+ channels raising cytosolic Ca2+ which activates the 
contractile machinery. Regulation of the constriction is thought to be due to increased 
shear stress in the narrowed vessel which causes the endothelial cells to increase 
synthesis of nitric oxide. 
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Vasoactive Metabolites 
Vasoactive metabolites secreted by skeletal muscle, myocardium or active brain 
regions can cause local increases in blood flow. Adensosine, interstitial K+, phosphate 
ions as well as CO2 and O2 levels can all affect local vascular tone. The type of tissue 
dictates the sensitivity and type of response that occurs. Many of these reactions are due 
to responses to exercise where oxygen and nutrient needs change and increased flow is 
needed for removal of byproducts such as lactic acid.  
Endothelial Secretions 
Endothelial cells secrete the vasodilators nitric oxide (NO), endothelium derived 
hyperpolarizing factor (EDHF) and prostacyclin, as well as the vasoconstrictor 
endothelin. Nitric oxide is important for regulating basal tone including the reduction in 
tone during pregnancy, and causing dilation in response during inflammation and due to 
increased flow during exercise. NO is regulated primarily by shear stress although 
circulating insulin and oestrogen also play a role. Basal tone is also regulated by the 
vasoconstrictor endothelin. Endothelin binds to the ETA and ETB receptors in arterial and 
venous smooth muscle cells causing constriction that can last 2-3 hours. Endothelin-1 has 
been shown to be one of the most potent vasopressors [25]. The activation of the 
receptors raises cytosolic Ca2+ through activation of the receptor operated Ca2+ channels 
and through the phospholipase C-IP3-DAG pathway. 
Autacoids 
Local vasoactive paracrine secretions, or autacoids, are primarily secreted in 
response in pathological events such as inflammation and bleeding. A brief list of some 
of the important autacoids and their primary functions are listed in Table 3.  
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Table 3: The Autacoids [14] 
Autacoid Function 
Histamine Mediates Inflammation 
Bradykinin Mediates Inflammation 
Serotonin 
Mediates Inflammation 
Arrests Bleeding 
Prostaglandins 
Mediates Inflammation 
Contributes to Reactive Hyperaemia 
Thromboxane Arrests Bleeding 
Leukotrienes Mediates Inflammatory Response 
Platelet Activating 
Factor 
Mediates Inflammation 
Mediates Bronchoconstriction 
 
Histamine 
Histamine is produced by the decarboxylation of histidine; it can cause 
constriction or dilation depending on which receptors are present in the vessel. Binding of 
histamine to the H1 receptors in the veins causes activation of the phospholipase C-IP3 
pathway which causes constriction. Conversely, binding of histamine to the H2 receptor 
activates the adenlyate cyclase-cAMP pathway which results in vascular relaxation in the 
arterioles.  
Bradykinin 
Bradykinin is generated by the enzyme kallikrein which is activated during 
inflammation. Bradykinin activates the bradykinin receptors B1 and B2. Bradykinin is 
considered a vasodilator, but can cause constriction. A biphasic response to bradykinin 
has been seen [26-28]. Activation of the B1 receptor results in vasodilation while 
activation of the B2 receptor results in constriction [26]. NO, EDHF and prostacyclin 
mediate dilatory effect of bradykinin.  
Serotonin 
Serotonin (5-hydroxytryptamine, 5-HT) is a vasoconstrictor that is produced from 
tryptophan in platelets, agentaffin cells in the intestine and some central neurons. The 
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main function of serotonins is to arrest bleeding, although it also plays a role in regulation 
of local blood flow in the intestine.  
Prostaglandin 
Prostaglandin is eicosanoid; it is produced from the fatty acid arachidonic acid 
through action of cyclo-oxygenase (COX). Endothelial cells, leukocytes, fibroblasts and 
macrophages all produce prostaglandins. Different prostaglandins have different effects 
and vascular tone. The E series of prostaglandins and prostacyclin are vasodilators while 
the F series of prostaglandins are mostly vasoconstrictors. 
Thromboxane 
Thromboxane is also an eicosanoid. Thromboxane A2 is a vasoconstrictor and 
thrombotic agent that is synthesized by COX within platelets. Its’ primary role is to help 
arrest bleeding. The function of aspirin as an antithrombotic agent occurs by blocking 
inhibiting COX and reducing thromboxane content. 
Leukotrienes 
Leukotrienes are vasoconstrictors produced by leukocytes from arachidonic acid 
by the enzyme lipoxygenase. They mediate the inflammatory response. It is a 
vasoconstrictor and also increases venular permeability. 
Platelet Activating Factor 
Platelet activating factor (PAF) is a lipid that is produced by activated 
inflammatory cells. PAF is involved in regulation of inflammation and mediates 
bronchoconstriction. 
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Extrinsic Regulation 
Extrinsic regulation originates outside of the organ to meet the needs of the body. 
It is comprised of neurotransmitters secreted by the vasomotor nerves and circulating 
hormones. 
Neurotransmitters 
Vasoactive neurotransmitters are secreted by the vasomotor nerves. There are 
three kinds of autonomic vasomotor nerves: the sympathetic vasoconstrictor nerves, the 
parasympathetic vasodilator nerves and the sympathetic vasodilator nerves. The 
sympathetic vasoconstrictor nerves are the most prevalent and have important 
physiological roles. The parasympathetic vasodilator nerves are not found in all tissues. 
They are responsible for increasing blood flow when required for organ function. There 
are limited sympathetic vasodilator nerves in the body. One function of these nerves is 
vasodilation in skin that occurs along with sweating. There are more roles for these 
nerves in non-primates. Several of the more common vasoactive neurotransmitters are 
described. 
Norepinephrine 
Norepinephrine, also known as noradrenaline, is both a neurotransmitter and a 
circulating hormone. It is synthesized by the sympathetic vasoconstrictor nerves and 
quickly diffuses across the junctional gap to bind to the α-adrenoceptors α1 and α2. The α1 
receptor is found on most blood vessels while the α2 receptor is found on resistance 
vessels. The effect of norepinephrine is mediated by many vasodilator metabolites and 
autacoids. Angiotensin II facilitates transmitter release and amplifies the constriction. 
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ATP 
Purine ATP is synthesized locally by the sympathetic vasoconstrictor nerves and 
is released along with norepinephrine. ATP stimulates post junctional P2x purinergic 
receptors which activate non-selective cation channels.  
Neuropeptide Y 
Neuropeptide Y is synthesized in the postganglionic cell body of sympathetic 
vasoconstrictor nerves and is stored with norepinephrine. It is released in response to high 
frequency stimulation that occurs during times of stress. Neuropeptide Y produces a 
slower and more prolonged response than ATP; it also causes increased sensitivity to 
norepinephrine. 
Acetylcholine 
Acetylcholine is secreted by the parasympathetic vasodilator nerves. It produces 
dilation through cholinergic stimulation of the endothelial cell to produce NO; 
acetylcholine also interacts directly with the smooth muscle cells by activating the M3 
muscarinic receptor.  
Circulating Hormones 
There are several hormones that affect blood vessel tone. Generally the effects of 
the hormones are less than that of the vasomotor nerves. Table 4 shows some of the more 
potent vasoactive hormones and the response that they elicit. Some of the hormones are 
discussed in more detail. 
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Table 4: Circulating Hormones and Their Vasoactive Response [14] 
Hormone Response 
Adrenaline  Primarily Vasoconstriction 
Norepinephrine Primarily Vasoconstriction 
Angiotensin II Vasoconstriction 
Vasopressin Primarily Vasoconstriction 
Insulin Vasodilator 
Oestrogens Vasodilator 
Relaxin Vasodilator 
Thyroxine Vasodilator 
 
Adrenaline and Norepinephrine 
Adrenaline is a methylated form of norepinephrine. Both hormones are secreted 
from the adrenal gland and cause vasoconstriction due to activation of the α-
adrenoceptors. While the response to adrenaline is most often vasoconstriction, 
vasodilation can occur in skeletal muscle, myocardium and liver through activation of the 
β-adrenoceptors.  
Angiotensin II 
While not its’ primary role, Angiotensin II has a direct effect on pressure 
regulation through vasoconstriction. Angiotensin II interacts directly with smooth muscle 
cells through activation of the angiotensin receptors. It also has an indirect effect by 
stimulating norepinephrine production through activation of angiotensin receptors on the 
sympathetic terminals. 
Vasopressin 
Vasopressin acts as a vasoconstrictor mainly during pathological events and acts 
to maintain blood pressure and volume through other means under normal conditions. It 
is produced by the mangnocellular neurons in the hypothalamus. Secretion is stimulated 
by a decrease in blood pressure and volume such as during hemorrhage. While 
18 
vasopressin is a potent vasoconstrictor in most tissues, it causes vasodilation of the 
cerebral and coronary arteries through stimulation of NO. 
Temperature 
Responses to temperature can be intrinsic or extrinsic. Change of vascular tone is 
important for regulation of tone in the blood vessels of the skin in order to help maintain 
core body temperature. Body temperature is maintained by balancing internal heat 
production with external heat loss; changes in cutaneous vascular tone help to regulate 
heat loss. There is an intrinsic response to local changes in temperature such as a person 
puts their hand in ice water. There are also extrinsic responses as a result of core 
temperature changes. Cutaneous blood vessels contain an abundance of α2-
adrenoreceptors which interact with the sympathetic transmitter norepinephrine. 
Norepinephrine is discussed in more detail in the extrinsic regulation section. 
The Vascular Smooth Muscle Cell in Culture 
Vascular smooth muscle cells are often defined as having either a ‘contractile’ or 
‘synthetic’ phenotype. There is some evidence that in a mature vessel there are some cells 
that seem to be of a more synthetic type while the majority is in the quiescent 
‘contractile’ phenotype. The reality is that there are not two distinct phenotypes but a 
gradient. Quiescent cells can synthesize extracellular matrix while retaining their 
contractile apparatus.  
In a mature blood vessel the majority of the smooth muscle cells will be 
quiescent; they will not proliferate nor synthesize much extracellular matrix. After 
isolation and placement into culture, the smooth muscle cells initially appear long and 
spindly; however, after a few passages their morphology becomes more fibroblastic (see 
Figure 2). Along with the change in morphology is a change to a more synthetic 
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phenotype and the contractile apparatus is significantly down regulated. This spontaneous 
phenotypic modulation happens after 6-8 days in culture when cells are kept in 
subconfluent conditions [29]. 
 
 
Figure 2: Vascular Smooth Muscle Cells in Culture. SMCs at P0 (A) have a long spindly contractile 
smooth muscle cell morphology. SMCs at P7 (B) have a more fibroblastic morphology associated 
with a more synthetic cell phenotype. 
Phenotype modulation is thought of as irreversible when seeding at low densities 
and passaging multiple times, techniques that are often used and required to generate 
cells for most tissue engineering applications [29]. More recent work has shown that 
synthetic adult smooth muscle cells can convert to a contractile phenotype after serum 
starvation [30, 31]. In vascular tissue engineering different biochemical and mechanical 
stimulation has been shown to alter smooth muscle cell phenotype, but little work has 
been done to determine if this has an effect on the contractile response [32, 33]. 
Tissue Engineered Small Diameter Blood Vessel 
Tissue engineering is the combination of cells, scaffold and mechanical and 
biochemical cues to create an engineered tissue. Tissue engineering approaches have 
attempted to create substitutes for one or more of these layers; these range from the use of 
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biopolymer scaffolds to biodegradable scaffolds with varying cell sources, mechanical 
and biochemical stimulation. A review of these approaches follows. Nanotechnology is 
being investigated for tissue engineering applications and is being considered for vascular 
tissue engineering, especially with respects to endothelialization. This work is still in its 
infancy with respect to vascular tissue engineering, and has been suggested but not 
practically used for creation of vascular tissue. For information on research into 
nanotechnology for tissue engineering please see the following reviews: [34-36]. 
Biopolymer Scaffolds 
The first biological blood vessel substitutes were created by Weinberg and Bell 
using type I collagen hydrogels to create all three layers of the blood vessel [37]. Since 
that time collagen I hydrogels have been explored by the Nerem lab and others as a 
scaffold choice for tissue engineering. The smooth muscle cells can be easily 
encapsulated with the hydrogel and will compact and remodel the gel. Endothelial cells 
can be seeded and will form confluent monolayers on the lumen [38]. The collagen gels 
are quite weak; Weinberg and Bell used Dacron support sleeves to achieve sufficient 
strength. For small diameter applications synthetic materials have not remained patent, so 
other methods of improving the strength of the collagen gels have been investigated. 
Several cross-linking agents have been investigated to improve strength. Most cross-
linking agents are cytotoxic, so Berglund et al investigated the used of chemical cross-
linking of a collagen support sleeve. An acellular collagen gel was created and 
dehydrated. Dehydrothermal, ultraviolet, and glutaraldehyde were used to cross-link the 
sleeves. All methods increased strength and collagen gel stiffness while retaining high 
cell viability [39], Only a few cross-linking techniques are non-cytotoxic and can be 
directly applied to the cell seeded hydrogels. Methylacrylamide photo-cross-linking has 
been used to improve shear modulus 12 fold with high cell viability [40]. Enzymatic 
glycation by transglutaminase has been shown to improve burst pressure of collagen 
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tubes by 35% [41]; collagen hydrogels populated with cell transfected to overexpress 
lysyl oxidase were almost twice as strong as those with non-transfected cells [42]. Non-
enzymatic glycation has also been used to cross-link and improve collagen gel strength; 
when applied after cell mediated compaction has ceased ribose and glucose both 
increased the tissue strength. Ribose resulted in better cross-linking than glucose [43, 44]. 
When cyclic strain was applied for 5 weeks to the glycated tissue cyclic, elastin 
deposition was found after. Elastin deposition in engineered tissue made from adult 
SMCs had not been previously reported. Incorporation of elastin into a tissue engineered 
blood vessel remains a challenge; elastin scaffolds have been isolated from mature 
vessels and incorporated into the collagen based engineered tissue. The elastin scaffolds 
not only improved the elastic modulus of the tissue but also greatly enhanced the tensile 
strength of the tissue [45]. In order to incorporate elastin into the scaffold a freeze dried 
collagen-elastin scaffold was created from a 1:1 collagen – elastin suspension. Different 
cross-linking methods were assessed. Smooth muscle cells were seeded into the scaffolds 
by filtration. Yield stresses of 4-50 kPa were obtained using the various cross-linking and 
culture conditions [46, 47]. 
While type 1 collagen is the most abundant protein in the body and blood vessel 
and is important for tensile strength, it may not be the best choice of scaffold material. 
The extracellular matrix has a profound effect on smooth muscle cell proliferation and 
phenotype. One review on the role of matrix in tissue engineering is that of Vogel and 
Baneyx [48]. Fibrin has been used successfully as an alternative material to the collagen 
hydrogels. As with collagen cells can be encapsulated in fibrin hydrogels. Smooth muscle 
cells encapsulated in fibrin have been shown to synthesize more collagen then cells in 
collagen hydrogels [49, 50]. Under similar culture conditions the tensile strength of the 
fibrin hydrogels was greater than that of the collagen hydrogels [50]. Fibrin based tissue 
engineered blood vessels have also demonstrated a vasoactive response to specific 
agonists [51-54], and have been tested in vivo [52]. To improve the mechanical properties 
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of the fibrin graft a second acellular fibrin layer has been added. This improved the 
tensile strength and caused a reduction in measured vasoactive response [53]. Fibrin gel 
compaction and strength can also be affected by the concentration of thrombin used for 
fibrillogenesis [55]. The combination of collagen I and fibrin has been investigated. The 
tensile strength was found to correlate highly with the degree of gel compaction with the 
composite collagen-fibrin hydrogel being the strongest [56]. Varying the concentrations 
of the proteins can also affect the material properties; tensile strength correlated to gel 
compaction so higher concentrations were not always the optimal choice [57]. 
Fibronectin-fibrinogen scaffolds have been studied; these grafts have demonstrated burst 
pressures approaching 200 mmHg [58]. While fibrin based TEVM has demonstrated 
substantial strength, ε-amino caproic acid (ACA) is needed to prevent proteolytic 
degradation. If the fibrin is not slowly degraded and replaced with ECM prior to 
implantation, the TEVM could fail in vivo.  
A chitosan based engineered tissue with a chitosan core and chitosan-gelatin outer 
layer was used; and a burst pressure over 4000 mmHg was achieved [59]. The use of a 
collagen mimetic combined with chitosan using a different fabrication process has 
recently been described with slightly lower burst pressures [60]. 
Esterified hyaluronic acid (HYAFF) has also been used as a scaffold for blood 
vessel tissue engineering. Initial studies showed that cells could attach to HYAFF and a 
tubular configuration could be created [61]. Further studies using perfusion or rotation 
cell seeding to promote cell infiltration improved the tissue strength; measured tensile 
strength of both seeding methods was in the MPa range [62]. One benefit to this material 
is that it has been approved for human use for skin and cartilage applications. Hyaluronic 
acid may also have additional benefits of promoting elastin synthesis and recruiting and 
retaining an endothelial cell layer [63, 64]. 
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Cell Sheets 
In cell sheet TEVM, the cells produce the matrix. Smooth muscle cells or 
fibroblasts are cultured until they are post confluent and have created their own tissue. 
The sheets are then wrapped around an inner mandrel to create a tube and cultured longer 
to promote adhesion of the layers. All three layers can be created by wrapping the 
fibroblast layer around the smooth muscle layer and then seeding endothelial cells into 
the lumen [38]. This approach results in burst pressures of over 2000 mmHg, similar to 
native vessel [65]. The vasoactive response of this engineered tissue has also been shown 
to be similar to native vessel [66-69]. This approach has been successful and is now being 
tested in clinical trials [70, 71]. Mechanical testing of an engineered blood vessel using 
fibroblast sheets only has been shown to have burst pressures comparable to artery and 
compliance between artery and vein [72]. The creation of tissue engineered blood vessels 
using the cell sheet approach requires long cultures times which can be problematic if 
autologous cells are required. These TEVM are being tested clinically, although not in a 
small diameter application [73]. 
Synthetic Scaffolds 
The most widely used polymer is polyglycolic acid (PGA). Because it is rapidly 
resorbed in vitro culture is required prior to implantation. SMCs cultured in PGA have 
been shown to synthesize and deposit elastin [74]. Cell seeded PGA engineered blood 
vessels have been shown to be vasoactive and have burst pressures over 2000 mmHg 
after 7 weeks in culture [75], while these vessels exhibit significant strength compared to 
most of the hydrogels, the strength and burst pressure is still below native and elastin 
deposition was not seen [76]. While the burst pressures are similar to native tissue, direct 
comparison of mechanical properties found that the engineered tissue was not as strong 
as the native tissues, even though collagen densities were similar [76], instead collagen 
fiber diameters and alignment were different [77].  
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Copolymers or multilayered polymers have been used, many using PGA for 
reinforcement. Many of these were tested as acellular grafts in a variety of animal models 
with all grafts remaining patent throughout the test. All grafts contained combinations of 
two or more of the following polymers: PGA, polyhydroxyalkanoate (PHA), polyglactin, 
poly-L-lactide (PLA), poly(ε-caprolactone) (PCL), poly-L-lactic acid (PLLA), 
polyglycolide fiber, poly(allylamine hydrochloride) (PAH), poly(styrene sulfonate) 
(PSS), poly-4-hydroxybutyrate (P4HB), poly(ester urethane)urea (PEUU), and poly(2-
methacryloyloxyethyl phosphorylcholine-co-methacryloyloxyethyl butylurethane) 
(PMBU). Table 5 shows the combinations of polymers used successfully in animal 
models and an occasional human patient. While there has been success using these 
polymers as blood vessel grafts, it is still unknown if they would remain patent in a small 
diameter application. 
Table 5: Polymers Tested In Vivo 
Polymer Authors 
PGA-PHA Shum-Tim [78] 
PGA-polyglactin Shinoka [79] 
PGA-PLA-PCL Watanabe [80] 
Matsumura [81] 
Shin’oka [82] 
PGA/PLA Isomatsu [83] 
PLA-PCL-PLA Matsumura [84] 
Shin’oka [85] 
PLA-PCL-polyglycolide Matsumura [86] 
PGA/collagen-PLLA Yokota [87] 
PCL Pektok [88] 
PGA/collagen-PCL-PLLA Torikai [89] 
PGA-PCL-PLA Brennan [90] 
PGA-P4GB Mettler [91] 
Umbilical Vein-PAH-PSS Kerdjoudj [92] 
PEUU-PMBU Hong [93] 
 
 
Other copolymers have been tested in vitro. PGA-P4HB grafts were made by 
coating PGA with a thin layer of P4HB. Myofibroblasts were seeded onto the inner layer 
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first followed by endothelial cells. The engineered blood vessels were then cultured using 
a pulse duplicator system. After 28 days in culture burst pressures over 300 mmHg were 
measured [94]. These grafts have now been tested in vivo with seeded endothelial 
progenitor and mesenchymal stem cells [91]. Poly(D,L-lactide)-7 co(1,3-trimethylene 
carbonate) dipped in collagen to create a collagen ‘microsponge’ inside the pores has 
been investigated as a potential polymer for small diameter blood vessel tissue 
engineering. The mechanical properties after seeding and culture with smooth muscle 
cells for 7 days was shown to be similar to native artery [95]. A multi-layered tissue 
engineered blood vessel was constructed to mimic the architecture of native vessel. A 
sheet of smooth muscle cell seeded PGA was wrapped around a mandrel followed by a 
SMC seeded sheet of PCL then a sheet of fibroblast seeded PGA. Finally endothelial 
cells were seeded on the lumen and the tissue was placed into a culture into a pulsatile 
bioreactor. Tensile strengths similar to native tissue were seen; measured values were 
greater than 800 kPa [96]. 
Poly(ethylene glycerol) (PEG) has been used as a biodegradable polymer 
hydrogel. Diacrylate PEG can be rapidly polymerized using ultraviolet light with little 
cell damage. The material has tunable properties producing strengths of 40-100 kPa [97]. 
More recently elastomeric biodegradable polymers have been used for tissue 
engineering of blood vessels. Poly(1,8-octanediol citrate) (POC) has been used along 
with a pulsatile bioreactor [98]. Poly(glycerol sebacate) can be fabricated in to a tubular 
form. Smooth muscle cells are seeded using gentle perfusion after which time endothelial 
progenitor cells were seeded onto the lumen. After 8 weeks of culture the pressure-
diameter responses were similar to native tissue and there was detectable elastin present. 
Tensile strength was approximately 25 kPa [99]. Poly(ester urethane) urea (PEUU) was 
fabricated in tubular form and seeded with muscle derived stem cells using a rotational 
vacuum seeding technique. After 7 days in culture the measured tensile strength was 
approximately 2.5 kPa [100]. 
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A copolymer of poly(lactide-co-β-malic acid) with extended carboxyl arms 
(PLMA-ECA) has been suggested as a scaffold for blood vessel tissue engineering due to 
the low adherence of platelets and high cell affinity [101]. 
There is some debate of the need for cell seeding in the biodegradable polymers. 
The references in Table 5 include studies both with cell seeding and without. One study 
has shown that expanded polytetrafluoroethylene (ePTFE) seeded with endothelial cells 
has lower platelet adherence than that of the unseeded controls when tested in an ex vivo 
shunt [102]. It is likely that other polymers will also require endothelial cell seeding in 
order to remain patent. Some of the polymers discussed are being used clinically in 
pediatric applications. For a review see Shinoka and Breuer [103]. For small diameter 
application these materials may not be successful. Polymers that remain patent in large 
diameter applications may not in small diameter vessels. Degradation byproducts may 
also alter the local environment and lead to alterations in cell function or cell death [104, 
105]. 
Decellularized Scaffolds 
Acellular matrices that can be repopulated by autologous cell in vivo have been 
explored; this approach could lead to off-the-shelf availability of graft material. Immune 
acceptance and cell source would not be a problem. Small intestinal submucosa (SIS) has 
been tested for use as a vascular graft since 1989 [106]. Only one of 9 dogs tested died of 
thrombosis when SIS was used as a large diameter vascular graft. After 90 days the grafts 
arterialized with a functional endothelial layer and a smooth muscle populated medial 
layer [107]. SIS grafts have been shown to have excellent mechanical properties both pre- 
and post-implantation with burst pressures greater than 3000 mmHg [108, 109]. The SIS 
grafts have also been tested successfully in vivo in a growth model showing that they are 
not only able to arterialize but also to adapt and grow in a pediatric model [110]. A 
similar study using acellular small intestine excluding the mucosa layer had similar 
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results. All the grafts grew, but one of seven did not remain patent [111]. In a similar 
vein, the intestinal collagen layer of the small intestine was also used as a vascular graft. 
This layer alone had poor patency rates until a small layer of bovine collagen was applied 
with heparin. These grafts exhibited burst pressures greater than 900 mmHg and 
remained patent. Cells populated the graft and the grafts exhibited a vasoactive response 
when explanted after 90 days. This is the only study where a small diameter graft (4 mm) 
was used as a graft for a rabbit carotid artery [112]. 
Decellularized porcine ureters have been suggested as a scaffold material for 
vascular tissue engineering. The decellularized ureters had similar mechanical properties 
as saphenous veins. They had significantly less immune response than cellularized 
controls in a subcutaneous implant [113].  
While SIS provides a more natural environment than many of the other 
approaches, the use of decellularized vascular tissue was investigated as well. 
Decellularized, heparin treated segments of porcine carotid artery were shown to have 
similar mechanical properties to that of native vessels. When tested in vivo as a 
xenogeneic graft, a confluent endothelial cell monolayer developed within 2 months 
[114]. Decellularized fetal pig aorta has been shown to have similar mechanical 
properties of fresh artery; endothelial cells cultured on the lumen remained viable and 
created a confluent monolayer [115]. Decellularization methods can affect cell viability 
and mechanical integrity [116, 117]. Decellularization method is important as some can 
affect collagen spacing and proteoglycan density which would impact the mechanical 
integrity [118]. Still the use of decellularized aortic segments show burst pressures of 
over 1000 mmHg; endothelial cells will form a confluent monolayer on the surface and 
will produce vasoactive agents in response to agonists [119]. 
Most of the approaches with decellularized tissues are used to provide a more 
natural extracellular environment and to avoid potential thrombosis found that occurs 
when polymers are used in small diameter blood vessel applications. There are some 
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studies that combine the decellularized matrix with a polymeric coating in the hopes of 
improving patency. Recently human umbilical arteries were decellularized and coated 
with PAH/PSS and tested in rabbits; all remained patent [92]. 
The Body as a Bioreactor 
In order to form a TEVM with autologous cells in a relatively short amount of 
time, the use of the body as a bioreactor to create a blood vessel like structure was 
developed  [120]. The body’s foreign body response forms granulation tissue around a 
silastic mold resulting in a blood vessel like structure with myofibroblasts and a 
monolayer of mesothelium after only 2 weeks in culture in rats. The tissue is removed 
from the tubing and everted so that the mesothelium is facing the lumen. The engineered 
tissue was then placed into the carotid artery of the same animal and remained patent for 
the 4 month trial [120]. The myofibroblasts responded to KCl, phenylephrine, and 
acetylcholine after 3 weeks implantation; after 4 months an adventitia layer with vasa 
vasorum was seen  [121]. Canine studies were performed using a variety of tubing 
materials. Histologically there was no difference in the granulation tissue, although the 
thickness varied. The tissue not grown on mesh had burst strengths over 2500 mmHg. 
When implanted, 8 out of 11 grafts remained patent for 6.5 months; these grafts did not 
respond to vasoactive drugs [122]. Use of the multilayered tubes was tested. PLA was 
coated with hyaluronic acid followed by one or more coatings including matrigel, elastin, 
tropoelastin, laminin, collagen I and collagen III. All materials resulted in a foreign body 
response. Matrigel resulted in the most significant cell response [123]. This approach is 
promising due to its short culture time and use of autologous cells. Off-the-shelf 
availability will likely be needed for some patients; this approach would not be able to 
meet that need. 
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Mechanical Stimulation 
The most common form of mechanical stimulation is the application of cyclic 
strain. The application of cyclic strain has been used to provide a more physiological 
environment for tissue engineered blood vessel culture; cyclic strain of the engineered 
tissue has been shown to increase tissue strength [47, 94, 98, 124-128], improve smooth 
muscle cell alignment [124, 129] and promote a more contractile cell phenotype [33, 75, 
129]. ECM synthesis and deposition is altered with cyclic strain, although the results are 
mixed due to different test conditions including but not limited to differences in cell type, 
scaffold choice, culture medium and strain profile. Several studies show increased 
collagen after cyclic strain [75, 94, 97, 128, 130]; this includes a study that saw 
differences in collagen content but no difference in elastin deposition when cyclic strain 
was applied to the PEG hydrogels [97]. This is counter to a study with cross-linked 
collagen hydrogels that had increased elastin deposition but no difference in collagen 
content [125]. MMP activity is affected by cyclic strain. An increase in MMP-2 activity 
was seen in collagen gels with human cells [131, 132]. While the increased MMP activity 
is of concern due to the decreases in strength seen at least in the short term, MMP activity 
is essential for remodeling. When non-specific MMP activity is inhibited cyclic strain no 
longer resulted in improved mechanical properties [131]; however, without inhibition the 
collagen based TEVM were strained for longer time periods the MMP activity resulted in 
reduced strength after 8 days in culture [132]. Studies have shown that strain amplitude 
and rate may influence the mechanical properties [133-136] and collagen deposition [134, 
135] in engineered tissue. High strain amplitudes of 10-15% have been shown to improve 
strength and collagen as compared to static with stepwise incremental strain increases 
having the best results [134]. Another study showed that pulse rate could affect collagen 
content and MMP-1 content [130]. Conversely a different study found that lower strain 
rates to be preferable for strength [98]. Differences may very well be due to cell type, 
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matrix type and the method for applying strain. Higher strain rates have led to increased 
collagen deposition and increased levels of tissue inhibitor of metalloproteinases type 1 
(TIMP-1) both of which would positively impact tensile strength [136]. 
Fluid shear stress is known to affect endothelial cells (for a review see [137, 
138]). Several of the pulsatile bioreactors also incorporate flow through the lumen. Most 
of the tissues using hydrogel scaffolds cannot be subjected to flow and cyclic strain at the 
same time due to insufficient mechanical properties, although recently fibrin based 
medial equivalents were subjected to pulsatile luminal flow with pressures up to 200 
mmHg [139]. Many polymer scaffolds have been subjected to both flow and strain [47, 
75, 94, 96-98]. Laminar flow alone does have an impact on collagen deposition which 
should affect tissue strength [140]. The combination of shear stress and cyclic 
circumferential strain may have different effects than cyclic strain alone. At this time the 
effects cannot be separated. Newer systems are combining cyclic circumferential strain 
with perfusion and shear [141, 142], electrical stimulation [143, 144], and longitudinal 
extension [145, 146]. Use of perfusion with pulsatile pressure was compared to a 
rotational bioreactor; the rotational bioreactor was shown to increase the ECM deposition 
and tensile strength of tissue engineered blood vessels compared to those cultured in the 
perfusion bioreactor [62]; this suggests that application of cyclic strain may not be 
necessary for a viable tissue engineered vascular graft. This is supported by in vivo and 
clinical studies that utilize cell secreted or biodegradable polymer scaffolds. 
Biochemical Stimulation 
Various forms of biochemical stimulation have been used to improve the 
properties of tissue engineered blood vessels. Growth factors such as transforming 
growth factor β (TGF- β) are a widely used for their effects on ECM synthesis (for 
reviews of growth factors in tissue engineering see [147, 148]). Ascorbic acid or sodium 
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ascorbate is often used to promote ECM production [70, 75, 149-151]. Retinoic acid has 
also been shown to increase ECM synthesis [151]. 
Addition of exogenous TGF- β and platelet derived growth factor (PDGF) has 
been shown to increase cell mediated gel compaction while heparin has been shown to 
decrease compaction [152]. There is strong correlation between gel compaction and 
tissue strength. PDGF and TGF- β are both been shown to affect smooth muscle cell 
phenotype. Addition of PDGF leads to reduction in smooth muscle α-actin while TGF- β 
leads to an increase [33]. The effects of TGF- β alone or in combination with other 
factors on tissue strength and ECM synthesis have been investigated. TGF-β has been 
shown to increase collagen production [153-155], increase strength [50, 155], increase 
elastin deposition [155], and promote a more contractile cell phenotype [33].  The 
addition of TGF-β along with insulin was also shown to improve the contractile response 
of the engineered tissue [54] and increase both collagen and elastin deposition [156]. This 
combination improve collagen synthesis and tissue strength more than TGF-β alone; the 
addition of plasmin further enhances collagen synthesis and strength [157]. The 
combination of TGF-β, insulin, and aprotinin also resulted in improvements in strength 
over TGF-β and insulin alone [54]. The method of TGF-β presentation can also have an 
effect. TGF-β tethered to the matrix was shown to increase matrix production compared 
to TGF-β provided in culture medium [153]. 
Extracellular Matrix 
This section seeks not to review all of the components of the medial extracellular 
matrix, but the matrix materials that are important to this work.     
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Collagen 
Collagen is the most abundant protein in blood vessels and throughout the body. It 
has a triple helical protein with an α-chain secondary structure made up of (Gly-X-Y)n 
repeats where X and Y are often proline or hydroxyproline. Within the triple helix, every 
backbone carbonyl and amide group interacts to form hydrogen bonds. In collagen types 
I, II, III, V and XI, the collagen monomers self-associate into periodic cross-striated 
fibers. Collagen is first synthesized as soluble triple-helical procollagen; enzymatic 
cleavage of the terminal propeptides by procollagen metalloproteinases is required to 
convert procollagen to collagen. Without this conversion collagen fibers will not form; 
with the conversion the fibers will self assemble. The fibers are then cross-linked via 
lysyl-oxidase. These fibers provide tensile strength for the tissues they are in, and as such 
the organization of the fibers is very important [158-160]. Collagen hydrogels can be 
easily created; neutralization of acid solubolized collagen will result in fibrillogenesis 
forming a gel at high enough concentrations. The collagen fiber diameter can be 
influenced by temperature with thinner fibers occurring at higher temperatures [161]. 
While collagen is attractive for use as a hydrogel based on it abundance and function, 
there are some issues. Alignment of the fibers in the tissue engineered blood vessel is 
important for strength and is not always easy to obtain [162]. Another concern is that 
when cells are entrapped in a collagen hydrogel, they exhibit little ECM synthesis [163]. 
This fact has led to the investigation of alternative matrix materials for creation of 
biopolymer tissue engineered blood vessels. 
Fibrin 
Fibrin is the structural protein in blood clots and is important to wound healing. 
Prior to clotting, fibrin can be found in its monomeric form, fibrinogen. Fibrinogen is 
enzymatically cleaved by thrombin; after this cleavage the molecules self-associate to 
form linear fibrils. These fibers are eventually degraded by plasminogen [164]. This 
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process can be resisted through use of the inhibitor ε-amino caproic acid. Fibrin has been 
used as a hydrogel for blood vessel tissue engineering; in this matrix smooth muscle cells 
have been shown to synthesis more collagen than when entrapped in Type I collagen gels 
[165].  
Small Leucine Rich Repeat Proteoglycans 
This section reviews a class of proteoglycans. These are some of the smallest 
proteoglycans; there are at least 9 members of the small leucine rich repeat proteoglycan 
(SLRP) family. Domain III of these proteins contains 6-10 repeats of a 24-amino acid 
residue sequence, LxxLxLxxNxLSxL, where L is leucine, isoleucine, or valine and S is 
serine or threonine. There are three classes of SLRPs based on protein and genomic 
organization. Class I consists of decorin and biglycan, two of the smallest proteoglycans 
with much homology and similar functions. Class II includes fibromodulin, lumican, and 
keratocan. Class III includes epiphican and osteoglycin [166-168]. 
Decorin 
Decorin is widely distributed in connective tissues throughout the body and plays 
an important role in collagen fiber formation. In the blood vessel it is found in the 
adventitial layer and to a lesser extent in the medial layer [169]. Decorin binds and 
interacts with a number of extracellular matrix proteins including collagen I, II, III, VI, 
XII, and XIV [170-176], tropoelastin [177], and fibronectin [178, 179], thrombospondin 
[180], and tenascin-X [181]. Through interactions with these proteins, decorin may 
influence cellular phenotype and adhesion [182]. The model structure of decorin is an 
arch shape with a single glycosaminoglycan (GAG) chain. The inner concave surface has 
a size and shape that can accommodate one collagen triple helix which could allow 
decorin to act as a spacer during collagen fiber assembly [183]. The binding of the d-band 
in each D period of collagen has been confirmed experimentally to occur at the leucine 
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rich repeats found in the arch of decorin [184, 185].  
Collagen fiber diameter and packing is affected by decorin and affects fiber and 
tissue strength. On the single collagen fiber level it has been shown that when decorin is 
present during fibrillogenesis, a stronger fiber is formed [186]. At the tissue level, a 
decorin knock-out model showed that lack of decorin resulted in abnormal collagen fiber 
size and alignment and in skin fragility [187]. When decorin is incorporated into a 
collagen hydrogel it has been shown to influence gel compaction. Compaction was 
shown to be delayed in cellularized gels exposed to exogenous or overexpressed decorin 
[188]. A second study showed that overexpression of decorin led to the increased 
compaction of the collagen hydrogel while exogenously applied decorin did not have the 
same effect. The transfected cells that overexpressed decorin also synthesized more 
collagen than empty vector controls [189]. Decorin knockout cells also increase gel 
compaction, most likely due to the dramatic increase in biglycan expression [190]. 
Increased synthesis of collagens I and V was also seen when exogenous decorin was 
added to a three dimensional culture of dermal fibroblasts in their own secreted matrix. 
No difference in collagen fiber diameter was found in the synthesized collagen [191].  
Matrix metalloproteinase (MMP) activity has been shown to be influenced by 
decorin. This influence is important for engineered tissue since too much activity could 
result in loss of mechanical integrity while too little hinder remodeling. When fibroblasts 
overexpressed decorin, MMP-1 and MMP-3 were down-regulated while MMP-2 was up-
regulated. Levels of tissue inhibitors of MMP (TIMP) as well as several cytokines were 
also affected by decorin.[192] Other studies confirm the influence of decorin on MMP 
secretion; however, the effects appear to be dependent on the ECM environment or to cell 
type [193, 194]. 
Decorin is also known to interact with TGF-β. Initial studies showed that decorin 
inactivates TGF-β [195-197]; however, more recent studies show that there is only 
selective inhibition [198, 199]. Binding of collagen and TGF-β is non-competitive, 
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suggesting separate binding sites [200]. This finding along with the finding of inverse 
correlation between decorin expression and TGF-β mediated stimulation of collagen 
hydrogel compaction has led to the hypothesis that decorin is involved in sequestering 
TGF-β rather than inactivating it [201]. This may be supported by the finding that TGF-β 
tethered to cell seeded polymer vascular constructs resulted in greater matrix production 
than when exogenous TGF-β was provided [202]. Additionally, MMP degradation of 
decorin can release TGF-β that is bound in the matrix [203]. Decorin also interacts and 
regulates the function of tumor necrosis factor-α [204], platelet derived growth factor 
[205], fibroblast growth factor-2 [206], and insulin-like growth factor I [207]. Decorin 
plays a role in wound healing, although the exact relationship is yet to be established. 
Expression of decorin is altered during wound healing and scar formation [208-219], and 
decorin deficiency impairs healing [220]. 
Along with its roles regarding matrix synthesis and stability, decorin also has 
effects on cell cycle, cell survival and angiogenesis. Decorin has been shown to suppress 
growth [221-225] through up-regulation of p21 [226]. It has been shown to promote cell 
survival by inhibiting apoptosis [227, 228]. Decorin effects on angiogenesis can be 
inhibitory [220, 229, 230] or promoting [227, 231, 232]. 
Biglycan 
Biglycan is homologous to decorin; the main differences in structure are the 
absence of one oligosaccharide chain and the presence of 2 dermatan or chondroitin 
sulfate chains. Biglycan interacts many of the same extracellular matrix proteins and 
growth factors, including collagen I, II, III, and VI [170, 176, 233], TGF-β [234, 235], 
and TNF-α [204]. Some of the differences may be attributed to proteoglycan distribution, 
biglycan is localized on the cell surface or in the pericellular matrix [236]; it is also 
synthesized by such as endothelial cells that do not constitutively synthesize decorin 
[237] . Biglycan knockouts lead to improper collagen fibril formation and organization 
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much like decorin, but biglycan primarily affects tissues of the musculoskeletal system 
[238, 239]. This along with its abundance in this tissue has resulted in most research 
being done in these tissues. Biglycan does play a role in the cardiovascular system 
though. Knocking out biglycan led aortic dissection and rupture has been reported in 
male mice [240]. Bigylcan is also known thought to play important roles in cardiac tissue 
in both physiologic and pathologic conditions [241]. Pathologically, increased biglycan 
expression by smooth muscle cells is associated with the formation of atherosclerotic 
plaques [242]. Physiologically biglycan is found in native vessels; it has a similar 
localization pattern as decorin with light medial staining and strong adventitial staining 
[243]. Biglycan binds to both tropoelastin and microfibril-associated glycoprotein 1 
(MAGP-1) forming a ternary complex and may play a role in elastinogenesis [177].  
Biglycan has been shown to influence cell proliferation; it has been found to 
enhance cell proliferation and migration [244]. A good review for more information on 
biglycan is [245]. 
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CHAPTER 3: GENERAL METHODS 
Introduction 
This chapter provides descriptions of common methods used in multiple chapters.  
These methods are intended to go into more depth than what is found in the individual 
chapters, but may be generalized slightly when subtle modifications can be made. Any 
deviations to these methods are described in the chapters.  
Cell Isolation and Culture 
Smooth muscle cells from the thoracic portion of the aorta of normal adult 
Sprague-Dawley rats were isolated previously [1]. Briefly, rat aortic smooth muscle cells 
(RASMC) were isolated using the facilitated migration method which combines 
enzymatic digestion and migration techniques. Cells were cultured using standard culture 
conditions of 37°C and 5% CO2. Cells were cultured and expanded in medium consisting 
of Dulbecco’s modified eagle medium (DMEM), 10% fetal bovine serum (FBS), 1% L-
glutamine and 1% penicillin-streptomycin. Experimental work was completed using cells 
between passages 6 and 9 unless otherwise noted. 
Tissue Engineered Vascular Media Fabrication 
Cell seeded collagen hydrogels are used in all experiments; this describes the 
general method for making a tissue engineered vascular media (TEVM). Deviations from 
this general method are sometimes required for specific experiments and are described in 
detail in the respective chapters.  
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Figure 3: TEVM Fabrication. Typically collagen and RASMC are mixed and placed in a tubular 
mold. After the solution gels the hydrogel is removed from the outer mold and placed into culture. 
TEVM Formation 
Prior to TEVM fabrication lyophilized type 1 bovine collagen (MP Biomedical) is 
solubolized in 0.02 N glacial acetic acid. To create the TEVM, RASMCs are trypsinized, 
counted. The appropriate amount of RASMC solution is removed, centrifuged and 
resuspended in culture medium so that there will be a final concentration of 1 x 106 
cells/ml. In a separate tube collagen is added to 5X DMEM and sodium hydroxide to 
neutralize the pH; the amounts are such to have a final concentration of 2 mg collagen/ml 
collagen and a final concentration of 1X DMEM.  The cell solution is then added to the 
collagen solution and the TEVM solution is then placed in a tubular mold and incubated 
at 37°C (see Figure 3). After the solution has polymerized, approximately one hour, the 
TEVM are removed from the outer molds and placed into a dish with culture medium. 
The gels are cut away from the stoppers to promote circumferential alignment of the cells 
and matrix [2]. The TEVM are cultured using standard culture conditions described 
previously. Two different serums were used for construct culture in this work. See 
Appendix A for more information. 
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Contractility Testing 
To test contractility ring sections were placed onto hooks in a physiological organ 
bath shown in Figure 4; each bath contains 5 ml Krebs Hensleit solution with continuous 
gaseous perfusion of 95% O2, 5% CO2 at 37°C [3, 4]. The hooks are connected to a 
force transducer and force changes are captured using a digital data acquisition system 
(Gould Instrument Systems, Valley View, OH). The hook height is adjustable so that a 
preload can be applied to the rings. An array of baths is setup to test multiple ring 
segments at one time; the current setup contains 12 organ baths. One bank of baths 
including the large reservoir containing the Krebs Hensleit solution is shown in Figure 4. 
 
 
          
Figure 4: Individual Organ Bath for Contractility Testing. Ring segments are loaded on wire hooks 
in a physiological organ bath containing Krebs Hensleit solution that is continuously gassed and 
maintained at 37°C. Tubing allows for solution to drain and be refilled. The change in force due to 
contraction or relaxation is measured with a force transducer. 
66 
 
Figure 5: Contractility Ring Test Set Up. One reservoir is used for one bank of 4 baths. 
The TEVM were cut into 2 mm rig segments. The segments were preloaded to 
0.15 g and allowed to equilibrate for 1 hour followed by stimulation with two doses of 
the nonspecific agonist KCl (60 mM, 120 mM). Then the rings were subjected to 
different agonists and antagonists. Unless specified in the individual chapters the method 
depicted in Figure 6 was used. Rings were subjected to the agonist endothelin-1 (10-8 M, 
10-7 M) followed by the antagonist papaverine (10-5 M, 10-4 M), bradykinin (10-5 M, 10-4 
M) and then a second application of  papaverine (Sigma, St. Louis, MO). The maximum 
change in force was recorded. Nominal stress was calculated by dividing the force by the 
cross-sectional area for the unloaded ring segment. Cell number was determined by using 
the Hoechst DNA assay and assuming 7.6 pg DNA per cell; this was used to calculate the 
force per cell. 
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Figure 6: Contractility Test Timeline. This is the procedure used for the majority of the testing. 
Sections are preloaded and equilibrated for 1 hour. The ring sections are allowed to equilibrate for 
30 minutes after each drug dose. Washes are completed between drugs or drug pairings. 
Histology and Immunohistochemistry 
Samples were rinsed in PBS and placed into 4% formalin at room temperature. 
After twenty four hours the samples were rinsed in PBS and transferred to 70% alcohol at 
4°C until processing. The samples were paraffin embedded; 7 µm sections were cut for 
histology and immunohistochemistry (IHC). Samples were deparaffinized prior to 
staining. Histological stains such as Masson’s trichrome and hematoxylin and eosin 
(H&E) were performed using standard histology protocols. 
IHC protocols may vary based on primary antibody; any deviations from this 
protocol will be noted in the chapter where used. After deparaffinization, samples were 
blocked in phosphate buffered saline (PBS) with10% serum for 20 minutes at room 
temperature. The samples were then incubated with the primary antibody in PBS with 
1.5% serum for one hour at 37°C. The samples were rinsed three times in PBS prior to 
incubation with the secondary antibody. The secondary antibody was used in a PBS 
buffer with 1.5% serum and Hoechst dye; samples were incubated for 45 minutes at room 
temperature. The slides were rinsed with PBS three times, coverslipped and imaged. 
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Gelatin Zymography 
Samples were rinsed in PBS and placed in RIPA buffer (Sigma). Hydrogels were 
homogenized using an ultrasonicator and all samples were stored at -80°C until use. Prior 
to protein quantification, samples were centrifuged at 12,000×g for 10 minutes; only the 
soluble protein in the supernatant was used. The protein content was determined using the 
modified Lowry method (Pierce) using albumin standards for the standard curve. 
Gel electrophoresis was performed using Novex 10% gelatin Zymogram gels 
(Invitrogen). Equal amounts of protein in loading buffer were added to each lane. The 
samples were not boiled and were run in nonreducing conditions. Electrophoresis was run 
at 125 V for 90 minutes at room temperature. After electrophoresis the gel was placed in 
renaturing buffer (Invitrogen) for 30 minutes at room temperature with gentle agitation. 
This removes the SDS and allows the proteins to renature. The solution was decanted and 
developing buffer (Invitrogen) was added for 30 minutes at room temperature with gentle 
agitation. Fresh developing buffer was then added and the gel was incubated overnight at 
37°C. The gel was stained with colloidal blue (Invitrogen) for 3-6 hours and then 
destained in dI H2O with gentle agitation overnight; the water was changed three times 
during this time. The gelatin stains blue; areas of MMP activity where gelatin has been 
degraded do not stain and appear clear. The gel was then imaged using the LiCor 
Odyssey imaging system and images were converted to gray scale. An example of a 
scanned zymogram gel is shown in Figure 7. As shown blue molecular weight ladders 
can be visualized using this system. 
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Figure 7: Stained Zymogram Gel. Along with experimental samples is a molecular weight ladder 
(lane 1) and an MMP 2/9 standard (lanes 5 and 10). The proteins are separated by weight using SDS-
PAGE under nonreducing conditions. Zymogen degrades the gelatin leaving unstained bands 
corresponding to the active MMP. 
Statistical Analysis 
Data is expressed as mean ± standard error of the mean. Statistical analysis was 
completed using a 95% confidence interval. Tests with two parameters were completed 
using the Student t-test. For three or more parameters one way ANOVA was used; post 
hoc testing was performed using the Student t-test. 
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CHAPTER 4: THE EFFECTS OF MATRIX TYPE AND PRESENTATION ON 
SYNTHESIS OF COLLAGEN TYPE I AND THE ASSOSCIATED 
PROTEOGLYCANS DECORIN AND BIGLYCAN 
Introduction 
Type I collagen is important for the mechanical integrity engineered tissue. While 
collagen can be added exogenously, the cell synthesized collagen in far superior in 
strength due to improved organization and cross-linking. Decorin and biglycan play key 
roles in collagen fibrillogenesis. These two homologous proteoglycans are part of the 
family of small leucine rich repeat proteoglycans (SLRP) [1, 2]. Knocking out decorin or 
biglycan results in irregularly sized collagen fibrils and fragility in skin [3] and 
orthopedic tissues [4, 5] respectively.  
Decorin is critical in extracellular matrix (ECM) assembly; it interacts with matrix 
materials such as collagen types I, II, III, VI, XII, and XIV [6-12], tropoelastin [13], and 
fibronectin [14, 15]. Decorin affects extracellular matrix production through interactions 
with transforming growth factor-β (TGF-β). Once thought to inactivate TGF-β [16-18], 
decorin is now thought to selectively inhibit [19-21] TGF-β by sequestering it in the 
extracellular matrix [22]. Decorin can bind to both collagen and TGF-β [23]; TGF-β can 
then be release cleavage by MMP-2 [24]. It also interacts and regulates the function of 
tumor necrosis factor-α [25], platelet derived growth factor [26], fibroblast growth factor-
2 [27], and insulin-like growth factor I [28]. Decorin plays a role in tissue remodeling; it 
can modulate matrix metalloproteinase (MMP) activity, although the response varies 
greatly by tissue [29-31]. MMP activity is important for remodeling of tissue engineered 
blood vessels. Non-selective inhibition of MMP activity results in diminished remodeling 
and reduced strength [32]; however, excessive MMP activity can lead to excessive 
extracellular matrix degradation and a reduction in tissue strength [33]. Decorin also 
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plays an important role in angiogenesis. It has been shown to both inhibit [34-36], and 
promote angiogenesis [37-39]. 
Biglycan also interacts with collagen I, II, III, and VI [6, 12, 40]. It may play a 
role in the mechanical integrity of the blood vessel; biglycan deficiency resulted in 
abnormal collagen fibrils in mice resulting in reduced strength and aortic dissection [41]. 
Decreased biglycan expression is also associated with abdominal aortic aneurysm [42]. 
Elastinogenesis is affected by biglycan. Biglycan binds to both tropoelastin and 
microfibril-associated glycoprotein 1 (MAGP-1) forming a ternary complex and may 
play a role in elastinogenesis [13]. Conversely, the glycosaminoglycan chains (GAG) 
have been shown to have an inhibitory role on elastin production [43]. Biglycan can also 
enhance proliferation and migration [44]. 
Decorin and biglycan expression play important roles in compaction of collagen 
hydrogels, which is important for many tissue engineering applications. Decorin 
expression has been shown to affect both collagen [45, 46] and fibrin [47] hydrogel 
compaction. When decorin is knocked out biglycan is up-regulated and collagen gel 
compaction also increases [48]. Expression of both decorin and biglycan are up-regulated 
during wound healing [49-52]. Deficiency of decorin reduces the wound healing response 
[35]. 
This study looks at how the expression of type I collagen, decorin and biglycan is 
affected by both matrix type and architecture. Culture of cells on an adsorbed protein 
versus within a hydrogel is known to affect multiple cell types, influencing cell 
phenotype and gene expression [53-61]. Differences are also seen when cells are cultured 
on top of 2D and 3D matrices [62]. Collagen I and fibrin were chosen as matrix materials 
due to their prevalence in vascular tissue engineering. 
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Materials and Methods 
Cell Isolation and Culture 
Smooth muscle cells were isolated and cultured as described previously.[63] 
Briefly, rat aortic smooth muscle cells (RASMC) were isolated from the thoracic portion 
of the aorta of normal adult Sprague-Dawley rats using the facilitated migration method 
which combines enzymatic digestion and migration techniques. Cells were cultured and 
expanded in medium consisting of Dulbecco’s modified eagle medium (DMEM), 10% 
fetal bovine serum (FBS), 1% L-glutamine and 1% penicillin-streptomycin using 
standard culture conditions of 37°C and 5% CO2. Cells were used between passages 6 
and 9. 
Fabrication of Monolayer (2D) and Hydrogel (3D) Culture Environments 
Two dimensional monolayer cultures conditions were obtained seeding rat SMC 
on adsorbed protein slides. SMC were cultured on either Type 1 dermal bovine collagen 
(Mediatech Cellgro, Kansas City, MO) or fibrinogen (Sigma). Glass slides were coated 
with 1 ml of 0.05 mg/ml protein in phosphate buffered saline (PBS) for 1 hour. The 
excess solution was then gently removed and the SMCs were seeded onto the slides at a 
density of 20,000 cells/cm2. After 30 minutes, 30 ml of cell culture medium were added 
to a dish containing two slides. The culture medium for the fibrin coated slides was 
supplemented with 2 mg/ml ε-amino-caproic acid (ACA) (Sigma) to prevent enzymatic 
degradation of the fibrin. Cells were cultured for 2 days prior to experimentation. Figure 
8 depicts the 2D setup. 
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Figure 8: 2D Culture - Cells on ECM Coated Slide. Collagen or fibrinogen is adsorbed onto a glass 
slide. RASMC are seeded on the slides. 
Three dimensional culture conditions were created by encapsulating RASMC in 
collagen or fibrin hydrogels. All hydrogels contain 2 mg/ml type I collagen or fibrin and 
1 million cells/ml. Collagen hydrogels were made by neutralizing the pH of acid 
solubolized bovine dermal collagen and combining it with rat aortic smooth muscle cells 
and culture medium. Fibrin gels were made by combining fibrinogen, rat smooth muscle 
cells, thrombin (0.1 U/mg fibrinogen) and culture medium containing ACA. Two 
milliliters of the protein/cell solution was placed into a well in a 12 well plate and 
incubated at 37°C for 1 hour to allow the solutions to gel at which time additional culture 
medium was added. The next day the gels were transferred to a 6 well plate and 7 ml of 
culture medium was added. Medium for the fibrin hydrogels contained 2 mg/ml ACA. 
The hydrogels were sampled at 2 and 14 days for experimental work. Figure 9 depicts 
hydrogel fabrication. 
 
Figure 9: 3D Culture - Hydrogel Fabrication and Culture. RASMC are encapsulated in collagen or 
fibrin. After the ECM forms a gel medium is added. The hydrogels are liberated from the walls. 
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RNA Isolation and qRT-PCR 
The RNA from monolayers was isolated using the RNeasy kit (Qiagen, Valencia, 
CA). The slides were rinsed twice with PBS prior to cell lysis; the samples were further 
homogenized using a Qiashredder (Qiagen). Due to the large amount of protein in the 
hydrogels, the RNeasy Lipid Tissue kit (Qiagen) was used to isolate suitable amounts of 
high quality RNA from the hydrogels. The hydrogels were rinsed in PBS, placed in lysis 
buffer and homogenized using a sonicator. For all samples the optional DNase digest was 
completed during all isolations per the RNeasy kit instructions using RNase-free DNase 
Set (Qiagen). 
The cDNA was reverse transcribed from the isolated RNA using Superscript III 
First Strand cDNA synthesis kit (Invitrogen) using oligo(dT) as the primer.  
Quantitative real time polymerase chain reaction (qRT-PCR) was used to study 
gene expression. Primers were designed using Primer Express software (Applied 
Biosystems) and are listed in Table 6. Collagen I expression was assessed by detecting 
the expression of the α1 subunit. SYBR green master mix (Applied Biosystems) was used 
for detection and the PCR reaction was run on a Step One Plus Real-Time PCR System 
(Applied Biosystems). Gene expression was determined using a relative standard curve 
and normalized to 18s. 
Table 6: PCR Primers 
Gene Forward Reverse 
Biglycan TGCTCCCGGTTGGCC GGACTAGGATGTCAGGCTGTCG 
Collagen I GGTGGAGATTCTGGCTTTTGC GAATGTAGGGCTTTGTCCGG 
Decorin TGAAAATGGAGCCTTGCAGG TGAAGGGTCTCGGATACA 
18s TAGAGCTAATACATGCCGACGG TCTGATAAATGCACGCGTCC 
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Western Blot 
Samples were rinsed in PBS, lysed in RIPA buffer with proteinase inhibitors 
(Sigma) and hydrogels were homogenized. When necessary the samples where 
condensed using ethanol precipitation. In order to detect decorin and biglycan the 
samples were treated with 0.3 U/ml chondroitinase ABC for 2.5 hours at 37°C. Equal 
amounts of protein were mixed with loading buffer and the samples were boiled for 5 
minutes at 95°C prior to loading. SDS-PAGE completed using 10% Tris-Glycine gels 
(Invitrogen) followed by protein transfer to a PVDF membrane (BioRad). A prestained 
molecular weight ladder (BioRad) was used to determine molecular weight; acellular 
homogenates or fresh medium were used as negative controls. The membrane was 
blocked in near IR blocking buffer (Rockwell) and then exposed to the primary 
antibodies in Tris-buffered saline with 0.1% Tween 20 (TBS-T). The decorin antibodies 
(LF-113) and biglycan antibodies (LF-159) were generously donated by Larry Fisher 
[64]. Secondary antibodies with fluorochrome in the near infrared spectrum (Rockwell) 
were used for detection. Blots were imaged using the LiCor Odyssey Infrared imaging 
system. 
Collagen Synthesis 
Collagen synthesis was determined using 3H proline. The cells and hydrogels 
were incubated in medium containing 15 µCi/ml 3H proline for 3 hours. The specimens 
were rinsed in PBS. Cells were trypsinized and collected. The hydrogels incubated in 
Proteinase K at 54°C overnight. Radioactivity was determined by counts per minute 
(cpm). Dead cell hydrogels were used for controls. The cpm of the dead cell hydrogels 
were subtracted from the cpm of the 2 and 14 day hydrogels. The cpm was normalized to 
DNA content which was determined by fluorescence of Hoechst 33258 dye binding. Calf 
thymus DNA was used as the standard curve for quantification.  
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MMP Activity 
MMP activity was assessed by gelatin zymography. Samples were rinsed in PBS, 
lysed in RIPA buffer and hydrogels were homogenized using a sonicator. Samples were 
centrifuged at 12,000×g for 10 minutes to remove insoluble protein. The modified Lowry 
method (Pierce) was used for protein quantification. Equal amounts of protein were 
loaded into each lane of a Novex 10% Zymogram (gelatin) gel (Invitrogen). An MMP-
2/9 standard (Millipore) was used for comparison. SDS-PAGE was run under non-
reducing conditions after which the gel was placed in renaturing buffer (Invitrogen) 
followed by incubation overnight at 37°C in developing buffer (Invitrogen). The gel was 
stained with colloidal blue (Invitrogen) and imaged using the LiCor Odyssey imagine 
system; images were converted to gray scale. 
Histology and Immunohistochemistry 
Samples were rinsed in PBS and placed into 4% formalin at room temperature. 
After twenty four hours the samples were rinsed in PBS and transferred to 70% alcohol at 
4°C until processing. The samples were paraffin embedded; 7 µm sections were cut for 
histology and immunohistochemistry (IHC). Masson’s trichrome staining was performed 
on deparaffinized sections. For decorin and biglycan detection sections were incubated in 
chondroitinase ABC at 37°C for 1 hour. Antibodies for decorin (LF-113) and biglycan 
(LF-159) were generously donated by Larry Fisher.  
Statistical Analysis 
Data is expressed as mean ± standard error of the mean. Statistical analysis was 
completed using a 95% confidence interval. Tests with two parameters were completed 
using the Student t-test. For three or more parameters one way ANOVA was used; post 
hoc testing was performed using the Student t-test. 
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Results 
Gene Expression 
Monolayers and disks were cultured for two days prior to isolating the RNA. 
Differences in gene expression were found for collagen, decorin and biglycan; expression 
is affected by both matrix type and presentation. The results are shown in Figure 10. In 
monolayers, cell cultured on fibrin expressed significantly higher amounts of collagen I, 
decorin and biglycan than with cells cultured on collagen. After 2 days of culture in 
disks, the cells within the fibrin matrices still produced more collagen I than the cells 
within the collagen matrices. There were no differences in gene expression for decorin 
and biglycan under these conditions. By 14 days no significant differences are seen with 
respect to the matrix material. The effects of 2D and 3D culture were significant for 
decorin and biglycan expression. The cells cultured on adsorbed fibrin had similar levels 
of decorin expression as those encapsulated within fibrin gels. Once encapsulated in 
collagen the smooth muscle cells up-regulated decorin to the level seen with cells 
encapsulated in fibrin. Biglycan was significantly down-regulated in both matrixes 
compared to cells cultured on adsorbed proteins. Cells within both types of matrix 
produced similar low levels of biglycan. There were no significant differences between 
the hydrogels of the same matrix materials at 2 and 14 days in culture. There is an 
insignificant increase in collagen expression within the collagen gels that may become 
significant with extended culture.  
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Figure 10: Effects of Matrix Type and Configuration on Gene Expression. Collagen (top), decorin 
(middle), and biglycan (bottom) are shown. * = p≤0.05 as compared to collagen monolayers or as 
depicted. Gene expression is affected by both matrix type and 2D/3D configurations. Only collagen 
expression is affected by time in culture in the hydrogels 
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Collagen Synthesis 
Due to the use of type I collagen on the slides and for the hydrogels, radiolabeling 
was used for collagen detection instead of western blotting; the results are shown in 
Figure 11. There was only one instance in which a significant difference between fibrin 
and collagen matrices was seen; at two days there is a significantly greater amount of 
collagen synthesized in fibrin disks versus collagen disks. This is due in part to a 
reduction in collagen synthesis after SMCs are encapsulated in collagen hydrogels. No 
significant differences were seen between monolayers and disks using either matrix after 
2 days in culture. After 14 days in culture collagen synthesis is increased in both collagen 
and fibrin gels compared to their monolayer and two day counterparts. One reason for the 
increased collagen synthesis is that by 14 days in culture the cells start to grow on top of 
the collagen or fibrin hydrogel, as shown in Figure 12. 
Protein Expression 
Western blotting was completed to confirm that the gene expression changes 
resulted in differences in protein expression. Western blots of decorin and biglycan from 
the cell lysates and hydrogel homogenates are shown in Figure 13. Decorin is being 
secreted and retained in both the collagen and fibrin hydrogels. Biglycan expression was 
low and was only seen in the collagen hydrogels after 14 days. Acellular controls were 
used and there was no detectable decorin or biglycan. 
Western blots of the spent medium are shown in Figure 14. While there was more 
decorin in the collagen gels, there is more decorin in the spent medium from the fibrin 
gels. Biglycan was found in the spent medium from the fibrin disks, suggesting that the 
biglycan is not being retained in the fibrin disks. 
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Figure 11: Effects of Matrix Type and Presentation on Collagen Synthesis. Collagen synthesis is 
assessed using tritiated proline incorporation. Results are normalized to DNA content. Cells 
encapsulated in fibrin initially produce more collagen. After 2 weeks in culture more collagen is 
synthesized in both matrices and no difference is seen between collagen and fibrin. 
 
 
    
Figure 12: Masson's Trichrome Staining of 14 Day Collagen (Left) and Fibrin (Right) Disks. 
Collagen is stained blue. A dense ‘cell capsule’ is seen on both the collagen and fibrin hydrogels.  
81 
 
 
Figure 13: Western Blots of Decorin and Biglycan. Samples from left to right: monolayer, 2 day disk, 
14 day disk for both collagen and fibrin. Acellular controls are not shown. More decorin and 
biglycan is found in the collagen disks than in the fibrin disks. Little proteoglycan is found in the cell 
lysates. 
 
Figure 14: Western Blot of Decorin from Spent Medium.  Samples from left to right: monolayer, 2 
day disk, 14 day disk for both collagen and fibrin. Last lane is fresh medium control. More decorin 
and biglycan is seen in the spent medium from the fibrin disks than the collagen disks. 
Cellularity 
Cellularity of the constructs was determined using the Hoechst DNA assay. The 
results were the scaled for volume and are shown in Figure 15. The monolayers have 
fewer cells than the hydrogels, although fewer cells were used initially. The collagen 
disks contain more cells than the fibrin disks. The difference can also be seen in the 
slightly larger cell capsule on the collagen hydrogels versus the fibrin. There is little 
difference in cell number between the disks which suggests an error in the data as there is 
a lack of a cell capsule at day 2. This data is based on the results from the collagen 
synthesis work. It is valuable as a normalizing measure for collagen synthesis but was not 
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completed as rigorously as would be for determining DNA content, especially as pertains 
to the different culture types. 
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Figure 15: Cellularity of the Monolayers and Disks. * is p≤0.05. The monolayers have significantly 
less cells than the disks. Collagen disks contain more cells than the fibrin disks. 
MMP Activity 
Gel zymography was performed to determine MMP activity. MMP activity 
increased in the hydrogels. Latent and active MMP-2 is seen at 68 kDa and 62 kDa 
respectively. In the collagen hydrogel there is a distinct shift from the latent to the active 
form of MMP-2 when placed in the hydrogels as seen in Figure 16. Encapsulation in 
fibrin did not result in a detectable activation of MMP-2. Spent medium samples were 
also analyzed; only the latent form of MMP-2 was detected, see Figure 17. 
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Figure 16: Effects of Matrix Type and Presentation on MMP Activity. Samples from left to right: 
monolayer, 2 day disk, 14 day disk for both collagen and fibrin. The collagen and fibrin samples are 
separated by an MMP 2/9 standard. The last lane is an acellular control. Acellular collagen is shown, 
but both have been have same results. Latent MMP-2 is found in all samples. MMP-2 is activated in 
the collagen hydrogels. 
 
Figure 17: Zymogram of Spent Medium. Samples from left to right: monolayer, 2 day disk, 14 day 
disk for both collagen and fibrin. The collagen and fibrin samples are separated by an MMP 2/9 
standard. The last lane is fresh medium control. Latent MMP-2 is found in all samples. 
Discussion 
There are several limitations to this study. Hydrogels are studied at 2 and 14 days 
of culture while the monolayers are only tested at 2 days. The monolayers could not be 
tested at 14 days as the cells grow on top of each other and can detach from the glass 
slide leading to a very different 3D model. By day 14 both the collagen and the fibrin 
hydrogels had formed small ‘cell capsules’ which also leads to a different 
microenvironment for the cells then the 2 day hydrogels. Only collagen and fibrin were 
chosen as they are popular biopolymer choices for tissue engineering. Certainly there are 
other matrix materials that could be of interest. The monolayer studies were only done 
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with adsorbed collagen and fibrin. Neither the hydrogels nor the monolayers provide an 
environment much like the in vivo condition. Use of higher cell concentrations could be 
an interesting study with different results. The ‘cell sheet’ method may also provide 
insight. A comparison to tissue culture treated plastic may also be of interest. 
Radiolabeling was done for detection of collagen and comparison to the PCR data. This 
method uses tritiated proline which is incorporated into all collagen types and a few other 
proteins, as well as collagen I. 
Collagen I synthesis is important for the mechanical integrity of engineered 
tissues such as blood vessels. The expression of decorin and biglycan are of interest due 
to their role in collagen fibrillogenesis [12, 65-69] and hydrogel compaction [21, 45-48]. 
The 2D and 3D environments are known to have different effects on cells as is the 
extracellular matrix. The three genes studied were all regulated differently with respect to 
matrix type and presentation. In all cases cells grown on adsorbed fibrin had higher levels 
of gene expression than those grown on adsorbed collagen. Fibrin is the structural protein 
in blood clots and plays a key role in wound healing; both decorin and biglycan are 
known to be up-regulated after injury [49-52]. Once encapsulated within the hydrogels, 
no significant differences in gene expression were seen in cells cultured within the two 
different matrices. Differences exist between cells in 2D and 3D culture. Cells within 
collagen hydrogels express decorin at levels similar to cells exposed to fibrin, 
significantly higher than cells cultured on adsorbed collagen. Biglycan is down-regulated 
in cells in 2D culture versus cells in 3D culture. Within the hydrogel biglycan is 
expressed at similar levels for both matrix types. While the increase of decorin may 
suggest a wound healing response, the decrease in biglycan is inconsistent with what is 
seen after arterial injury. The additional culture time had no significant affect on gene 
expression on cells within the hydrogels. The presence of the cell capsule does seem to 
have some affect, and may have an affect on other genes of interest. Time may need to be 
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considered when using these smaller biopolymer hydrogels as model systems for tissue 
engineering applications. 
Collagen synthesis has been shown to be greater in fibrin hydrogels then in 
collagen hydrogels [70]. This study has shown that collagen I gene expression is not 
significantly different in cells within these two matrix materials. Both collagen I gene 
expression and proline incorporation show elevated collagen synthesis in cells within 
fibrin versus collagen at day 2 in this experiment; however, by day 14 the difference no 
longer exists. The change in synthesis is most likely due the different microenvironment 
within the cell dense layer that is not present at day two. The work by Grassl et al [70] 
never discusses a cell capsule. This difference may explain the different outcomes. The 
concentration of ACA in the medium appeared to influence collagen synthesis in the 
Grassl work. This study used a lower fibrin concentration and a higher ACA 
concentration which may affect collagen synthesis in the fibrin hydrogels. The culture 
conditions that were used by this group are not expected to deter cell proliferation on the 
ECM surface; however, differences in serum or ECM lots may influence the cell capsule 
formation. Conversely, the Grassl work uses a higher concentration of neonatal RASMC 
in a smaller hydrogel which may form a cell capsule earlier. This could lead to a different 
microenvironment with a greater cell dense region that may also influence collagen 
synthesis. 
Decorin is known to be retained within fibrin and collagen hydrogels [38, 45, 47]. 
In this study we show that decorin retention in collagen gels is superior to retention in 
fibrin gels. There was significantly more decorin within the collagen hydrogels than the 
fibrin hydrogels and more decorin in the spent medium from the fibrin hydrogels than the 
collagen. 
MMP studies show that cells encapsulated in collagen activate MMP-2 which 
degrades both collagen and decorin [24]. The presence of large amounts of collagen most 
likely triggers this remodeling response, where as there is only small amounts of collagen 
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comparatively within the fibrin gels. Proteolytic degradation is still a problem with fibrin 
hydrogels. ACA must be added to the culture medium or the cells will degrade the matrix 
more rapidly then they can lay down new matrix.  
This study highlights the importance of considering the effects of monolayer 
versus 3 dimensional culture. Many biological studies are completed with cells in 
monolayers which is not how most cells are found in vivo. The results from these studies 
may not directly relate to tissue engineering research where cells are cultured in 3 
dimensional environments. Collagen, fibrin, or other matrix hydrogels can be used as 
model systems for the study of matrix biology and for tissue engineering. Few differences 
were seen in the disks between two and fourteen days; the disk shaped gels require less 
material and short culture times. This would be an ideal model for study of biochemical 
treatments such as transforming growth factor-β. 
Collagen synthesis is important for tissue strength. This study shows that the 
smooth muscle cells produce equal amounts, if not more, collagen in collagen hydrogels 
than in fibrin hydrogels. Collagen gels also do not require the supplementation of enzyme 
inhibitors as do fibrin. The activation of MMP-2 could be problematic, but MMP activity 
has been shown to be important for remodeling and engineered tissue strength [32]. 
These facts led to the choice of collagen for future studies.  
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CHAPTER 5: VASOACTIVITY OF A COLLAGEN BASED TEVM 
Introduction 
Tissue engineering of small diameter blood vessels has long been considered the 
‘Holy Grail’ of tissue engineering due to the need for a material for bypass grafting that 
will remain patent.[1] An engineered blood vessel must be non-thrombogenic, have 
similar mechanical properties and be vasoactive. While much work has focused on the 
first two requirements, there has been little investigation of the vasoactive response. One 
reason may be that vascular smooth muscle cells in culture revert to a more synthetic 
phenotype, losing much of their contractile proteins and reducing their capacity to 
respond to vasoconstrictors and vasodilators [2, 3].  Even with these concerns, contractile 
responses have been shown with tissue engineered vascular media (TEVM) made with 
umbilical cord derived [4-7], neonatal [8, 9], and adult smooth muscle cells (SMC) [10-
13]. While some of these TEVM come close, none match the response of native blood 
vessels. 
Regulation of vascular tone is regulated by both intrinsic and extrinsic factors to 
meet the needs of local tissue and the body as a whole. In addition to the numerous 
classes of receptors, many receptors have multiple subtypes that can actually elicit 
different vasoactive responses. Adrenaline causes vasoconstriction when it acts as an α-
adrenoceptor agonist and vasoconstriction when it is an agonist of the β-adrenoceptor 
[14]. Likewise, bradykinin is known as a vasoconstrictor, but the bradykinin B2 receptor 
can trigger contraction in veins [15, 16]. A biphasic response has been seen in veins and 
arterioles [15, 17, 18].  
Endothelin-1 is one of the most potent agonists known [19]; it is used to study the 
contractile response in most of the reported studies along with bradykinin. In this study 
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we are investigating the vasoactive response of adult rat SMCs. We study the response 
over time and tested for the responses to different classes of vasopressors and 
vasodilators. 
Materials and Methods 
Cell Isolation 
Smooth muscle cells from the thoracic portion of the aorta of normal adult 
Sprague-Dawley rats were isolated as previously described [20]. Briefly, rat aortic 
smooth muscle cells (RASMC) were isolated using the facilitated migration method 
which combines enzymatic digestion and migration techniques. Cells were cultured using 
standard culture conditions of 37°C and 5% CO2. Cells were cultured and expanded in 
medium consisting of Dulbecco’s modified eagle medium (DMEM), 10% fetal bovine 
serum (FBS), 1% L-glutamine and 1% penicillin-streptomycin. Experimental work was 
completed using cells between passages 6 and 10 unless otherwise noted. 
Porcine aortic smooth muscle cells were isolated and expanded using the same 
facilitated migration technique. Smooth muscle cells were isolated from the abdominal 
aorta of neonatal Yorkshire piglets. Cells were used between passages 5 and 8. 
Human aortic smooth muscle cells were purchased from Lonza. Lonza’s smooth 
muscle cell growth medium-2 was used for cell expansion. Cells were used between 
passages 5 and 7. 
Tissue Engineered Vascular Media Fabrication 
Tissue engineered vascular media (TEVM) were made as described 
previously.[20] Rat aortic smooth muscle cells were used unless otherwise noted. The 
smooth muscle cells were incorporated into a type 1 collagen hydrogel for final 
concentrations of 1 million cells/ml and 2 mg/ml collagen. The collagen-cell solution was 
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placed into the tubular mold and allowed to polymerize. The hydrogel was then removed 
from the mold and placed into culture in medium consisting of Dulbecco’s Modified 
Eagle Medium (DMEM, Mediatech Cellgro), 10% bovine growth serum (Hyclone, 
Logan, UT), 1% L-glutamine and 1% penicillin–streptomycin (Gibco, Grand Island, NY) 
unless noted. Culture medium was changed weekly.  
Contractility Testing 
TEVM were cut into 2 mm long rings that were mounted on hooks in a 
physiological organ bath of 5 ml Krebs Henseleit solution with continuous of 95% O2, 
5% CO2 at 37°C [21-24]. The segments were preloaded to 0.15 g; the rings were first 
stimulated with the nonspecific agonist KCl (60 mM). Unless noted, the ring segments 
were then subjected to endothelin-1 (10-8 M, 10-7 M) or bradykinin (10-5 M, 10-4 M); both 
were followed by the antagonist papaverine (10-4 M) (Sigma, St. Louis, MO). Changes in 
tension due to chemical stimulation were measured using a digital data acquisition system 
(Gould Instrument Systems, Valley View, OH). The maximum change in force was 
recorded. Nominal stress was calculated by dividing the force by the cross-sectional area 
for the unloaded ring segment. 
Also used in this study were phenylephrine, 5,6,7,8-tetrahydro-6-(2-propenyl)-
4H-thiazolo[4,5-d]azepine-2-amine dihydrochloride (BHT-920), isoproterenol, ATP 
disodium salt, 5-hydroxytryptamine (5-HT), and sodium nitroprusside (SNP). All were 
purchased from Sigma. 
Statistical Analysis 
All graphs are shown as mean ± SEM. Statistical analysis was completed using a 
95% confidence interval. Tests of two parameters were completed using a t-test. Tests of 
three or more parameters were completed using one way ANOVA with a post hoc t-test. 
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Results 
Time Course 
Up to now contractility in collagen hydrogels has not yet been demonstrated by 
either our group or any others except with a high concentration of low passage cells.[13] 
The response was measured weekly between 2 and 8 weeks in culture (Figure 18). While 
there are no statistical differences in contractility between the weeks, the response to 
endothelin-1 seems to peak around week 3 while bradykinin appears to provoke the 
maximum response at 4 weeks. There is significant batch to batch variability; if this 
variability could be reduced statistical differences might be seen or a more consistent 
contractile response might be found. To better understand the variability, the contractile 
response of the passage number of the TEVM in the time course was investigated and is 
shown in Figure 19. The cells used for this study were between passage 6 and passage 10; 
there is no significant difference in the contractile response as a function of passage. 
Differences due to batch are significant. 
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Figure 18: Contractile Force as a Function of Culture Time. No significant differences in response 
are found. 
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Figure 19: Contractile Force as a Function of Cell Passage. Shown is the data combined (left) and by 
week in culture (right). No differences due to passage number are found. 
While the most significant variation was batch to batch, there was still some 
variability within the batches. For a subset of the rings tested the ring location from the 
TEVM was noted. The ring locations are noted in Figure 20, and the results are shown in 
Figure 21. The center rings produce a greater contractile force in response to endothelin-1 
than the end segments. This is true only for endothelin-1 and not for bradykinin. There is 
a similar trend with papaverine, but this is most likely due to the fact that the initial 
contractile force is higher and may not actually be an enhanced response to the 
antagonist. The results thus may be slightly misleading. While there is a significant 
difference, the difference does not always hold. In at least one batch the end segments 
actually produced the greatest response to both agonists. The ring location was not noted 
for every test, so there is significantly less data than for the time course or the passage 
number study.  
 
Figure 20: TEVM Sections. Locations noted are the end segments (A), the midsections (B), and the 
center (C). 
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Figure 21: Contractile Force of Ring Segments Based on Position in TEVM. There are significant 
differences in the response of the rings from the ends versus the rings from the center of the TEVM. 
Response to Different Agonists and Antagonists 
To get a better understanding of which receptors were present and functional, 
several agonists and antagonists were chosen. Representative responses to the chosen 
agonists and antagonists are shown in Figures 22 through 31. Unless noted the bars 
shown are 10 mg in the y-direction and 1 minute in the x-direction. Arrows indicate the 
dosage of the drug in mM. All rings were stimulated with the non-specific agonist KCl 
prior to application of other drugs. A representative response to KCl is shown in Figure 
22. 
 
 
Figure 22: Representative Response to KCl 
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To look at responses to endothelial cell secretions, responses to endothelin-1 and 
SNP were measured. Endothelin-1, shown in Figure 23, was the most potent 
vasoconstrictor tested.  Endothelin-1 is an agonist of the endothelin receptors, ETA and 
ETB. SNP, a nitric oxide donor, was used to try to elicit a relaxation response. The rings 
that relaxed did so very slowly, in some cases more slowly than untreated rings. A 
representative response to SNP when relaxation was seen is shown in Figure 24. It is 
probable that this is not a receptor mediated response, but a naturally occurring non-
receptor mediated relaxation. A representative force trace showing lack of response is 
shown in Figure 25. 
 
 
Figure 23: Representative Response to Endothelin-1 
 
 
Figure 24: Representative Response of SNP When a Response was Present 
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Figure 25: The Lack of Response to SNP 
The response to bradykinin is shown in Figure 26. Bradykinin interacts with the 
bradykinin receptors B1 and B2. Bradykinin can elicit a contractile or dilatory response 
depending on the receptors involved. In this model of the media, bradykinin elicits a 
contractile response. 
 
 
Figure 26: Representative Response to Bradykinin 
There are four adrenergic receptors: α1, α2, β1 and β2. Phenylephrine is an α1 
agonist; the response to phenylephrine is shown in Figure 27. The response appears to be 
dose dependent; a contractile response is seen with the higher doses of phenylephrine. 
BHT-920 is an α2 agonist; the data is shown in Figure 28. In each case an excellent 
contractile response to endothelin-1 was observed after the last dose of BHT-920 
demonstrating that the vessels were vasoactive. There may have been a small drug-
induced relaxation from baseline. This may be receptor mediated or may be a non-
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specific tissue relaxation.  To test for the presence of β receptors, isoproterenol was 
given. A dose responsive relaxation is seen (see Figure 29). 
 
Figure 27: Representative Response to Phenylephrine 
 
 
Figure 28: Representative Response to BHT-920 Followed by a Dose of Endothelin-1(*) 
 
Figure 29: Representative Response to Isoproterenol 
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The presence of purinergic receptors was confirmed using ATP. Contraction was 
evident after ATP was given, although the contractions were short lived with the smaller 
doses (see Figure 30). 
 
Figure 30: Representative Response to ATP 
 5-HT, also known as serotonin, was used to look for the serotonergic receptors. 
There appears to be a biphasic response, with the highest dose resulting in the highest 
contraction (see Figure 31). 
 
 
Figure 31: Representative Response to 5-HT 
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A summary of the results of the drugs tested is found in Table 7. Most of the 
drugs elicited a vasoactive response. 
Table 7: Summary of Responses to Drugs 
Drug Receptor Response 
KCl Non-specific Contraction 
Endothelin-1 ETA and ETB  Contraction 
SNP NO  No response 
Bradykinin Kinin B1 and B2  Contraction 
Phenylephrine α1-adrenergic Biphasic 
BHT-920 α2-adrenergic No response 
Isoproterenol β-adrenergic Dilation 
ATP Purinergic Contraction 
5-HT Serotonergic Fair Contraction 
 
Contractility and Species 
Contractility testing was completed on TEVMs made with human, rat and pig 
SMC. Only the vasoconstrictors endothelin-1 and bradykinin were tested. All species 
responded to the agonists; no significant differences in the amplitude of the response 
were seen between species, this is shown in Figure 32. 
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Figure 32: Contractile Force due to Species Difference. There are no significant differences in 
contraction between species. 
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Discussion 
The majority of the work was done with rat smooth muscle cells; however, some 
studies were performed between species. The response to endothelin-1 and bradykinin 
was found to be similar across the species tested, but that may not be the same for the 
other drugs tested. While rat smooth muscle cells are easy to obtain and grow and are 
used often, they are very different from the human cells that would most likely be 
required for an implantable graft or for a pharmacological model. Cells in this study were 
used up to passage 10 with rats. This is much higher than would be used with human 
cells. While no differences in vasoactive response were seen with passage with rat cells, 
this may not be the case when human cells are used. 
For this study only force data is being presented since the wall thickness and cell 
content was not measured for all samples. Traditionally the contractile response is 
reported as force or as a percentage compared to the maximum response to ATP. While 
this is sufficient to study the response, stress is a more appropriate measure for 
comparison of samples with different wall thickness or lengths.  
The majority of the work in this and the following chapters focuses on the 
response to endothelin-1, bradykinin, and papaverine. While other agonists and 
antagonists were investigated, the number of replicates is small. This thus allows for a 
discussion of the presence of function, but not for a complete assessment of the presence 
of certain receptors or the magnitude of the response with much confidence.  
The TEVMs maintained a consistent vasoactive response between 2 and 8 weeks, 
consistent with a similar study of the cell sheet TEVMs [6]. The cell passage number had 
no effect on the response within the range tested. There are spatial effects to the TEVM 
contractility. While not consistent, the ring segments in the center of the graft in general 
produced a larger contractile force than those close to the ends. Creation of a longer 
TEVM may allow for more rings with less variability.  
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While not completely characterized, the cells in the TEVMs have functional 
endothelin, bradykinin, adrenergic, purinergic and serotonergic receptors. The contractile 
response to bradykinin shows the presence of the B2 bradykinin receptor. The response to 
the α2-adrenergic receptor agonist was lacking, as was a clear response to SNP. The 
TEVM can dilate as shown with isoproterenol, so the receptors may be lacking. It is 
possible that culturing with endothelial cells may affect the presentation and function of 
the receptors, but cell-sheet TEVMs without endothelial cells have responded to SNP [6].  
In comparison with the literature, this study has more extensively tested 
vasoactivity in response to both vasopressors and vasodilators than most. The cell sheet 
TEVMs model is the best characterized. It has been shown to be a good model for 
pharmacological studies, employing a variety of agonists and antagonists [6]. Several 
studies of the endothelin receptors have also been completed [10, 25]. The PGA-based 
TEVMs have shown responses to prostaglandin F2α, serotonin and endothelin-1 [11, 12, 
26]. Fibrin based TEVMs have shown responses to KCl, norepinephrine and the 
thromboxane A2 mimetic U-46619 [5, 7-9]. Only one study has been done with collagen; 
it used high numbers of lower passage cells. While it is a TEVM, only small rings were 
made to investigate the role of RhoA in the regulation of contractility. The agonists tested 
were K+, bradykinin, histamine and endothelin [13]. This work shows that a larger panel 
of vasopressors and vasodilators are required to show a fully functional TEVM. For 
example, Swartz et al. [5] have demonstrated that their fibrin based TEVM are responsive 
to norepinephrine. Norepinephrine is an α-adrenoceptor agonist, it is possible that as in 
the present work the response is due to the α1-adrenoceptor alone and that the α2-
adrenoceptor may not elicit a response. 
While there was a measurable response to most agonists, it was less then native 
tissue and less than found with TEVM made using the cell sheet method [6]. Compared 
to the other collagen TEVM, the effects of bradykinin and endothelin-1 were different. Bi 
et al. saw a more potent reaction to bradykinin, with endothelin-1 producing the weakest 
108 
response [13]. This study saw the strongest response to endothelin-1, with bradykinin 
eliciting a smaller response. There are multiple factors that might play a role including 
cell density, cell source and cell expansion methods as well as the order in which the 
drugs were used. The TEVMs in this study have a rather large sparsely populated 
collagen inner layer with a highly cellular cell layer around this. As for cell source, this 
work has shown no difference in response between adult human and rat cells. The cell-
sheet work used human umbilical vein smooth muscle cells, which may influence the 
vasoactive response [27]. There may be ways to improve the vasoactive response. Cyclic 
strain, transforming growth factor-β (TGF-β) and platelet derived growth factor [20] have 
been shown to influence smooth muscle cell phenotype and may result in a stronger 
contraction. The combination of TGF-β and insulin has been shown to improve 
contractile force [9]. 
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CHAPTER 6: CYCLIC STRAIN IMPROVES TEVM MECHANICAL 
PROPERTIES AND VASOACTIVITY 
Introduction 
Autologous blood vessels, veins or arteries, are the “gold standard” for both 
coronary and peripheral arterial bypass grafting. However, many patients do not have 
veins suitable for grafting [1]. This has resulted in research into tissue engineered blood 
vessels (TEBV) as a potential alternative source of vascular grafts for patients.  
Experimental and clinical vein grafting indicates that it is not necessary to implant a fully 
developed artery as veins undergo arterialization upon transplantation [2]; therefore, our 
ultimate clinical and commercial target for blood vessel engineering should be a construct 
that can be sutured, is non-thrombogenic and non-immunogenic, able to withstand 
arterial pressures, compliant enough to form non-hyperplastic anastomoses, and 
vasoactive [1, 3, 4]. 
The medial layer of the blood vessel is responsible for the mechanical integrity 
and vasoactivity of blood vessels and is an important are of focus for tissue engineering. 
The application of cyclic strain has been used to provide a more physiological 
environment for tissue engineered vascular media (TEVM) culture; cyclic strain of 
TEVM has been shown to increase tissue strength [5-12], increased ECM deposition [6, 
11-14] and improved smooth muscle cell alignment [5, 15]. Only a few studies have 
shown an increase in contractile protein expression in TEVM [13, 15, 16]; however, 
studies stretching monolayers of cells adhered to silicone sleeves have also shown 
improvements in contractile protein expression with the application of stretch [17-19].  
Vasoactivity is a desirable trait for a TEVM; however, it may be difficult to 
achieve in a commercially viable TEVM. One issue with a TEVM is that, to create 
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enough tissue for a graft, large numbers of cells are needed. To this end much of the work 
has used primary cells cultured out several passages. After a short time in culture these 
cells shift to a more synthetic phenotype, losing much of their contractile proteins and 
reducing their capacity to respond to vasoconstrictors and vasodilators [20].  Even with 
these concerns, contractile responses have been shown with a TEVM made with 
umbilical cord derived [21-24], neonatal [25, 26], and adult smooth muscle cells (SMC) 
[13, 27, 28] as well as bone marrow progenitor cells [24]. Cyclic strain may improve the 
vasoactive response of the TEVM through improvements in cell alignment and 
phenotype. 
Typically TEVM are subjected to cyclic strain very early in culture; this 
significantly increases compaction of a hydrogel-based TEVM [5, 16]. A concern with 
this is that longitudinal compaction suggests incomplete adherence of the tissue to the 
silicone sleeve which is important for application and recovery of strain. To overcome the 
issue with compaction of the hydrogels one group has investigated the use of collagen 
cross-linking after hydrogel compaction ceased [6]. This study aims to build upon our 
previous work investigating how cyclic strain affects TEVM strength by improving the 
gel adherence to the sleeve to better control the applied strain and then study effects of 
strain on the mechanical properties and vasoactivity. 
Materials and Methods 
Tissue Engineered Vascular Media Fabrication 
Rat aortic smooth muscle cells (SMC) were isolated previously from Sprague-
Dawley rats weighing ~300-350 g [16]. The cells were isolated using a facilitated 
migration method which combines enzymatic digestion with cell migration from the 
partially digested tissue. The cells were expanded and used between passages 6 and 9. 
The TEVM were fabricated as described previously [5]. Briefly, prior to TEVM 
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fabrication the silicon sleeves were etched with 10 N sulfuric acid, rinsed and sterilized. 
The sleeves were coated in a 1 mg/ml type 1 bovine collagen (Mediatech Cellgro, Kansas 
City, MO) solution to aid gel adherence; the sleeves were placed onto glass mandrels 
used in the tubular molds. TEVM were created by neutralizing acid solubolized type 1 
bovine collagen (MP Biomedicals, Solon, OH) and adding SMCs for final concentrations 
of 1 million cells/ml and 2 mg/ml collagen. The collagen-cell solution was placed into the 
tubular mold and incubated at 37°C. After polymerization, the hydrogel on the inner 
mandrel was then removed from the outer mold and placed into culture medium 
consisting of Dulbecco’s Modified Eagle Medium (DMEM, Mediatech Cellgro), 10% 
bovine growth serum (Hyclone, Logan, UT), 1% L-glutamine and 1% penicillin –
streptomycin (Gibco, Grand Island, NY). The gel was cut away from the stoppers and 
cultured statically for two weeks unless otherwise noted. This was done to allow for gel 
compaction and adherence of the gel to the silicone sleeve. Culture medium was changed 
weekly.  
Compaction Assessment 
Hydrogels were made as described with the exception that 2 ml of solution was 
placed in a well dish to create a disk shape. The gels were gently detached from the sides 
of the dishes and cultured in an unconstrained condition. At 2, 7, 14, 21, 28, 35 and 42 
days disks were removed from culture and the volume assessed using volumetric 
displacement. A 10 ml volumetric flask was filled with DMEM for better visualization. 
The disks were rinsed in PBS and excess fluid was gently removed using a kimwipe. The 
disk was then added to the flask and the excess liquid removed so that the volume was 
reduced to the original volume. The displaced volume represents the compacted volume 
of the construct. The volumetric flask conforms to ASTM E 237 and the volume was 
assessed as described in ASTM E 542. 
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Cyclic Strain 
Cyclic strain was applied to the collagen TEVM using a system previously 
developed in our lab [5]. Unlike previous studies, TEVM were cultured for two weeks to 
allow compaction to cease prior to the application of strain. The tubular constructs on the 
silicone sleeves were mounted on hollow mandrels in the strain bioreactor containing 300 
ml of culture medium.  The lumen and reservoir were filled with culture medium. Two 
0.2 µm filters were placed in the vents in the lid to allow for oxygen exchange. The 
bioreactor was placed in a CO2 incubator at 37°C, and connected to a filtered regulated 
air supply. The pneumatic pressure was controlled in order to produce 10% 
circumferential strain at a rate of 1 Hz. TEVM were cyclically strained for 5 days; 
statically cultured controls were used for comparison. At the conclusion of testing, the 
TEVM were gently removed from the silicon sleeves prior to testing. 
Tensile Testing 
TEVM were cut into 5 mm rings; black beads of approximately 300 µm were 
affixed to one side of the rings in order to measure strain.  The segments were mounted 
onto hooks in a phosphate buffered saline (PBS) bath on an Instron single column test 
system (Instron). The rings were preloaded to 0.3 mN and precycled for five cycles to 
approximately 20% of the yield strain. The rings were then loaded to failure at a constant 
strain rate of 0.2 mm/s. 
 
Figure 33: Uniaxial Tensile Test of Ring Sample. Shows frames from 6 timepoints in the test. 
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 Matrox Inspector 8 was used to capture and analyze images taken during the test.  
Wall thickness was measured in order to determine cross-sectional area and calculate 
stress. Bead displacement was tracked so that local strain could be calculated (see Figure 
33). The recorded force and displacement data were then converted to stress and strain 
where the ultimate tensile strength, yield strength and elastic modulus could then be 
determined. 
Contractility Testing 
TEVM were cut into 2 mm long rings that were mounted on hooks in a 
physiological organ bath of 5 ml Krebs Henseleit solution with continuous gaseous 
perfusion of 95% O2, 5% CO2 at 37°C [29-32]. The segments were preloaded to 0.15 g 
for 60 minutes; the rings were first stimulated with the nonspecific agonist KCl (120 
mM). Responses to the vasoconstrictor endothelin-1 10-8 M, 10-7 M) or bradykinin (10-5 
M, 10-4 M) and followed by the antagonist papaverine (10-5 M, 10-4 M) (Sigma, St. Louis, 
MO). Changes in tension due to chemical stimulation were measured using a digital data 
acquisition system (Gould Instrument Systems, Valley View, OH). The maximum change 
in force was recorded. Nominal stress was calculated by dividing the force by the cross-
sectional area for the unloaded ring segment. 
MMP Activity Assay 
To determine the MMP activity, gelatin zymography was performed. Ring 
segments were rinsed in PBS, placed in RIPA buffer (Sigma) and homogenized using an 
ultrasonicator. Samples were stored at -80°C until use. Prior to protein quantification, 
samples were centrifuged at 12,000×g for 10 minutes. The protein content of the 
supernatant was determined using the modified Lowry method (Pierce) with albumin 
standards for comparison. 
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Gel electrophoresis was performed using Novex 10% Zymogram (gelatin) gels 
(Invitrogen). Equal amounts of protein in loading buffer were added to each lane. MMP 
2/9 standards (Millipore) were used for determination of molecular weight; acellular 
hydrogels or fresh medium were used for controls. After electrophoresis the gel was 
placed in renaturing buffer (Invitrogen) followed by overnight incubation at 37°C in 
developing buffer (Invitrogen). The gel was stained with colloidal blue (Invitrogen) for 3-
6 hours and then destained in water. The gel was then imaged using the LiCor Odyssey 
imaging system and images were converted to gray scale. 
DNA Quantification 
Segments of the tissue were taken, rinsed in PBS and lyophilized using a 
Freezone freeze dry system (Labconco). The tissue was digested in 0.5 mg/ml Proteinase 
K in phosphate buffer with EDTA at 60°C. The samples were loaded in triplicate into a 
96 well plate along with DNA standards diluted from calf thymus DNA (Sigma) stock 
solution. The samples were incubated for 15 minutes at room temperature with 0.1 µg/ml 
Hoechst 33258 dye in 10 mM Tris-HCl buffer with 1 mM EDTA and 0.2 M NaCl. The 
plate was read on a flurometer using an excitation wavelength of 365 nm and emission 
wavelength of 458 nm. DNA quantity was determined by comparing to the standard 
curve made from calf thymus DNA (Sigma). The DNA content was converted to cell 
number assuming 7.6 pg DNA/cell [33]. The results were normalized to dry weight to 
account for differences in amount of tissue. 
Collagen Quantification 
TEVM sections were digested in 0.5 mg/ml Proteinase K. Digested samples and 
collagen I standards were added to 0.8 mM direct Sirius red dye in 0.5 M acetic acid. The 
samples were centrifuged at 10,000×g for 15 minutes and the supernatant loaded into a 
96 well plate in triplicate. The plate was read on a spectrophotometer at 540 nm 
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wavelength. The collagen content was determined by comparison the standard curve and 
normalized to dry weight to account for differences in amount of tissue. 
Histology and Immunohistochemistry 
Samples were fixed in 4% formalin, paraffin embedded and sectioned. The 7µm 
thick sections were deparaffinized and stained with Masson’s Trichrome. Smooth muscle 
alpha actin was studied employing antibodies and immunofluorescent microscopy. Slides 
stained with Masson’s trichrome were imaged using a standard light microscope. 
Fluorescently labeled slides were imaged using a Zeiss confocal microscope. 
Statistical Analysis 
All graphs are shown as mean ± SEM. Statistical analysis was assessed using a 
95% confidence interval. Tests of two parameters were assessed using a Student’s t-test. 
Tests of three or more parameters were assessed using one way ANOVA with a post hoc 
t-test. 
Results 
Gel Compaction 
Volumetric displacement measurements of disk shaped hydrogels were performed 
to determine the duration of compaction with our TEVM. Disks were chosen since the 
starting volume could be better controlled. More than 50% of the gel compaction 
occurred during the first 2 days of culture; however, measurable compaction was 
observed for 2 weeks (Figure 34). Girten et al. showed that in a similar TEVM 
measurable compaction continued until 2 weeks in culture. The volumetric data showed 
similar results to Girten et al. where tubular sections were used [34]. 
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Figure 34: Volumetric Compaction Over Time   * = p≤0.05 when compared to the previous 
timepoint. There is significant compaction up to 2 weeks in culture. 
In previous studies, the TEVMs were subjected to cyclic strain after just 2 days in 
static culture. Under these conditions significant changes in longitudinal compaction are 
seen suggesting incomplete adherence to the silicone sleeve that [5, 16]. Since adherence 
to the silicone sleeve is important for controlling strain amplitude of the tissue, the initial 
culture time was increased to 2 weeks to allow for the construct compaction to cease 
before strain was applied. By waiting two weeks instead of two days, the TEVMs were 
more firmly attached to the silicone sleeves. This was seen first in the improved handling. 
The younger constructs had to be handled very carefully and could be easily detached 
from the sleeves while mounting them in the bioreactor. The two week old constructs 
were not as easily dislodged.  
 The firmer attachment also resulted in a difference in gel compaction. Unlike the 
two day old constructs, no longitudinal compaction was visible as seen in Figure 35. 
While no changes in length were visible, radial compaction still increased. The wall 
thickness of the cyclically strained TEVM was slightly thinner than that of the statically 
cultured controls, 0.41 mm and 0.48 mm respectively (see Figure 36).  
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Figure 35: Compaction of TEVM. The culture conditions were statically cultured for 2 days (A), 
statically cultured for 2 weeks (B), 5 days of cyclic strain applied after 2 days (C), and 5 days of cyclic 
strain applied after 2 weeks (D). Delaying application of strain allows for better adherence and 
eliminates the longitudinal compaction (D) seen when TEVM are exposed to strain at 2 days (C). 
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Figure 36: Wall Thickness TEVM. TEVM were cultured for 2 weeks statically followed by 5 days of 
cyclic strain or additional static culture. Strained samples have a thinner wall than the strained 
samples. 
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Effect of Cyclic Strain on Vasoactivity 
Preliminary physiology studies were performed and showed a consistent 
contractile response from 2 to 8 weeks in static culture. This contributed to the choice of 
5 days of cyclic strain after the initial 2 weeks of static culture. Upon completing the 5 
days of strain or static culture, the TEVMs were cut into rings and contractility testing 
was performed on the segments. The contractility data is presented three ways (Figure 
37), each of which gives slightly different information. First it is presented as the 
maximum recorded force. This is traditionally the way contractility data has been 
presented and is acceptable for comparing homogeneous samples. Nominal stress was 
calculated by dividing the measured force by the unloaded cross-sectional area. This 
allows for better comparisons across heterogeneous samples and gives us properties of 
the tissue. The force per cell is also calculated by dividing the force by the number of 
cells determined by the Hoechst DNA assay. This assessment shows differences in 
contractile forces that the cells are exerting, but differences in cell number and 
mechanical properties of the tissue can confound the results. The results of this study 
show that the application of cyclic strain resulted in a significant increase in contractile 
stress in response to endothelin-1 as well as an increased relaxation in response to 
papaverine. The response to bradykinin was not significantly different after application of 
strain. The improved response to papaverine may be due to the improvement in 
contraction since the relaxation force cannot exceed the load on the ring. The same trends 
are present regardless of analysis method; however, the statistical significance of the 
responses to endothelin-1 and papaverine are lost when normalized to cell number. 
Effects of Cyclic Strain on Mechanical Properties 
Uniaxial tensile testing was completed to assess the mechanical properties of the 
strained and statically cultured TEVM. The mechanical stimulation enhanced the strength 
of the engineered tissue in this study by more than 20%, without the large gel compaction 
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seen previously. The modulus of elasticity was also higher although not significantly (see 
Figure 38). The increase is due in part, but not entirely, to the thinner wall. The average 
forces are also higher suggesting that there are other factors involved. Representative 
stress-extension curves are shown in Figure 39. Extention is shown instead of strain as 
the strain measurements taken are only valid for the linear portion of the curve. 
MMP Activity 
Gelatin zymography showed little gelatinase activity other than that of MMP-2. 
All samples showed the presence of MMP-2. In Figure 40, the 72 kDa band corresponds 
to latent MMP-2 and the 68 kDa band corresponds to activated MMP-2. The 
homogenates contained both latent and active MMP-2 and the strained samples had more 
active MMP-2 than the static controls. The spent medium from the static controls 
contained more MMP which is surprising since the medium to construct volume is 
consistent between the two experimental groups. While there might be differences in 
latent MMP-2 in the spent medium, neither sample contained significant amounts of 
activated MMP-2.  
TEVM Composition 
Masson’s trichrome staining was used to look at collagen content as well as 
overall general tissue composition. This staining demonstrated a more compact hydrogel 
layer and more circumferentially aligned cells in the strained TEVM, (see Figure 41). 
The cell layer in the strained TEVM had more collagen staining than the statically 
cultured TEVM. The increased collagen content in the strained TEVM was confirmed 
with the Sirius red assay (see Figure 42). Unlike previous studies, using this regimen 
DNA quantification showed no difference in the amount of DNA per dry weight (Figure 
43). 
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Figure 37: Contraction and Relaxation Data for Static and Strained Samples. The data is presented 
as maximum measured force (A), as well as the calculated values for force per cell (B), and nominal 
stress (C). The trends remain the same for all analysis methods, although the statistical significance is 
affected by the normalization to cell number. Strained samples have a greater contraction in 
response to endothelin-1 than the static controls. No significant differences in response to bradykinin 
are seen. 
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Figure 38: Mechanical Properties of TEVM Subjected to Cyclic Strain and the Static Controls. The 
strained TEVM are stronger than the static controls. 
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Figure 39: Representative Stress-Extension Curves for Static and Strained Samples. Static is shown 
on the left. Strained is shown on the right. 
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Figure 40: Zyomograms. Samples shown are for tissue homogenates (A) and spent medium (B). The 
samples run in each case are an acellular or medium only control (lane 1), statically cultured (lane 2), 
and cyclically strained (lane 3).  There is more active and latent MMP-2 in the strained TEVMs. 
 
Figure 41: Masson's Trichrome. Statically cultured (Left) and cyclically strained (Right). Collagen is 
stained blue. 
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Figure 42: Collagen Content as Assessed by Sirius Red. Collagen content is greater in the strained 
TEVMs than in the static controls. 
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Figure 43: Cellularity of Static and Strained TEVMs. There are no significant differences in the 
cellularity of the static and strained TEVMs. 
The TEVM were stained for smooth muscle α-actin. All of the TEVM had 
positively stained samples; however, the strained samples had more staining (see Figure 
44), most of which was located in the cell capsule rather than in the encapsulated cells 
(see Figure 45). 
 
 
Figure 44: Alpha Actin Staining of Cell Capsule. Smooth muscle alpha actin is stained green; DNA is 
stained blue. There is more alpha actin in the strained TEVMS than the static controls. 
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Figure 45: Alpha Actin Staining of TEVM.  Static culture (left) has significantly less alpha actin than 
the strained TEVM (right). The majority of the staining is seen in the cell capsule, not in the 
encapsulated cells. 
Discussion 
One limitation of this study is the choice of cell type. While rat smooth muscle 
cells are easy to obtain and grow and are used often, they are very different from the 
human cells that would be required for an implantable graft. Rat cells continue to 
proliferate to a much higher passages than other cell types including human. TEVMs 
have been made with rat SMCs up to passage 30 [35]. Human cells produce more MMP, 
and additional collagenase types, than rat cells and can have different reactions to cyclic 
strain [36]. This can affect remodeling and may result in different optimal culture 
conditions. 
The choice of the collagen hydrogel method for TEVM creation has inherent 
limitations. Smooth muscle cells will contract the collagen fibers of the hydrogel leading 
to a stronger, stiffer matrix. The blood vessel wall has a basal tone; the smooth muscle 
cells are never in a completely relaxed state. This nature of the smooth muscle cell 
requires that TEVM be culture on the glass mandrels or similar mold so that a basal tone 
can be established. The tubular geometry will be lost within days due to cells contracting 
the gel to try and maintain this partially contracted state. The collagen gels are very weak, 
porous and exhibit significant creep without cross-linking. In order to apply cyclic strain 
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to the hydrogels they must be attached to a non-porous sleeve for application of cyclic 
strain. Without adherence to an elastic sleeve, no significant strain would be possible due 
to rupture. Even if possible at a low strain, recovery of strain is unlikely during the 
cycles. Since an inner mandrel or sleeve is needed for both static and dynamic culture, 
the nutrients and oxygen are supplied on the outside of the TEVM and not at the lumen 
which would be more consistent with the in vivo condition where nutrients come from the 
lumen or vasa vasorum. The smooth muscle cells do not proliferate much inside the 
collagen gels, but will proliferate on the gels leading to a cell capsule starting after 
approximately 2 weeks in static culture, thus creating a non-homogeneous tissue 
composition. 
Disk shaped constructs were used rather than tubular for initial gel compaction 
studies. The method used for making the gels requires that some of the starting material 
be cut away resulting in high variation in starting material. The cells also start contracting 
the gels early, even before the gels were removed from the molds, thus adding further 
error to the starting volume. The unconstrained disks do compact to a greater degree than 
that of the constrained tubes [16]. The duration of compaction was thought to be the same 
and the results agree with other published work [34]. Using this method the gels adhered 
better to the sleeves so that no longitudinal compaction could occur. 
The strain profile was chosen based on previous work from our lab [5, 16]; 
however, to determine the effects of waiting until compaction ceased before applying 
strain, the strain rate and amplitude needed to be the same as used previously. The 10% 
strain amplitude is physiological, but very aggressive and only seen in the larger, more 
elastic vessels.   
The only mechanical properties assessed were ultimate tensile strength and elastic 
modulus. While these parameters are important, these assessments are not sufficient. The 
tensile test is uniaxial and does not assess the mechanical properties in the longitudinal 
direction of the tissue which also influence burst pressures. Testing viscoelastic 
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properties such as creep is important; too much creep could lead to aneurysm. Fatigue 
testing may also be important to assure that the tissue can withstand the in vivo 
hemodynamics without failure.  
Only two drugs were tested to look at the physiological contractile response. 
There are multiple receptors involved in the regulation of vascular tone which may or 
may not be affected by cyclic strain. The calculation of nominal stress is not ideal. For 
future studies the measurement of the cross-sectional area under load could be completed 
so that the actual stress could then be calculated. While not ideal, it is preferable to the 
other methods that have been tried such as force per dry weight. 
An ideal tissue engineered vascular media would not only be able to withstand 
blood vessel hemodynamics, but would also be vasoactive. The application of cyclic 
strain is often used in TEVM culture to mimic in vivo conditions and help develop a 
tissue more suitable for implantation. Previous studies from our lab have shown that 
cyclic strain increases compaction of collagen hydrogels suggesting incomplete adhesion 
to the silicone sleeve used to confer strain [5, 16]. To overcome this issue, Isenberg et al. 
cultured collagen based TEVM statically until compaction ceased. This was followed by 
cross-linking by using glycation to assure there was no gel compaction [6]. The results 
from the first study with glycation were very encouraging, including elastin deposition in 
long term culture; however, the use of glycation increases necessary culture time and may 
result in undesirable effects due to the advanced glycation endproducts. Later Syedain et 
al. also delayed application of strain until after compaction ceased. In this instance fibrin 
scaffolds were used and no cross-linking was used [37]. 
While vasoactivity is a desirable trait in a TEVM, there is only one study that 
shows contractility using a collagen hydrogel model [38]. This model was used to study 
contraction so cells were used at low passage and at a very high cell to collagen 
concentration which would be difficult to maintain for the larger tissues needed for 
grafting. Studies have been performed to look at how mechanical stimulation affects 
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SMC phenotype, primarily by looking at smooth muscle α-actin. The change in 
phenotype has been associated with an increase in cell contraction. The measured 
contractile response of the tissue is more complex than the force from a single cell. It 
involves the integration of the cells and tissue; the cells have to work together to compact 
the tissue. Differences in tissue stiffness, cellularity and cell orientation may all affect the 
actual measured results as such a functional test is necessary to determine actual changes 
in the performance of the tissue.  
Cyclic strain has been shown to increase the amount of smooth muscle α-actin, 
caldesmon and in some cases calponin and myosin heavy and light chains, all responsible 
for cellular contraction [13, 15-19]. The previous work from our lab found an increase in 
smooth muscle α-actin associated with strain, but only with the addition of TGF-β to the 
culture medium. The increase in α-actin expression was 1.7 times the unstrained control, 
similar to what is shown in this study where strain improves the contractile strength by 
two fold in response to endothelin-1. This study was able to demonstrate that strain does 
not only qualitatively improve α-actin expression, but quantitatively shows a functional 
improvement in TEVM with relatively high passage SMC. The α-actin staining was 
almost exclusively found in the cell dense capsule of the TEVM, with little to no staining 
of the cells encapsulated in the collagen hydrogel. The cell-cell contact or cell density 
may be important in generation of measurable force. 
Cyclic strain has been shown to improve the strength of engineered tissue in 
multiple tissues. As expected the strained TEVM were significantly stronger than the 
statically cultured controls, although the increase was not as large in magnitude as other 
studies including those from our lab have shown. Seliktar et al. demonstrated a 57% 
increase in TEVM strength after 4 days of strain [5]. While cyclic strain had more of an 
effect previously, the TEVM in this study are approximately 10 times stronger than what 
was previously published. The differences in strength are due to the increased culture 
time (19 versus 6 days) and the different serum source. The diminished improvement in 
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strength by strain may be due to the reduction in compaction, the serum or the additional 
day in dynamic culture.  
While some of the improvement to strength in this study is due to increased radial 
compaction of the collagen gel, the measured force was also higher. The increased 
collagen deposition in the strained TEVM also plays a part. This is consistent with some 
of the literature as the impact of cyclic strain on collagen production is mixed. Several 
studies show increased collagen after cyclic strain [11-14]. Hahn et al. noted the increase 
in collagen, but no difference in elastin deposition. This is counter to what Isenberg et al. 
saw with cross-linked collagen TEVM where increased elastin deposition but no 
difference in collagen content was observed [6]. All of the cited studies tested the tissue 
after long term cyclic distention of 5 weeks or more. The current study saw an increase in 
collagen content after only 5 days in culture. Long term culture may further improve the 
collagen content and strength. A recent study by Syedain et al looked at the effects of 
cyclic strain over time and found that porcine valvular interstitial cells (VIC) in a fibrin 
hydrogel led to greater collagen contents at higher strains or with incremental strain 
profiles [37]. Interestingly with these VIC/fibrin  gels the static gels had greater collagen 
content after 1 week. By two weeks the strained samples contained more collagen; this 
difference increased with further culture. This suggests that collagen synthesis varies over 
time. 
One result of this study is that an increase in MMP activity that is seen, much like 
what was seen previously with human smooth muscle cells [39-41]. This was not seen 
with rat cells in work done previously in our lab [5]. In studies with rat cells the ultimate 
tensile strength continued to improve with cyclic strain, a 265% increase compared to 
controls after 8 days of strain. In this study the cells behaved more like the human cells 
where strain resulted in activated MMP-2. Differences may be due to the differences in 
compaction or differences in serum. While the increased MMP activity is of concern due 
to the decreases in strength seen at least in the short term, MMP activity is essential for 
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remodeling. When non-specific MMP activity is inhibited, cyclic strain no longer 
resulted in improved mechanical properties [39]; however, without inhibition the 
collagen based TEVMs eventually decreased in strength due to the MMP activity [40]. 
Preliminary work showed that, with this strain regime, the strength of the strained 
TEVMs started to decrease by day 6. It is unknown whether longer culture times would 
result in continued degradation of the tissue mechanical properties or eventually result in 
improved remodeling and a superior tissue. It is possible that like Syedain et al. an initial 
decrease in strength and collagen content will be seen prior to increases in both. The 
differences in cell type and matrix material may affect the outcomes. As shown in 
Chapter 4 significant amounts of MMP-2 activity is seen in the collagen hydrogels while 
the fibrin hydrogels have little activated MMP.  
This study has shown improvements in mechanical properties and physiological 
contractile response of the collagen based TEVM. While these improvements are 
significant, they are far from optimized. Studies have shown that different strain 
amplitudes and rates may be preferable for improved mechanical properties [37, 42-44] 
and collagen production [37, 43]. Syedain et al. found 10-15% strain led to improved 
strength and collagen as compared to static, with stepwise incremental strain increases 
having the best results. Conversely, Joshi and Webb [42] and Boerboom et al. [43] found 
that lower strain rates to be preferable for strength. Differences may very well be due to 
cell type, matrix type and the method for applying strain. Solan et al found that higher 
strain rates led to increased collagen deposition and increased levels of tissue inhibitor of 
metalloproteinases type 1 (TIMP-1) [44]. 
While improvements are seen, the strengths reported are significantly lower than 
that of native vessel and what would be required for in vivo testing. Further 
improvements may be made through longer culture times, biochemical stimulation such 
as platelet derived growth factor or transforming growth factor-β, or collagen cross-
linking.  
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CHAPTER 7: BIOCHEMICAL STIMULATION AFFECTS TEVM STRENGTH 
AND VASOACTIVITY  
Introduction 
Since the time of Weinberg and Bell [1], cell seeded hydrogels have been utilized 
for the tissue engineering of blood vessels. While this method has its advantages, the 
resulting tissue still lacks the strength required for in vivo testing and has a weak 
contractile response. Several groups have studied the effect of transforming growth factor 
β (TGF- β) alone or in combination with other biochemical stimulation on tissue strength, 
collagen synthesis and cell phenotype and reactivity. In a TEVM TGF-β has been shown 
to increase collagen production [2-4], increase strength [4, 5], increase elastin deposition 
[4, 6], and promote a more contractile cell phenotype [7].  The addition of TGF-β along 
with insulin was also shown to improve the contractile response of the TEVM [8].  
TGF-β is a member of a superfamily of highly plieotropic polypeptides that 
includes the bone morphogenetic proteins, avidins and inhibins. Three mammalian forms 
of TGF-β exist, TGF-β1, TGF-β2, and TGF-β3. This family of proteins has been found to 
regulate extracellular matrix production, cell proliferation, apoptosis, differentiation and 
migration. Vascular cells including endothelial cells and smooth muscle cells (SMC) 
express TGF-β1. In monolayer culture, TGF-β1 has been shown to influence SMC 
proliferation in a dose dependent manner and increase synthesis of elastin, fibrillin-1 and 
collagens I, III, V, VI and VIII [9-14]. It has also been shown to increase lysyl oxidase 
enzyme activity which cross-links collagen [15]. Cell phenotype has also been shown to 
be affected by TGF-β [16-18].  
TGF-β is part of the Smad signaling pathway shown in part in Figure 46. It is 
synthesized in an inactive form where the latency-associated peptide (LAP) is cleaved 
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intracellularly to generate the mature polypeptide. The TGF-β domain will then bind to 
the cleaved LAP to form a dimeric complex called the small latent complex which can 
bind to other members of the latent TGF-β binding protein family to form an inactive 
larger latent complex. The latent TGF-β can be sequestered within the pericellular matrix 
to create a store for later use. The regulation and activation of TFG-β is quite complex. 
For a review of TFG-β signaling see Massagué and Chen and Massagué and Wotton [19, 
20]. For a review of the role of TGF- β in the vascular system see Ghosh et al [21]. 
 
Figure 46: The TGF-Beta/Smad signaling Pathway. Adapted from Massagué and Chen [19]. 
Previous work from our lab has shown TGF- β to promote a more contractile cell 
phenotype in a collagen based TEVM [22]. As an extension of this work we are 
investigating its effect on tissue strength and on contractile response. Results presented in 
Chapter 5 suggest that there is a soluble factor that enhances the contractile response. To 
investigate whether TGF- β may play a role, the response to tumor necrosis factor α 
(TNF- α) was studied alone and in combination with TGF- β. TNF- α acts as an inhibitor 
in the Smad pathway and has been shown to promote a less contractile cell phenotype. 
Materials and Methods 
Tissue Engineered Vascular Media Fabrication 
Tissue engineered vascular medias (TEVMs) were made as described 
previously.[7] Rat aortic smooth muscle cells from passage 6 to 9 were incorporated into 
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a type 1 collagen hydrogel for final concentrations of 1 million cells/ml and 2 mg/ml 
collagen. The collagen-cell solution was placed into the tubular mold and allowed to 
polymerize. The hydrogel was then removed from the mold and placed into culture in 
medium consisting of Dulbecco’s Modified Eagle Medium (DMEM, Mediatech Cellgro), 
10% bovine growth serum (Hyclone, Logan, UT), 1% L-glutamine and 1% penicillin–
streptomycin (Gibco, Grand Island, NY). Medium was supplemented with 2 ng/ml TGF-
β1 (Sigma), 10 ng/ml TNF-α (Sigma) or both; controls with no added growth factors 
were maintained. Culture medium was changed three times a week to assure that growth 
factor concentration remained high.  
Contractility Testing 
TEVM were cut into 2 mm long rings that were mounted on hooks in a 
physiological organ bath of 5 ml Krebs Henseleit solution with continuous of 95% O2, 
5% CO2 at 37°C.[23-26] The segments were preloaded to 0.15 g; the rings were first 
stimulated with the nonspecific agonist KCl (120 mM). Responses to the vasoconstrictor 
endothelin-1 (10-7 M) or bradykinin (10-4 M) and followed by the antagonist papaverine 
(10-4 M) (Sigma, St. Louis, MO). Changes in tension due to chemical stimulation were 
measured using a digital data acquisition system (Gould Instrument Systems, Valley 
View, OH). The maximum change in force was recorded. Nominal stress was calculated 
by dividing the force by the cross-sectional area for the unloaded ring segment. 
Tensile Testing 
TEVM were cut into 5 mm rings; black beads of approximately 300 µm were 
affixed to one side of the rings in order to measure strain.  The segments were mounted 
onto hooks in a phosphate buffered saline (PBS) bath on an Instron single column test 
system (Instron,). The rings were preloaded to 0.3 mN and precycled for five cycles to 
approximately 20% of the yield strain. The rings were then loaded to failure at a constant 
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strain rate of 0.2 mm/s. Matrox Inspector 8 was used to capture and analyze images taken 
during the test.  Wall thickness was measured in order to determine cross-sectional area 
and calculate stress. Bead displacement was tracked so that local strain could be 
calculated. The recorded force and displacement data were then converted to stress and 
strain where the ultimate tensile strength, yield strength and elastic modulus could then 
be determined. 
MMP Activity 
MMP activity was assessed using gelatin zymography. Ring segments were rinsed 
in PBS, placed in RIPA buffer (Sigma) and homogenized using an ultrasonicator. 
Samples were stored at -80°C until use. Prior to protein quantification, samples were 
centrifuged at 12,000×g for 10 minutes. The protein content of the supernatant was 
determined using the modified Lowry method (Pierce) with albumin standards for 
comparison. 
Gel electrophoresis was performed using Novex 10% Zymogram (gelatin) gels 
(Invitrogen). Equal amounts of protein in loading buffer were added to each lane. MMP 
2/9 standards (Chemicon) were used for comparison; acellular hydrogels or fresh medium 
were used for controls. After electrophoresis the gel was placed in renaturing buffer 
(Invitrogen) followed by overnight incubation at 37°C in developing buffer (Invitrogen). 
The gel was stained with colloidal blue (Invitrogen) for 3-6 hours and then destained in 
dI H2O. The gel was then imaged using the LiCor Odyssey imaging system and images 
were converted to gray scale. 
DNA Quantification 
Segments of the tissue were taken, rinsed in PBS and lyophilized with a Freezone 
freeze dry system (Labconco) overnight. The dry weights were recorded. The tissue was 
then digested by incubating with 0.5 mg/ml Proteinase K in phosphate buffer with EDTA 
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for 12-16 hours at 60°C or until no tissue was visible. The samples were loaded in 
triplicate into a 96 well plate along with DNA standards diluted from calf thymus DNA 
(Sigma) stock solution. The samples were then incubated for 15 minutes at room 
temperature with 0.1 µg/ml Hoechst 33258 dye in 10 mM Tris-HCl buffer with 1 mM 
EDTA and 0.2 M NaCl. The plate was then read on a flurometer using an excitation 
wavelength of 365 nm and emission wavelength of 458 nm. DNA quantity was 
determined by comparing to the standard curve. The results were normalized to dry 
weight to account for differences in amount of tissue. 
Collagen Quantification 
Segments were taken and were digested in Proteinase K as described previously 
for DNA quantification. Samples were loaded in triplicate in a 96 well plate along with 
collagen standards made from Type I bovine collagen (MP Biomedical). The samples 
were then incubated for 30 minutes in a solution of 0.8 mM direct Sirius red dye in 0.5 M 
acetic acid. The samples were then centrifuged at 10,000×g for 15 minutes; the 
supernatant was loaded into a 96 well plate in triplicate. The plate was then read on a 
spectrophotometer at 540 nm wavelength. The collagen content was determined by the 
standard curve and normalized to dry weight to account for differences in amount of 
tissue. 
Histology and Immunohistochemistry 
Samples were rinsed in PBS and placed into 4% formalin at room temperature. 
After twenty four hours the samples were rinsed in PBS and transferred to 70% alcohol at 
4°C until processing. The samples were paraffin embedded; 7 µm sections were cut for 
histology and immunohistochemistry (IHC). Masson’s trichrome staining was performed 
on deparaffinized sections as was IHC for smooth muscle α-actin.  
143 
Statistical Analysis 
All graphs are shown as mean ± SEM. Statistical analysis was completed using a 
95% confidence interval. Tests of two parameters were completed using a t-test. Tests of 
three or more parameters were completed using one way ANOVA; post hoc testing was 
completed using a t-test. 
Results 
Gel Compaction 
The different biochemical treatments resulted in large visible differences in gel 
compaction, see Figure 47. The TEVM treated with TGF-β alone or in combination with 
TNF-α resulted in significant gel compaction. The majority of the visible compaction 
occurred within the first week of culture. Much of the compaction was longitudinal 
resulting in differences in wall thickness as well, see Figure 48.  
Mechanical Properties 
The mechanical properties of the TEVM were assessed using uniaxial tensile 
testing. The biochemical treatments had significant impact on the mechanical properties 
of the TEVM. Results are shown in Figure 49. Even with the thicker cross-sectional area, 
the treatment with TGF-β resulted in a 56% increase in strength compared to control. 
Treatment with TNF-α, which resulted in the thinnest wall, resulted in a 77% decrease in 
strength. Combining the two growth factors still improves strength, but not to the same 
extent as TGF-β alone. The modulus of elasticity follows the same general trend as the 
strength although only the TNF-α treated group was significantly different. 
Representative stress-extension curves for the treatments are shown in Figure 50. 
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Figure 47: Compaction due to Biochemical Stimulation. TEVMs are shown after 3 weeks of culture 
with no additives (A), TNF-α  (B), TGF-β (C), and the combination of TNF-α  and TGF-β (D). The 
addition of TGF-β alone or in combination with TNF-α  leads to increased longitudinal compaction. 
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Figure 48: Wall Thickness of TEVMs Exposed to Different Biochemical Stimuli. * = p≤0.05 as 
depicted. The combined growth factor treatment resulted in a significantly thicker wall as compared 
to all other treatments. The difference in wall thickness between the TGF-β and TNF-α treated 
TEVMs was also significant. 
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Figure 49: Mechanical Properties of TEVMs Subjected to Biochemical Treatment. * = p<0.05 as 
depicted. TEVMs treated with TGF-β alone had the greatest ultimate tensile strength. Those treated 
with TNF-α had the least strength. 
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Figure 50: Representative Stress-Extension Curves. Shown are the untreated control (A), TNF-α 
treated (B), TGF-β treated (C) and the combined treatments of TNF-α and TGF-β. 
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Cell Phenotype/Contractile Protein Expression 
TGF-β and TNF-α have been shown to influence smooth muscle cell phenotype. 
IHC was completed on ring sections to look at smooth muscle α-actin, myosin heavy 
chain and calponin expression. Only α-actin was detectable (see Figure 51); TEVM 
exposed to TGF-β expressed the highest levels of α-actin, followed by the control TEVM. 
TEVM given TNF-α alone or in combination with TGF-β did not contain significant 
amounts of α-actin. 
Vasoactivity 
All biochemical treatments resulted in a significant decrease in contractile force 
and stress in response to both vasoconstrictors, with no significant difference between the 
any of the treated groups (see Figure 52). When looking at contractile force per cell, the 
difference between TGF-β and TNF-α treatment also becomes significant. The fact that 
the TEVMs treated with TNF-α had a higher contractile response than those treated with 
TGF-β does not mean that the actual force exerted by the cells was stronger in the TNF-α 
treated TEVMs than in the TGF-β treated TEVMs. The force measured is that of the 
tissue, not of the cells. The cells have to compress the hydrogel layer in order for a 
contraction to be measured. In the case of the TGF-β treated TEVMs the thick, dense 
collagen layer requires more force from the cells to compact the tissue, resulting in a 
lower tissue contraction. 
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Figure 51:  Alpha Actin Staining. Alpha actin is stained green, nuclei blue. The sections shown are of 
the non-treated control (A), TNF-α  (B), TGF-β (C), and the combination of TNF-α  and TGF-β (D.) 
The TEVMs treated with TGF-β stained the strongest for smooth muscle alpha actin. Those treated 
with TNF-α alone or in combination with TGF-β had very weak alpha actin staining. 
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Figure 52: Vasoactive Response of TEVM Subjected to Biochemical Treatment. * = p≤0.05 as 
compared to control or as depicted. Data shown as measured force (A), and the calculated results for 
nominal stress (B), and force per cell (C). Trends generally remain the same; however, due to the 
differences in cellularity larger differences are seen and statistical significance is affected. All 
treatments resulted in a significant decrease in contractile strength as compared to the untreated 
controls. 
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MMP Activity 
Gelatin zymography was performed to see qualitative differences in MMP 
activity, results are shown in Figure 53. While several MMPs have gelatinase activity, 
MMP-2 activity was significantly higher than other MMPs. Other bands could only be 
seen when MMP-2 was overloaded. Both the latent and active form of MMP-2 can be 
detected using gelatin zymography. The 72 kDa bands correspond to latent and 68 kDa 
bands correspond to active MMP-2. All homogenates contained latent and active MMP-
2; the two groups that were exposed to TGF-β showed increased MMP-2 activity, with 
the combination of TGF-β and TNF-α resulting in the most activation. The MMP-2 
activity levels correspond to the degree of hydrogel compaction with the combined 
treatment having significant MMP-2 activity and gel compaction. Spent medium samples 
did not contain significant amounts of activated MMP-2. 
 
 
Figure 53: Gelatin Zymography for Biochemically Treated Homogenates and Spent Medium. The 
zymogram show samples from tissue homogenates (A), and spent medium (B). The samples run were 
no additive controls (lane 1), TGF-β treated (lane 2), TNF-α treated (lane 3), combined treatments 
(lane 4), acellular or fresh medium controls (lane 5), and MMP 2/9 standards (lane 6). The TEVMs 
treated with TGF-β alone or in combination with TNF-α had higher levels of MMP-2 activity. 
TEVM Composition 
There is a noticeable difference in the wall thickness and the collagen density in 
the hydrogel portion of the TEVMs. The TEVMs subjected to TGF-β alone or with TNF-
α had thick dense collagen hydrogels, while the TNF- α treated TEVMs had a thinner 
wall with a thinner cell capsule layer, as shown in Figure 54. 
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There are differences in cellularity between the treatment groups. The 
combination of TGF-β and TNF-α results in the lowest cell number, which is 
significantly lower than the untreated control. The addition of TNF-α alone or in 
combination with TGF-β reduces the number of cells compared to TGF-β treated 
TEVMs. Results are shown in Figure 55.  
Sirius red collagen assay shows no difference in the collagen content per dry 
weight of any of the TEVMs (see Figure 56). 
 
 
 
Figure 54: Masson's Trichrome Staining of Biochemically Treated TEVM. Collagen is stained blue. 
No additive control (A), TGF-β treated (B), TNF-α treated (C), and combined treatment (D) samples 
are shown. The wall thicknesses and collagen densities vary greatly between samples. 
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Figure 55: DNA Content for TEVM Subjected to Biochemical Treatment. * = p≤0.05 as depicted. 
The combined growth factor treatment resulted in the lowest number of cells. TGF-β treated TEVM 
contained the highest number of cells. 
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Figure 56: Collagen Content of Biochemically Treated TEVM. No significant differences were seen 
after 3 weeks of static culture. 
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Discussion 
This study only looked at one concentration of TGF-β and TNF-α. There may be 
different levels that result in better mechanical and contractile responses. The culture 
medium was changed 3 times per week. This was done so as not to deplete the growth 
factors; however a more consistent time frame such as every 2 to 3 days may have made 
a difference in the results. 
By looking at both TGF-β and TNF-α, it is possible to get an idea of whether 
these factors may play a part in TEVM mechanical and contractile properties. TGF-β 
does have a biphasic response so an increase in strength or contraction may not be seen 
by adding additional TGF-β to the culture medium. To better understand if TGF-β plays a 
role in contraction it should have been added to the culture medium where no contractile 
function was seen would have given additional information. In both cases where TGF-β 
was added to the culture medium there was increased gel compaction. When combined 
with TNF-α, the TEVM compaction was so significant that it was difficult to cut into ring 
segments and only one or two per construct could be tested. Total collagen content was 
assessed using the Sirius Red assay. Newly synthesized collagen may not be detectable 
amidst the large amount of collagen present in the TEVM.  
The addition of TGF-β and TNF-α had significant effects on the TEVMs. Most 
noticeable was the increased compaction, most of which occurred in the first week. In 
both of the culture conditions where TGF-β was added to the culture medium there was a 
significant increase in compaction, much of this in the longitudinal direction. The 
combination of TGF-β and TNF-α resulted in a dramatic decrease in TEVM length. 
When taken in context with the wall thickness data, it is difficult to determine if the 
overall volume changed or if only the direction of compaction was altered. A previous 
study in our lab did not find differences in volume associated with the addition of TGF-β; 
however, the TEVM were adhered to silicone sleeves and the total culture time was only 
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6 days [7]. Neidert et al also did not notice differences in compaction with TGF-β. In this 
case the compaction was determined by measuring the height of the hemisphere shaped 
gels that were adhered to the bottom of a dish [27]. It is also possible that differences in 
serum or collagen lot could contribute to the changes. While none of these studies saw 
differences in compaction, it has been shown that TGF-β can influence hydrogel 
compaction [28, 29].  
As expected, TGF-β increased the strength of the tissue and TNF-α reduced the 
strength. The addition of TGF-β resulted in more than a 1.5 fold increase in strength after 
3 weeks of culture. This is compared to a 12 fold increase that was reported by Grassl et 
al [5]. While the magnitude wasn’t the same, the Grassl work used neonatal smooth 
muscle cells at four times the concentration. Neonatal SMC have been shown to produce 
more collagen than adult cells which would impact the results [30]. 
The improvements in strength are almost exclusively due to the increased 
compaction. There were no differences in collagen deposition seen, this may be real or 
this may not be detectable differences using the Sirius red assay within this culture time. 
While TGF-β is known to regulate ECM synthesis, it has not always been shown to 
improve collagen synthesis in a TEVM. Grassl et al showed that TGF-β and insulin 
resulted in increased collagen synthesis, whereas the addition of TGF-β alone gave 
variable results [5]. It may also be that a different concentration is required. 
The addition of TGF-β and TNF-α impacted the level of MMP-2 activity. The 
TEVMs treated with TGF-β alone or in combination with TNF-α resulted in an increase 
in MMP-2 activity. This is consistent with what was seen by Ross et al. where the 
addition of TGF-β resulted in increased MMP-2 expression. This may also have an effect 
on the TEVM strength. It has been shown that an increase in MMP-2 activity can 
negatively impact the strength of a collagen-based TEVM. The increase in MMP-2 
activity resulted in a reduction in strength within 8 days [31]. In this study the TEVM 
were cultured for 3 weeks. Conversely in Ross et al the increase in MMP-2 and MMP-1 
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expression did not result in any loss of strength in the fibrin based TEVMs. As seen in 
Chapter 6, the MMP-2 activity also correlates with the degree of compaction. The 
addition of TNF-α resulted in the highest level of MMP-2 activity and the most 
longitudinal compaction.  
The addition of TNF-α alone or in combination with TGF-β resulted in a drastic 
reduction in α-actin expression as compared to untreated controls, consistent with the 
literature. The addition of TGF-β resulted in increased smooth muscle α-actin expression 
as compared to the control as seen with immunofluorescence staining. This is consistent 
with previous work that showed that TGF-β increased α-actin expression by 
approximately 25%. Even with the increased α-actin expression, the actual contractile 
response of all treatments was reduced by more than 65% to almost undetectable levels. 
The contraction of the TNF-α was actually greater than that of TGF-β. While the 
measured force was reduced, that does not mean that the force generated by each cell was 
actually reduced. The TGF-β treated TEVMs were much more compact with a thicker 
wall and stronger matrix. This would mean that the cells would need to generate more 
force to move the tissue.  
The collagen compaction that occurred due to the addition of the biochemical 
agents was significant and impacted the strength and contractile function. While some 
compaction is desired in order to increase collagen density and improve TEVM strength, 
too much longitudinal compaction is not ideal. A graft must be of a certain length and 
must be reproducible, and longitudinal compaction is highly variable. As seen with the 
cyclic strain work in Chapter 6, the cessation of longitudinal compaction does not 
necessarily result in reduction in strength. By controlling this length, the effects of TGF-β 
on cell phenotype may result in a measurable improvement in contractile response. To 
control the length, the TEVMs could be cultured on a silicone sleeve as done previously, 
or the growth factors could be added after compaction ceases. The combination of insulin 
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and TGF-β could be further studied as it has been shown to improve the strength, the 
collagen production, and the vasoactive response of fibrin based TEVM [8, 27]. 
The results seen here suggest that TGF-β is not the factor in the culture medium 
that resulted in measurable TEVM contraction. Finding that factor, or factors, is of 
interest to the tissue engineering community. This could be achieved by using a 
proteomics approach comparing the serum that result in TEVM with and without a 
measurable vasoactive response. 
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CHAPTER 8: EFFECTS OF CRYOPRESERVATION ON VASOACTIVITY 
Introduction 
Tissue engineering of small diameter blood vessels has long been considered the 
‘Holy Grail’ of tissue engineering due to the need for bypass grafting that will remain 
patent. An ideal tissue engineered blood vessel will be non-thrombogenic, non-
immunogenic, possess sufficient mechanical properties to withstand blood pressure and 
be vasoactive. To be commercially viable, the graft material must have ‘off-the-shelf’ 
availability as most patients cannot wait the weeks or months that it takes to create tissue 
engineered substitutes. Cryopreservation could provide a solution for this need. 
The two methods of cryopreservation available are freezing and vitrification. 
Freezing of cells or tissue is done using a slow cooling method, often in the presence of 
cryoprotectants. With freezing preservation is assisted by ice formation as the 
cryoprotectant concentration is gradually increased as ice crystals form. Even with 
controlled-rate freezing, ice damage can occur causing both cellular and extracellular 
matrix damage [1, 2]. Vitrification is an ‘ice-free’ preservation method where fast cooling 
rates and cryoprotectants are chosen to prevent ice formation and to transition the liquid 
into a glass state. With vitrification higher cryoprotectant concentrations are needed 
which can be deleterious to the cells and thus these need to be chosen carefully [3]. 
For cryopreservation to be considered successful, the preserved tissue would need 
to be viable and maintain the properties of the fresh tissue. For a blood vessel the 
mechanical properties and contractile function are two important properties that should 
be maintained. While results vary due to differences in cryopreservation methods, studies 
show that most cryopreservation methods do not negatively impact the mechanical 
properties of native tissue [3, 4]. Tissue engineered blood vessels behave similarly and 
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some even gain strength after rewarming [4-6]. Studies of vasoactive function after 
cryopreservation of native vessels have shown that freezing results in diminished 
function, but that function is maintained with vitrification [1, 7]. Only one study has been 
done with engineered tissue. With both methods the response was diminished as 
compared to fresh tissue. Vitrification was far superior to freezing and retained 
significantly more vasoactive function; vitrification also resulted in higher cell viability 
then freezing [4].  The difference in functional response was much more dramatic then 
the difference in viability suggesting that vasoactive response is a more stringent 
assessment of cryopreservation success in a tissue engineered blood vessel. 
Previously our lab has studied the effects of cryopreservation on mechanical 
properties and the viability of a tissue engineered vascular media [5]. This study looks at 
the effects of freezing and vitrification on the vasoactivity of the tissue. 
Materials and Methods 
Tissue Engineered Vascular Media Fabrication 
Tissue engineered vascular medias (TEVMs) were made as described previously 
[8]. Rat aortic smooth muscle cells from passage 6 to 9 were incorporated into a type 1 
collagen hydrogel for final concentrations of 1 million cells/ml and 2 mg/ml collagen. 
The collagen-cell solution was placed into the tubular mold and allowed to polymerize. 
An etched collagen I coated sleeve was used in the mold for constructs to be subjected to 
cyclic strain as well as to the static control counterparts. The hydrogel was then removed 
from the mold and placed into culture in medium consisting of Dulbecco’s Modified 
Eagle Medium (DMEM, Mediatech Cellgro), 10% bovine growth serum (Hyclone), 1% 
L-glutamine and 1% penicillin –streptomycin (Gibco, Grand Island, NY). Culture 
medium was changed weekly.  
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Cyclic Strain 
Cyclic strain was applied to the collagen TEVMs using a system previously 
developed in our lab [8]. The TEVM were cultured for two weeks prior to being 
subjected to cyclic strain to allow for better adherence of the tissue to the silicone sleeve. 
The tubular constructs on the silicone sleeves were mounted on hollow mandrels in the 
strain bioreactor containing 300 ml of culture medium.  The lumen and reservoir were 
filled with culture medium. Two 0.2 µm filters were placed in the vents in the lid to allow 
for oxygen exchange. The bioreactor was placed in a CO2 incubator at 37°C, and 
connected to a filtered regulated air supply. The pneumatic pressure was controlled in 
order to produce 10% circumferential strain at a rate of 1 Hz.  TEVMs were strained for 5 
days. Statically cultured controls were created for comparison. At the conclusion of 
testing, the TEVMs were gently removed from the silicon sleeves prior to testing. 
Contractility Testing 
TEVMs were cut into 2 mm long rings that were mounted on hooks in a 
physiological organ bath of 5 ml Krebs Henseleit solution with continuous perfusion of 
95% O2, 5% CO2 at 37°C.[9, 10] The segments were preloaded to 0.15 g, and the rings 
were first stimulated with the nonspecific agonist KCl (120 mM). Responses to the 
vasoconstrictor endothelin-1 (10-8,10-7 M) or bradykinin (10-5,10-4 M) were measured. 
Each agonist was followed by the antagonist papaverine (10-4 M) (Sigma, St. Louis, 
MO). Changes in tension due to chemical stimulation were measured using a digital data 
acquisition system (Gould Instrument Systems, Valley View, OH). The maximum change 
in force was recorded. Nominal stress was calculated by dividing the force by the cross-
sectional area for the unloaded ring segment. 
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Controlled-Rate Freezing 
Freezing of the TEVM rings was done using a commercial procedure.[9] The ring 
segments were placed into Hepes-Buffered DMEM with 1M dimethyl sulfoxide 
(DMSO), 2.5% chondroitin sulfate and 10% fetal calf serum at 4C. The segments were 
then placed vials and cooled to -80°C at 1°C/min. The vials were then transferred to 
liquid nitrogen and stored for a minimum of 12 hours. 
To thaw, the vials were placed in a 37°C waterbath until ice was no longer visible. 
DMSO was then eluted by placing the samples in DMEM containing mannitol at 
decreasing concentrations of 0.5 M, 0.25 M and 0 M.  
Vitrification 
TEVM rings were vitrified using VS55 vitrification solution containing 2.2 M 
propylene glycol, 3.1 M formamide and 3.1 M DMSO [1, 11]. Precooled (4°C) VS55 was 
introduced to the samples in 6 steps of 15 minutes each, gradually increasing the VS55 
concentration. At the final concentration of 55%, isopentane was added to the air-liquid 
interface to prevent condensation. The samples were cooled rapidly (43°C/min) to -
100°C followed by slow cooling (3°C/min) to -135°C. The TEVMs were stored at 135°C 
for a minimum of 12 hours. 
Rewarming was completed in two stages. First the samples were slowly rewarmed 
(30°C/min) to -100°C using convection. This was followed by rapid rewarming 
(225°C/min) to 4°C. The VS55 concentration was decreased to 0 M in seven sequential 
steps.  
Statistical Analysis 
All graphs are shown as mean ± SEM. Statistical analysis was assessed using a 
95% confidence interval. Tests of two parameters were assessed using a Student’s t-test. 
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Tests of three or more parameters were assessed using one way ANOVA with a post hoc 
t-test. 
Results 
Vasoactivity After Cryopreservation 
TEVMs were cultured statically for two weeks followed by 5 days of 10% cyclic 
strain at 1 Hz. The TEVMs were cut into 2 mm ring segments. At least one ring from 
each tube was either cryopreserved by vitrification, cryopreserved by freezing, or not 
preserved (‘fresh’). Cryopreserved samples were rewarmed after a minimum of 12 hours 
of storage. After rewarming, the specimen rings underwent physiological testing for 
contractile function. The contractile and relaxation data is being shown both as measured 
force and nominal stress (see Figure 57). Both freezing and vitrification had a negative 
effect on contractile response to endothelin-1; the contraction of the frozen samples was 
14-20% of the fresh samples, while the contraction of the vitrified samples was 7-17% of 
fresh. The response to bradykinin was not as affected by the preservation, especially in 
the frozen samples. Freezing resulted in 42-43% functional response while vitrification 
resulted in 20-27%. The contractile response to bradykinin may appear to be less affected 
by freezing than endothelin-1 since the response in fresh tissue is more than half of that to 
endothelin-1. While there appears to be subtle trends, there is no significant difference in 
function between vitrified and frozen TEVMs. Application of strain had no effect on the 
function of the cryopreserved specimen. The statically cultured TEVMs retained 17-20% 
of endothelin-1 function and 27-43% of bradykinin function, while the strained samples 
retained 7-14% of endothelin-1 function and 20-42% of bradykinin function. The 
percentages are misleading here as well since the fresh dynamic samples produced twice 
the force as the statically cultured rings. Neither freezing nor vitrification was able to 
preserve any substantial function for this tissue using the current protocols. 
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Figure 57: Contractility of Fresh and Cryopreserved TEVMs.  Data is presented as measured force 
(left) or calculated nominal stress (right). Results are shown for the agonists endothelin-1 (A) and 
bradykinin (B) and the antagonist papaverine (C). Both cryopreservation methods resulted in 
significant decreases in contractile force. No differences were found between freezing and 
vitrification or between static and strained TEVMs.                                                                                               
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Vasoactivity After Modified Vitrification Protocol 
To try to improve function after vitrification, the rewarming temperature was 
reduced. For this study all TEVM were cultured statically for 3 weeks prior to testing and 
the silicone sleeve was not used, resulting in a slightly thicker tissue. TEVMs were cut 
into 2 mm rings with at least one ring from each tubular construct going into each test 
group. Rings were either tested fresh or vitrified. Vitrified rings were rewarmed at either -
10°C or 4°C and tested for contractile function. The decreased rewarming temperature 
had no effect on the contractile response after cryopreservation. Both methods resulted in 
significant deterioration of the contractile response as shown in Figure 58. No relaxation 
data is shown since it was not tested on more than 75% of the vitrified samples due to a 
lack of response to the agonist. The bradykinin data for the ring segments rewarmed at 
4°C may be skewed slightly as one batch was not tested due to poor performance. The 
nominal stress presented is lower than in the cyclic strain study. No sleeve was used for 
this study, changing the thickness of the tube which can affect remodeling and growth as 
well as stress due to the increased wall thickness. 
Discussion 
The one freezing method was used may not be optimized for this tissue. Since 
vitrification has been shown to be superior for many applications including other tissue 
engineered blood vessels modifications to the freezing protocol were not undertaken. The 
vitrification method is certainly not optimized. Only one modification to the technique 
was investigated: the final temperature in the two step rewarming procedure. There are 
many variables to investigate in both the cooling and rewarming stages as it is unknown 
when the damage occurs. The vitrification cocktail as well as cooling and rewarming 
rates and temperatures can be investigated. 
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Figure 58: Contractility of Ring Segments Before and After Vitrification. Data presented as 
measured force (top) and calculated nominal stress (bottom). No improvements were seen with the 
modified protocol. 
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The contractile response was the only assessment used on the majority of the 
samples. Early testing showed that viability was lower than with other TEVMs from our 
lab and others using the same protocols. It is unknown whether viability was improved 
with the change in the rewarming protocol; the decrease in contractile response may be 
related to the decreased viability, damage to cell-cell junctions, damage to the receptors, 
or to the combination of these factors. 
For tissue engineered blood vessels to be commercially viable, they would need to 
have ‘off the shelf’ availability; cryopreservation may fill that need. In order for 
cryopreservation to be considered successful, the preserved tissue must remain viable, 
maintain function and mechanical integrity. Assessment of these requirements after 
cryopreservation has been undertaken by a small number of groups; in most cases 
vitrification results performs better than conventional cryopreservation (freezing). A 
summary of this data is found in Table 8. For a review of vitrification of engineered 
tissue see Kulkeshova et al [3]. Previously our lab showed vitrification to have 
comparable viability to freezing of a collagen-elastin hybrid TEVM [5]. Viability can be 
greatly influenced by the method used. Neidert et al. showed viability of approximately 
40% to >90% by varying the cryoprotectant choice and concentration as well as the end 
temperature [6]. Baicu et al. has shown a 10% improvement in viability after vitrification 
just by varying the rewarming rate [10]. The ultimate tensile strength of the tissue 
engineered blood vessels has been assessed before and after cryopreservation. 
Cryopreservation by all but the unoptimized freezing protocols not only maintained the 
mechanical properties but often enhanced the strength [4-6]. These results are consistent 
with results for native tissue. Thakrar et al. showed no difference in the viscoelastic 
properties of human vascular grafts after vitrification [11]. Venkatasubramanian et al. 
shows that freezing affects the stress-strain relationship, especially in the toe region of the 
curve [12]. A study with a valve leaflet showed no significant difference in maximum 
stress, but the valves did exhibit a different modulus [13]. 
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Table 8: Assessments of TEVM and native vessels after Cryopreservation. An * indicates native 
tissue. • indicates work done in our lab. Ranges are due to multiple methods used or multiple 
contractile agents. 
  Viability  Strength  Contractile Response 
Author  Frozen Vitrified  Frozen Vitrified  Frozen Vitrified 
*Song et al. [1]  n/a n/a  n/a n/a  15-29% 83-87% 
 Neidert et al. [6]  40->90% n/a  40-200% n/a  n/a n/a 
•Elder et al. [5]  65% 67%  130% 200%  n/a n/a 
*Baicu et al. [7]  n/a n/a  n/a n/a  n/a 30-50% 
 Dahl et al. [4]  50% 70%  140% 190%  10.7% >82% 
*Brockbank et al. 
[14] 
 n/a n/a  n/a n/a  n/a 25->80% 
*Hoenicka et al. [15]  58% 22%  n/a n/a  23-28% 2.5-4.5% 
*Baicu et al. [10]  n/a 80-90%  n/a n/a  n/a 30-70% 
 •Current Study  n/a n/a  n/a n/a  14-43% 7-27% 
  
Since the effects of cryopreservation on viability, ice formation and mechanical 
properties were studied previously in our lab for a similar TEVM [5], this study focused 
on the contractile response after cryopreservation. Only one other study has looked at 
function of an engineered tissue after cryopreservation and few studies have looked at 
function of native tissue after cryopreservation. Dahl et al. used the same freezing and 
vitrification methods as were used in this study on their PGA based TEVM [4]. 
Vitrification was shown to preserve over 80% of the functional response of fresh tissue as 
compared to 10% for frozen samples. The differences in function correlate to viability 
with vitrified samples possessing significantly more metabolic activity. Vitrification also 
has been shown to preserve function in native tissue. Song et al. demonstrated that veins 
could retain over 80% of the contractile function after vitrification which was 
significantly better than the frozen vein segments [1]. While vitrification often results in a 
more functional tissue, human umbilical vein performed better after freezing rather than 
after vitrification even though the same vitrification method was used. The cell viability 
169 
was better with freezing than with vitrification which clearly plays a role [15]. Compared 
to all of the reports in the literature, the segments tested in this study had severely 
diminished contractile response after both freezing and vitrification with function after 
freezing being slightly but not significantly better. Some of the differences may have to 
do with the different agonists chosen for functional testing. The work in the chapter and 
the cited literature suggests that there are some receptor pathways are affected by 
cryopreservation. In all cases the retention of functional response correlates with the 
viability, suggesting that the reduction in function is due in part to the cell viability. 
Unfortunately we cannot confirm that for this study as viability testing was not done 
except in preliminary work. While the previous study in our lab shows viability at or 
above 65%; the TEVMs in this study are similar but not exactly the same as the 
previously published work. In Elder et al. the TEVM is a collagen-elastin hybrid cultured 
in fetal bovine serum [5], resulting in tissue where the SMCs are found evenly dispersed 
in the collagen hydrogel in relatively low density. The TEVM in this study were made 
with collagen only and cultured in bovine growth serum. These conditions resulted in a 
bi-layered TEVM with the hydrogel layer having evenly dispersed cells. The SMC 
proliferate on top of the collagen hydrogel creating a cell ‘capsule’ that is cell dense.  
Freezing and vitrification may affect the tissues differently resulting in a different 
viability. The preliminary testing suggests that the viability is reduced in this tissue. This 
is surprising since the tissue tested by Dahl et al. is more cell dense and still retained 70% 
viability after vitrification and over 80% contractile function [4]. Native artery has also 
been successfully vitrified with the vitrified tissue assessed both in vitro and in vivo [1, 
16-18]. All of the cited work showing functional data after preservation has used the 
same or similar vitrification protocols with varied results. There may not be one optimal 
procedure for all tissue, and there may be a few key parameters that need to be adjusted 
for successful preservation of tissues of different cell type, cell density and thickness. 
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To attempt to improve the post-cryopreservation function, the end temperature 
after the rapid rewarming stage was decreased. This is the temperature at which the 
cryoprotectant concentration is decreased through sequential steps. This made no 
improvement in function after vitrification. There are many other variables such as choice 
of cryoprotectant and its concentration, cooling and rewarming rates to name a few. 
Investigation into the cell viability and ice formation in the tissue could guide the 
changes. The TEVMs tested here still do not have the strength required for in vivo testing 
nor have they demonstrated the appropriate suture retention strengths or viscoelastic 
properties. Modifications to the method that would result in improved mechanical 
properties may also impact the way the cryopreservation techniques affect the tissue. 
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CHAPTER 9: DISCUSSION AND CONCLUSIONS 
Discussion 
Taken as a whole this work provides insight into the use of the tissue engineered 
vascular media (TEVM) as a model system and gives insight into the vasoactive response 
and factors that influence the magnitude of this response. Matrix type and presentation 
was shown affect collagen I, decorin and biglycan synthesis and deposition. The 
collagen-based TEVM was shown to be vasoactive using high passage smooth muscle 
cells (SMC). The contractile force measured is influenced by many factors, while looking 
at shifts in cell phenotype may yield insights, functional testing is required. Modulation 
to a more contractile cell phenotype may not result in increased contraction of the tissue 
due to influence by the matrix. Both cyclic strain and transforming growth factor-β (TGF-
β) were shown to increase TEVM strength and promote a more contractile phenotype. 
Vasoactivity was affected by both types of stimulation, but in different ways. Cyclic 
strain improved vasoactivity while TGF-β decreased the contractile force of the TEVM. 
This work shows the influence of both cell phenotype and cell/matrix interactions on the 
vasoactivity of the tissue.  
TEVM as a Model System 
The TEVM can be used as a model system, both in disk and tubular form. In 
Chapter 4, disk shaped TEVMs were used for study of gene expression and protein 
synthesis. The use of hydrogels as a model system is beneficial for the study of matrix 
biology. Many studies are done using monolayer cultures on tissue culture plastic or 
adsorbed matrix material. This study shows that some genes and proteins are affected by 
matrix, by the 3D configuration, or by both. This system is a good choice for studying 
effects of different matrix materials or different biochemical stimulation as small 
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amounts of material and cells and short culture times are needed. It is beneficial for 
matrix biology as smooth muscle cells, and many other cell types, live in a 3D 
environment. The architecture of the extracellular matrix (ECM) can also have effects on 
cells like endothelial cells that are found in monolayers in vivo [1]. For tissue engineering 
applications this model can be used a method of screening for different biochemical 
stimuli. For use in tissue engineering, longer culture times may be required as some of 
the regulation of genes changed with increased culture time. The disk shaped TEVM can 
be used to look at gene expression and protein synthesis and incorporation as shown in 
Chapter 4. It can also be used to look at compaction, as shown in Chapter 6. The disks are 
limited in this capacity as they compact more than constrained tissue and can only be 
used to look at total volume changes. The differences in volume between disks and tubes 
should be comparable; however, constraint and other factors can affect the direction of 
compaction as seen in Chapter 7. There different biochemical treatment resulted in tissue 
with different lengths and wall thicknesses. The volumetric assay with disks could be 
used here though to determine whether the compaction is in different directions, 
longitudinal versus radial, or if the total volumes are different. 
Use of collagen hydrogel and cell sheet TEVMs has already been demonstrated 
[2, 3]. This work has shown that even cells that were not cultured using the methods 
employed by both groups can be used in hydrogels culture. This work also used a lower 
cell density, but longer culture times and longer tissues. Differences were seen between 
the work by Bi et al. [2] which used collagen hydrogels and this study. The differences 
may be due to the culture techniques, cell densities and culture times or collagen and 
serum lots. 
Vasoactivity 
This study is important as it shows a vasoactive response to cells that were not 
isolated using techniques to maintain a contractile phenotype and without serum 
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starvation. As compared to much of the work, this study has looked at the vasoactivity in 
response to more vasopressors and vasodilators then most. The cell sheet TEVM have 
been the best characterized. It has been shown to be a good model for pharmacological 
studies, looking at a variety of agonists and antagonists [3]. Several studies of the 
endothelin receptors have also been completed [4, 5]. Comparisons to other studies are 
difficult due to the wide choices in agonists and antagonists and the methods for 
presenting the contractility data. The most common way to present the data is as grams 
force or as a % of the maximum contractile force to ATP. Table 9 attempts to compare 
the results of this work with the other published work. The results shown are data 
presented in Chapters 5 and 6; it is the average of the maximum change in force for any 
given drug. It excludes the work in Chapter 7 where media change frequency was higher. 
Only work from static samples is shown. Results from phenylephrine are used to compare 
to norepinephrine. This should be a good approximation as phenylephrine is an α1-
adrenergic agonist and norepinephrine is an α-adrenergic agonist. The TEVM had no 
response to an α2-adrenergic agonist, so the responses should be similar. 
It is difficult to compare the results from this study to those done with PGA 
scaffolds. If the assumption is made that the ring segments in Dahl et al. [6] are also 2 
mm then the response is significantly lower. This could be due to differences in cell 
density, or the fact that the PGA TEVMs are cultured under pulsatile flow for 7 weeks. 
Compared to the cell sheet TEVM, the response is similar if you consider the differences 
in length. The results are also comparable to contractility of the fibrin TEVM. 
Surprisingly the largest differences are to the other collagen hydrogel TEVM. These 
reacted more strongly to bradykinin, and less to endothelin-1. Difference could be due to 
the addition of endothelial cells or different culture times, cell densities, cell isolation 
techniques, or differences in medium. This study used 10% BGS; the Bi study used 20% 
FBS with ascorbic acid, insulin, TGF-β1 and aprotinin. 
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Table 9: Comparison of TEVM Vasoactivity with Literature. * Work with other agonists that are 
presented as % Emax is not shown. ** Ranges are due to different factors being studied. *** 
Norepinephrine is being compared to phenylephrine results. 
Published Work Agonist Published Result In This Study 
PGA Scaffolds    
Niklason et al. [8] Prostaglandin F2α 
Serotonin 
Endothelin-1 
0.17 g / 2mm 
response 
response 
n/a 
response 
response 
Dahl  et al. [6] Endothelin-1 ~0.8 g 0.16 g / 2 mm 
Cell Sheet TEVM    
L’Heureux et al. [3]* Histamine 
Bradykinin 
ATP 
182 mg / 5-7 mm 
104 mg / 5-7 mm 
80 mg / 5-7 mm 
n/a 
60 mg / 2 mm 
62 mg / 2 mm  
Laflamme et al. [4]* Endothelin-1 
ATP 
0.7 g / 5 mm 
0.3 g / 5 mm 
0.16 g / 2 mm 
0.06 g / 2 mm 
Laflamme et al. [9]* Endothelin-1 100% KCl at 10-8M 250% KCl 
Fibrin Hydrogels    
Swartz et al. [10] KCl 
U-46619 
Norepinephrine 
~60 g/g dry weight 
21 g/g 
9 g/g 
47 g/g 
n/a 
11 g/g*** 
Yao et al. [11]** KCl 
NE 
U-46619 
5-75 g/g dry weight 
5-15 g/g 
0-40 g/g 
47 g/g 
11 g/g*** 
n/a 
Liu et al. [12]** KCl 
Norepinephrine 
0.60 N/g dry weight 
0.20 N/g  
0.46 N/g 
0.11 N/g*** 
Yao et al. [7] KCl 
KCl 
0.8 – 1.2 mN 
0.05-1.15 kPa 
0.46 mN 
0.40 kPa 
Collagen Hydrogel    
Bi et al. [2] K+ 
Bradykinin 
Histamine 
Endothelin-1 
44.1 mg / 1mm 
90.9 mg / 1mm 
91.9 mg / 1 mm 
8.6 mg / 1 mm 
n/a 
60 mg / 2 mm 
n/a 
161 mg / 2 mm 
 
The varied methods of presenting the data make comparisons difficult. Grams 
force and force per dry weight are good choices if there is no interest in comparisons or if 
the tissues being studied are homogeneous. Grams force can be greatly affected by the 
geometry of the ring segments, especially with differences in length. While the 
normalization to dry weight can account for differences in length, different tissues can 
have very different dry weight for segments with similar lengths and wall thicknesses. 
Differences in compaction and ECM synthesis would affect this and are common 
between different cell types. The most correct way to present the contractile data would 
be actual stress. This work has presented the contractile response as nominal stress. 
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While not as accurate, it is still better than what has been used. Only one study has 
presented the data as stress [7]; since the method for calculating was not described it is 
assumed to also be nominal stress. 
For these studies bovine growth serum was used instead of fetal bovine serum 
(FBS). The choice of serum was found to have a significant effect on the contractile 
response of the TEVM made with either rat or human SMC, Figure 59. TEVMs with rat 
aortic SMC were cultured in medium containing 10% fetal bovine serum (FBS) had 
almost no measurable function. A slight but statistically insignificant increase in 
contractile force was seen when the medium change frequency was increased in the 
cultures containing 10% bovine growth serum (BGS). The same phenomenon was seen 
with human aortic SMC. Human SMC were cultured in either smooth muscle growth 
medium 2 (SMGM-2) from Lonza which contains 5% FBS, or medium with 5% or 10% 
BGS. The SMGM-2 medium resulted in TEVM with a weak contractile response; while 
the 5% BGS resulted in a response similar to the rat SMC. The human TEVM cultured in 
10% BGS could not be tested; the wall was too thin to handle without damage. 
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Figure 59: Differences in Contractile Response due to Serum. TEVM with rat SMC (Left) and with 
human cells (Right). * is p≤0.05 compared to the medium containing FBS. The use of BGS 
significantly increased the contractile force in response to both drugs. BGS resulted in increased 
contraction of both rat and human SMC. Increasing the medium change frequency from once a week 
to 3 times a week increases the contractile force, although not significantly. 
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Further evidence for a soluble factor in the culture medium that can be exploited 
is the difference in smooth muscle α-actin staining that is seen when the medium change 
frequency is changed. The increase in contractile apparatus would result in a greater 
contractile force, assuming no major differences in the wall thickness, collagen density or 
tissue strength. A comparison of α-actin staining is shown in Figure 60. 
 
   
Figure 60: Effects of Medium Change Frequency on Smooth Muscle Alpha Actin Expression. 
Increasing the medium change frequency from once a week (left) to three times a week (left) resulted 
in an increase in alpha actin staining. 
Mechanical and Biochemical Stimulation 
Both cyclic strain and biochemical stimulation impacted the strength, vasoactivity 
and composition of the TEVM. A comparison of the two types of treatment is presented 
in Table 10. The data are presented as percent change from the value of the control 
TEVMs. Media change frequency affected the properties of the controls in each case. 
Both types of stimulation improved the strength of the tissue over the controls, but had 
opposing effects on the contractile stress.  
Both cyclic strain and TGF-β promoted a more contractile cell phenotype, but 
TGF-β resulted in significant compaction leading to a thick dense collagen layer. To 
overcome thickness alone a larger contractile force would be needed to elicit a 
measurable tissue contraction. Combination of TGF-β and cyclic strain has been shown 
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to effect cell phenotype [13]. If the longitudinal compaction could be controlled, the 
contractile strength and tensile strength could be further improved. 
Table 10: Change in Properties from Control TEVM. Results are shown as a percent change from 
the static or untreated controls. * = p≤0.05 
Treatment 
Strength 
(kPa) 
Vasoactivity 
(kPa) 
Wall 
Thickness 
(mm) 
Cellularity 
(M cells/mg) 
Collagen 
(mg/mg) 
Cyclic Strain 23%* 99%* -16%* 4.6% 19%* 
TGF-β 56%* -83%* 9% 18% -0.2% 
 
Cryopreservation 
Studies of vasoactive function after cryopreservation of native vessels have shown 
that freezing results in diminished function, but that function is maintained with 
vitrification [14, 15]. Similar results were seen with a PGA based TEVM [6]. While 
vitrification often results in a more functional tissue, human umbilical vein performed 
better after freezing rather than after vitrification even though the same vitrification 
method was used. The cell viability was better with freezing than with vitrification which 
clearly plays a role [16]. 
Importance of the Cell Capsule 
The importance of the cell capsule is highlighted throughout this work. In Chapter 
4, cell capsules were seen on both collagen and fibrin gels. The collagen I gene 
expression varied as a function of time in the hydrogels, most likely due to the absence of 
a cell capsule and 2 days and presence at 14 days of culture. The collagen and other ECM 
that the cells produce affect the TEVM strength. The cell capsule is responsible for much 
of the TEVM strength. Figure 61 shows a representative force displacement curve where 
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there are two distinct areas, one corresponding to when the cell capsule is the primary 
load bearing component and one after the cell capsule fails and the hydrogel is loaded. 
The picture on the right shows a ring segment where the cell capsule has failed and the 
hydrogel layer is still intact. 
The cell capsule is also responsible for much of the vasoactivity of the TEVM. As 
shown in Figure 62, most of the α-actin staining is found in the cell capsule. Little to no 
staining is found in the cells within the collagen hydrogel.  
Masson’s trichrome staining of a TEVM is also shown in Figure 62. The cell 
layer is densely populated and contains cell synthesized collagen which improves the 
TEVM strength. Cells may produce more collagen while encapsulated in fibrin rather 
than collagen [17], but the SMCs produce more collagen when grown on top of collagen 
then fibrin. The trend existed in the work shown in Chapter 4; however, significance is 
found when the monolayers are cultured on higher concentrations of collagen. The results 
shown in Figure 63 are from cells grown in monolayer culture on top of 1 mg/ml collagen 
or fibrin. This is essentially a thin layer of hydrogel. At this concentration the collagen is 
not likely in monomeric form; a collagen hydrogel can be created. Cell produced more 
collagen when cultured on 1 mg/ml matrix than on the 50 µg/ml matrix. The difference 
between the collagen production on the two surfaces was amplified with the higher 
concentration substrate. 
Importance of Decorin and Biglycan 
While decorin and biglycan were only discussed in Chapter 4, they are 
proteoglycans worth studying in tissue engineering. These are two homologous 
proteoglycans that are part of the family of small leucine rich repeat proteoglycans 
(SLRP). Both SLRPs play a role in collagen fibrillogenesis. Knocking out these 
proteoglycans results in irregularly sized collagen fibrils and fragility in skin (decorin) 
[18] and orthopedic tissues (biglycan) [19, 20].  
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Figure 61: The Cell Capsule and Tensile Strength. The force – displacement graph is shown on the 
left. Note the two distinct regions of the graph that correspond to the cell capsule and the collagen 
hydrogel after rupture of the capsule. A picture of a ring after the failure of the cell capsule is shown 
on the right. 
 
 
   
Figure 62: Histology of the TEVM. Alpha actin staining of the TGF-β treated TEVM is shown (Left). 
Alpha actin is stained green; nuclei are stained blue. Note that the alpha actin staining is almost 
exclusively in the cell capsule, not in the hydrogel. Masson’s Trichrome staining of untreated TEVM 
is shown (Right). Note the significant amounts of collagen seen in the cell capsule. 
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Figure 63: Proline Incorporation of Cells Grown on 1 mg/ml Collagen or Fibrin. Collagen synthesis 
is greater in cells grown on collagen I than those grown on fibrin. 
Both decorin and biglycan bind to tropoelastin; biglycan binds to both 
tropoelastin and microfibril-associated glycoprotein 1 (MAGP-1) forming a ternary 
complex and may play a role in elastinogenesis [21]. Both proteoglycans also bind to 
transforming growth factor-β (TGF-β). The role of decorin has been better studied. Once 
thought to inactivate TGF-β [22-24], decorin is now thought to sequester and modulate 
the activity of TGF-β [25-27]. Decorin is also known to modulate MMP activity, 
although the response and the specific MMPs affected varies greatly by tissue [28-30].  
Decorin and biglycan expression play important roles in compaction of collagen 
hydrogels, which is important for tissue engineering. Decorin expression has been shown 
to have a direct effect on hydrogel compaction [31]. Transfected cells where decorin was 
either upregulated [32] or knocked out [33] led to significant increases in hydrogel 
compaction. In the case of the decorin knock out the increased compaction may be 
related to an increase in biglycan synthesis. Both studies highlighted the different effects 
of exogenous and endogenous decorin on gel compaction.  
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Cyclic strain [34], TGF- β and TNF- α [35] are all known to influence the 
synthesis of decorin and biglycan in monolayers. The application of these factors to the 
TEVM also affected the synthesis of decorin, see Figure 64. Biglycan levels were very 
low and are not shown. The results of cyclic strain are consistent with those shown with 
cyclic stretch; decorin is not as abundant in the strained TEVM. The results do not 
directly compare to those shown with monolayer cultures. The addition of TGF- β or 
TNF- α caused a decrease in decorin, but not to the same extent as seen with monolayer 
cultures. The combination of TGF- β and TNF- α caused an increase in decorin, contrary 
to the drastic decrease seen in monolayers.  
 
A.     B.  
Figure 64: Western Blots for Decorin in Mechanically and Biochemically Treated TEVM. 
Comparisons of static and strained TEVM are shown (Right). The strained samples contain 
significantly less decorin than the static controls. The biochemically treated TEVM are also shown 
(B). From left to right: untreated control, TGF-β, TNF-α, and combined TGF-β and TNF-α.  
Future Recommendations 
There are several directions that this work can be taken. The main areas are: using 
the TEVM as a model system for matrix biology, further investigations of vasoactivity 
and the factors that influence it, application of cyclic strain, and new TEVM fabrication 
methods. 
TEVM as a Model System 
The disk shaped TEVM provide a nice 3D environment for studying matrix 
biology. The effects of growth factors and other soluble factors could easily be studied. 
One factor of interest is TGF-β. While the effects on TEVM strength and vasoactivity 
were studied, the effects on gene expression were not. TGF-β is known to influence 
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decorin and ECM expression. This model could also be used to study effects of cell 
density and other matrix materials such as SIS, Matrigel, and hyaluronic acid. The 
expression of collagen type I, decorin and biglycan were studied due to their importance 
in tissue strength; however, multiple genes could easily be studied from the same sample. 
Use of the Qiagen RNeasy lipid kid resulted in very high yields of good quality RNA 
which would allow for a large number of genes to be explored using one sample. Along 
with gene expression the model system can be used to study protein synthesis and 
retention in the hydrogels as well as gel compaction. One note is as follows. The disks 
can be used to look at overall volume changes but cannot determine the direction of 
compaction. Additionally some of the constraints used in TEVM fabrication such as the 
silicone sleeve may also impact the final gel compaction. 
TEVM and Vasoactivity 
The importance of serum was discussed previously. Clearly there is a soluble 
factor (or factors) that are involved in the improvement of cell contraction. Finding these 
factors would be of great interest, especially as the field moves toward the use of a 
defined culture medium. A proteomics approach to look at differences between medium 
that produces functional and non-functional tissue would help to identify these potential 
factors. Understanding how these factors are working would also be of interest. It is 
possible that the differences in function are due to differences in the phenotype of the cell 
and the amount and type of contractile machinery contained in the cells. It is also possible 
that the differences may be due to the presence or absence of certain receptors.  
There may be ways to improve the vasoactive response. Mechanical and 
biochemical stimuli [13] have been shown to influence smooth muscle cell phenotype 
and may result in a stronger contraction. This work has shown that cyclic strain can lead 
to improved function. The addition of TGF-β resulted in a more contractile phenotype; if 
the longitudinal gel compaction could be eliminated, improvements in vasoactivity 
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possibly could be seen. There are certainly other biochemical factors that may also be of 
interest. 
Mechanical Stimulation 
This study has shown improvements in the mechanical properties and the 
physiological contractile response of the collagen-based TEVMs. While these 
improvements are significant, they are far from optimized. Studies have shown that 
different strain amplitudes and rates may be preferable for improved mechanical 
properties [36-39] and collagen production [37, 38]. Work with valvular interstitial cells 
has shown that incremental increases of strain amplitude may yield superior results for 
strength [37]. None of these studies have looked at the effects of the strain parameters on 
vasoactivity. Additionally, if the mechanical properties can be improved prior to 
application of strain, the silicone sleeve could be removed and pressure could be applied 
directly to the TEVM. This would work best with the incremental strain regime as lower 
strains and pressures would be used initially. To accomplish this, the bioreactor would 
need to be modified slightly to allow for control of flow through the lumen and would 
require instrumentation to measure the TEVM circumferential strain in a sterile manner 
while the TEVMs were in the bioreactor.  
Biochemical Stimulation 
This study looked at the effects of TGF-β on TEVM strength and vasoactive 
function. The large gel compaction was beneficial for TEVM strength, but detrimental to 
TEVM vasoactivity. Additionally, longitudinal compaction is highly variable and not 
desirable. If the longitudinal compaction could be eliminated, different results may be 
seen with regards to strength and vasoactivity. To accomplish this, the TEVM could be 
cultured on silicone sleeves or TGF-β could be added after 2 weeks in culture, when cell 
mediated compaction ceases. There are other factors that may be of interest alone or in 
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combination with TGF-β. The combination of insulin and TGF-β could be further studied 
as it has been shown to improve the strength, the collagen production, and the vasoactive 
response of fibrin based TEVM [11, 40]. Ascorbic acid or sodium ascorbate is often used 
to promote ECM production [8, 41-44]. Retinoic acid has also been shown to increase 
ECM synthesis [44]. These factors alone or in combination could yield desirable results. 
Additionally, the combination of biochemical and mechanical stimulation is of interest. 
An interactive effect on cell phenotype has been shown [13]. Applying the correct 
stimulation at the correct time could lead to large improvements in tissue strength and 
function. 
Cryopreservation 
One item lacking in this work is cell viability after cryopreservation. Native and 
engineered blood vessels that were vitrified using the same protocol have retained 
significant vasoactive function after being rewarmed [6, 14]. It is important to understand 
if the differences are linked to cell viability such as was seen with the human umbilical 
cord vein [16]. It is possible that vasoactivity is a more stringent test of cryopreservation 
success, or we may find that if viability can be maintained, vasoactivity will also be 
retained. One difference between the composition of TEVM in this study versus native 
and the PGA-based TEVM is the presence of the hydrogel layer. Compared to the other 
tissues, this layer is not densely populated with cells. A similar TEVM from our lab 
consisting of a cell-populated collagen hydrogel with an elastin scaffold has been vitrified 
and found to have over 65% cell viability upon rewarming [45]. This suggests that if the 
problem is with viability it is not entirely due to the collagen hydrogel layer. There are 
multiple factors that can be modified to improve the viability including cooling and 
rewarming rates and choice of cryoprotectant.  
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Strategies for further improving TEVM composition, mechanical properties and 
function 
As discussed previously, the cell capsule is an important feature of the TEVM in 
these studies. The majority of the strength and the vasoactivity comes from the cells and 
matrix in this cell dense layer. The collagen hydrogel itself is fairly weak and does not 
promote cell proliferation or extracellular matrix production within the gel. The most 
successful strategies for creating a TEVM with mechanical properties similar to native 
tissue have relied on the cells creating their own matrix. Cell sheet TEVMs have burst 
pressures greater than 2000 mmHg [46]. Cell seeded PGA engineered blood vessels have 
been shown to be vasoactive and have burst pressures over 2000 mmHg after 7 weeks in 
culture. At this time most of the PGA has been degraded and replaced with cell 
synthesized ECM [8]. The use of fibrin gels is also moving in this direction. By allowing 
the fibrin to be degraded in a slow, controlled manner the cells can replace the fibrin with 
secreted ECM. 
The use of collagen hydrogels for tissue engineering has many benefits over fibrin 
and synthetic materials. While cells may not like to be encapsulated in type I collagen, 
they are proliferative and secrete matrix when cultured on top of collagen I. A possible 
new strategy for using collagen hydrogels would be to create a thin, cell dense collagen 
gel. The SMCs would quickly form a ‘cell capsule’ and lay down significant amounts of 
collagen and other matrix. The collagen layer could be minimized to be like an internal 
elastic lamina, or may be degraded by the cells. This approach is beneficial over fibrin, as 
no supplementation would be needed to slow down the proteolytic degradation. Unlike 
PGA there is no concern over any undegraded polymer. Compared to cell sheets, the 
culture time could be shorter since the matrix would not have to be wrapped and the 
layers would already be integrated. This also reduces the risk of possible delamination 
that could occur with the cell sheet TEVMs. 
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Conclusions 
This work has shown that a tissue engineered vascular media can be used as a 
model system for study of matrix biology. Differences in gene expression were seen in 
response to both matrix material and to matrix presentation (2D or 3D culture). For study 
of matrix biology, shorter timeframes should be used as cells can proliferate on the 
surfaces of the hydrogels and create a ‘cell capsule’ where the matrix is cell secreted and 
not as well defined. For studies regarding tissue engineering, longer cultures may be of 
interest as tissues require longer culture times. Some of the gene expression observed was 
affected by culture time. 
Both cyclic strain and TGF-β improved tissue strength; however, the stimulation 
used in this work was not sufficient to increase the strength to the physiological levels 
needed for implantation. The viscoelastic properties were not studied; the hydrogels 
without cross-linking are known to creep. It is likely that the mechanical properties are 
such that the grafts would fail due to aneurysm or damage due to fatigue, even if the graft 
strength could withstand blood pressure. Cyclic strain improved tissue strength due to 
increased radial compaction and increased collagen deposition. TGF-β improved strength 
primarily through increased compaction. It is possible that there was additional collagen 
deposition that could not be measured. The presence of additional cross-linking was not 
investigated which could also play a role. 
The presence of endothelin, kinin, adrenergic, serotonergic and purinergic 
receptors was demonstrated in these collagenous TEVMs. While multiple receptors 
where shown to be present and functional, not all are fully characterized. For example, 
endothelin-1 and ATP bind to more than one receptor, and it is possible than only one of 
the endothelin or purinergic receptors is present and functional. This possibility was 
demonstrated with the adrenergic receptors where a contractile force was measured in 
response to an α1-adrenergic agonist but not to an α2-adrenergic agonist. Not all receptors 
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were present and functional; relaxation was not seen in response to SNP, a nitric oxide 
donor. The presence of a vasoactive response is especially interesting in this case as cells 
were isolated and expanded using techniques that have been shown to cause a phenotypic 
shift toward a synthetic phenotype which some believe cannot be reversed [47]. Serum 
starvation has been shown to cause cultured smooth muscle cells to shift to a more 
contractile phenotype [48, 49]. The application of cyclic strain was shown not only to 
affect cell phenotype but also to improve the function of the TEVM. The application of 
TGF-β is a reminder that contractility is due to integration of cells and matrix. 
Improvements in strength can create a tissue that cannot be easily contracted by the 
smooth muscle cells, even when a shift towards a more contractile phenotype is seen. 
This work as a whole has shown the importance of the cell-matrix interaction. The 
matrix type and presentation can affect ECM synthesis. The interaction of cell and matrix 
can affect the tissue vasoactivity and the mechanical properties. For example, increased 
compaction of the exogenously supplied ECM can improve the tissue strength while 
reducing the measured contractile strength. The studies presented here provide insights 
into future directions such as future matrix biology studies and strategies for creating a 
TEVM. 
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APPENDIX A1: FBS VS. BGS 
Introduction 
Importance of serum is well known in cell biology and many purchased cell lines 
come with ‘qualified’ serum. Serum lot matching is important and many labs will even 
screen lots. In order to reduce cost, bovine growth serum (BGS) was compared with the 
fetal bovine serum (FBS) lot that was being used. BGS is obtained from calves which 
results in reduced cost and improved availability. There is a claim of less lot to lot 
variability than with FBS due to choice of farms and supplementation of the BGS. The 
serum was tested for cell culture and for construct culture.  
Results 
Preliminary cell proliferation studies were completed. Equal numbers of rat 
smooth muscle cells were plated sparsely. After 8 days the cells were trypsinized and 
counted using the Coulter Counter. The cells cultured in FBS had proliferated 26 fold, 
while the cells cultured in BGS had proliferated 45 fold.  
TEVM were cultured in medium containing either 10% FBS or 10% BGS serum. 
Initially medium was changed weekly. By the second week in culture noticeable 
differences in the medium color were noted indicating higher metabolism, which may be 
due to an increased number of cells in the TEVM. An additional condition was added 
where BGS medium was changed twice a week. The results are shown in Figure 65. At 
one week in culture the TEVM had similar strengths, although the strength of the TEVM 
cultured in BGS medium was slightly higher (8 kPa versus 5.5 kPa). The TEVM that 
were cultured in FBS maintained a relatively constant tensile strength over the 4 weeks of 
culture; however, there is a small increase after 4 weeks in culture which may be the start 
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of an upward trend of strength. The TEVM cultured in BGS increased in strength up to 3 
weeks in cultured where the tensile strength leveled off even with more frequent media 
changes. At 7 days the TEVM in BGS were almost twice as strong as those cultured in 
FBS. By 14 days the strength of the TEVM BGS medium was 5 times that of the TEVM 
in FBS. Changing the medium more frequently increased the strength further to more 
than double the TEVM with weekly changes of BGS medium. The plateau seen with 
BGS may be overcome with additional medium changes or may be due to problems of 
nutrient diffusion due to the large cell capsule at 4 weeks. 
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Figure 65: Serum Effects on UTS Over Time. TEVMs cultured in BGS are stronger than those 
cultured in FBS at most timepoints. Increasing the change frequency of the BGS medium also 
increased the TEVM strength. 
The study was repeated with TEVM that were cultured for 3 weeks. The FBS 
medium was supplemented with 50 ug/ml ascorbic acid, 3 ng/ml cupric sulfate and 1% 
non-essential amino acids; the BGS medium was not supplemented. The results for the 
tensile testing are shown in Figure 66. Once again the strength of the TEVM cultured in 
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BGS was more than double that of those cultured in FBS. There were no differences in 
wall thickness associated with the serum, see Figure 67. 
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Figure 66: Serum Effects on Ultimate Tensile Strength at Four Weeks. BGS increased the TEVM 
strength versus FBS medium. 
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Figure 67: Serum Effects on Wall Thickness. No differences in wall thickness were seen between the 
two serums. 
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As discussed in Chapter 9, there were significant effects on vasoactive response. 
For completeness the figure is presented here as well in Figure 68. This study was done 
with rat cells cultured for 3 weeks. The same phenomenon was seen with human smooth 
muscle cells. Human cells were cultured in smooth muscle growth medium-2 (SMGM-2) 
(Lonza) initially. This medium contains 5% FBS with insulin, EGF and FGF. No 
response was recorded in response to the agonists. When the human TEVM were cultured 
in 10% BGS, the walls were so thin that the TEVM could not be handled without 
damage, thus there are no contractility results. When 5% BGS was used, a robust 
contractile response was seen similar to that of the rat TEVM.  
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Figure 68: Serum Effects on Vasoactivity. Work was completed with rat cells (Left) and human cells 
(right). BGS medium leads to increased contractile force in response to both drugs tested. This is true 
for TEVMs made with both rat and human SMC. 
Discussion 
Serum choice is important for tissue engineering. BGS medium was chosen for 
TEVM culture due to the increases in strength and the presence of vasoactive response. 
With all serum the cell to medium ratio is important, but the results are more dramatic 
with BGS. The construct numbers in a dish, the size of the constructs and the medium 
change frequency should be rigorously maintained to reduce variability. The cost of BGS 
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was approximately ⅓ that of FBS. Even with the increased media changes, the cost is 
similar for the two serums. 
The results presented here are not meant to suggest that BGS is better than FBS, 
although it is true that BGS is better for some tissue engineering applications than some 
lots of FBS. Other groups have shown a vasoactive response using medium containing 
FBS. It is possible that this is due to differences in cell type, source or choice of scaffold. 
It is also possible that the lot of FBS that is being used promotes a more contractile cell 
phenotype. Comparisons of strength are difficult due to scaffolding differences and the 
addition of other growth factors. It is interesting to note that there is a soluble factor (or 
factors) that can promote a more contractile smooth muscle cell. Finding this factor 
would be beneficial so that lot screening isn’t necessary, or so a defined medium could be 
used rather than serum. 
One thing to note in these studies is that the strengths presented in this appendix 
are significantly less than what is presented in the main chapters. Just as some groups 
screen serum lots, others screen collagen lots. During the course of this work the collagen 
lots changed and resulted in significantly stronger tissues. Even with the different 
collagen lots, the strength difference between TEVM cultured in BGS versus FBS still 
exists. The differences in strength also are seen with TEVM made with different species. 
Both rat and porcine TEVM are stronger when cultured in BGS. 
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APPENDIX A2: EFFECTS OF EXOGENOUS DECORIN AND BIGLYCAN 
 
 
Introduction 
Decorin and biglycan are homologous small leucine rich repeat proteoglycans 
(SLRP). The structure of decorin and biglycan is very similar. Both core proteins have a 
horseshoe configuration; decorin has one more oligosaccharide chain than biglycan. 
Decorin has one dermatan sulfate or chondroitin sulfate glycosaminoglycan (GAG) 
chain. Both decorin and biglycan interact with extracellular matrix (ECM) and growth 
factors by binding to the core protein [1].  Both SLRPs play a role in collagen 
fibrillogenesis. Knocking out these proteoglycans results in irregularly sized collagen 
fibrils and fragility in skin (decorin) [2] and orthopedic tissues (biglycan) [3, 4]. More 
severe consequences are not seen since the other SLRPs are upregulated and compensate 
for part of the lost function. Even dual knockouts of both decorin and biglycan result in 
additional fragility of the orthopedic tissues [5, 6]. Differences in function between 
decorin and biglycan are in part due to differences in proteoglycan localization. Decorin 
is found bound to collagen in the ECM as well as in the pericellular matrix; biglycan is 
primarily found on the cell surface and in the pericellular matrix [7, 8]. 
Both decorin and biglycan bind to tropoelastin; biglycan binds to both 
tropoelastin and microfibril-associated glycoprotein 1 (MAGP-1) forming a ternary 
complex and may play a role in elastinogenesis [9]. Both proteoglycans also bind to 
transforming growth factor-β (TGF-β). The role of decorin has been better studied. Once 
thought to inactivate TGF-β [10-12], decorin is now thought to sequester and modulate 
the activity of TGF-β [13-15]. Decorin is also known to modulate MMP activity, 
although the response and the specific MMPs affected varies greatly by tissue [16-18].  
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Decorin and biglycan expression play important roles in compaction of collagen 
hydrogels, which is important for tissue engineering. Decorin expression has been shown 
to have a direct effect on hydrogel compaction [19]. Transfected cells where decorin was 
either upregulated [20] or knocked out [21] led to significant increases in hydrogel 
compaction. In the case of the decorin knock out the increased compaction may be 
related to an increase in biglycan synthesis. Addition of exogenous decorin did not affect 
gel compaction in either case. While the addition of exogenous decorin did not result in 
differences in compaction, it was hypothesized that it might have other influences that 
could affect TEVM strength. There is one study that has shown that synthesis of 
collagens I and V increased with both overexpression of decorin and addition of 
exogenous decorin into the secreted matrix [22].  
The effects of exogenous decorin on TEVM strength and collagen synthesis 
follows. The results are broken into two sections: ‘pre-’ and ‘post-’ 2006. Around this 
time the collagen lot changed and the effects changed. In the ‘post-2006’ work effects 
due to addition of biglycan were also investigated. 
Results 
Pre-2006 
To determine the most effective way to deliver decorin, a study was completed to 
investigate the addition of decorin to the culture medium or to the TEVM during 
fabrication. TEVMs were made using the method described in Chapter 5, using porcine 
aortic smooth muscle cells isolated from neonatal pigs. For TEVM exposed to decorin in 
the culture medium, the decorin was added fresh with every weekly media change. For 
decorin in the hydrogel, decorin was only added to the gel at that time. For both 
circumstances 0.5 µg/ml decorin was used. The results are shown in Figure 69. By four 
weeks in culture there were significant differences in strength. Adding decorin to the 
204 
medium did improve the strength versus the untreated controls, but not to the same level 
as the TEVMs where decorin was added to the hydrogel alone. This application method 
was chosen both for the improvements in strength and the lower cost. 
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Figure 69: Effects of Method of Decorin Delivery on TEVM Strength. Adding decorin increased the 
TEVM strength. Adding it to the hydrogel during fabrication only led to the greatest increase in 
strength. 
The effect of decorin dose was then explored. Six different dosages were used and 
the TEVM were cultured for 4 weeks at which time tensile testing was completed. As 
shown in Figure 70, the strength was affected by dosage. The strength improved from 1.8 
to 4.7 fold as compared to the untreated controls. All of the dosages except for 0.25 µg/ml 
resulted in significant improvements in strength over the untreated controls. There were 
no significant differences in strength between 0.15, 0.25 and 0.5 µg/ml dosages or 
between 0.01 and 0.075 µg/ml. All other doses were statistically different from each 
other.  
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Hydrogel compaction was compared over a 6 week timeframe using the method 
described in Chapter 6. Disk shaped gels were made with 0 or 10 ng/ml decorin, see 
Figure 71. No differences in gel compaction were seen at any timepoint.  
0
0.
00
01
0.
01
0.
07
5
0.
15
0.
25 0.
5
0
100
200
300
400
Decorin Content (µg/ml)
U
lt
im
a
te
 T
e
n
si
le
 S
tr
e
n
g
th
 (
k
P
a
)
 
Figure 70: The Effect of Decorin Concentration on TEVM Strength. Decorin concentration 
influenced the TEVM strength. The maximum strength appears near 10 ng/ml. 
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Figure 71: Effect of Decorin on Hydrogel Compaction. No differences in hydrogel compaction are 
seen when exogenous decorin is added to the hydrogels. 
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Tubular shaped TEVMs were made with 0 or 10 ng/ml decorin. The TEVMs were 
cultured for 4 weeks at which time the cellularity, collagen content and GAG content 
were measured. The cellularity of the gels was measured using the Hoechst DNA assay. 
Collagen content was assessed using the Sirius Red assay. Both of these methods are 
described in Chapter 6. GAG content was determined by using the DMMB assay. The 
results are shown in Table 11. There are no significant differences in cell or GAG 
between hydrogels with or without exogenous decorin. The collagen content is significant 
for a 90% confidence interval. It is possible that with additional samples significance to 
95% would have been seen. This could not be completed due to the change in collagen 
lot. 
Table 11: Effects of Decorin on TEVM Composition 
Treatment DNA Content  
(µg/mg) 
Collagen Content 
(µg/mg) 
GAG Content 
(µg/mg) 
Control 10.17 ± 2.57 24.67 ± 3.88 34.70 ± 4.06 
Decorin 12.30 ± 1.35 46.67 ± 11.25 32.01 ± 2.53 
p-value p>0.1 p<0.1 p>0.1 
 
Qualitative comparisons were also completed by using histology. Masson’s 
trichrome was done to look at collagen content and localization. Saffronin-O staining was 
done to look at GAG content and localization. Masson’s trichrome stains collagen blue 
and nuclei purple, see Figure 72. Saffronin-O stains GAG red and nuclei purple, see 
Figure 73. Both pictures show a partial-cross section of the TEVM wall. The lumen is to 
the right and the cell capsule is found on the left. No differences are seen in the collagen 
hydrogels. Both have cells evenly dispersed throughout. The cell capsules of the decorin 
hydrogels appear slightly more compact and have darker staining for collagen. The GAG 
staining appears to be darker in spots, but the cell capsule appears slightly more compact 
which may account for this difference.  
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Figure 72: Masson's Trichrome. Shown are Controls (Left) and Decorin Containing (Right) TEVM. 
More collagen is seen in the cell capsule of the decorin containing TEVM. 
 
 
 
   
 
 
Figure 73: Saffronin-O Staining. Shown are Controls (Left) and Decorin Containing (Right) TEVM. 
Both TEVMs have significant amounts of GAG in the cell capsule region. 
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Post-2006 
After the collagen lot was changed, the effect of decorin could no longer be seen. 
This was not due to a decrease in strength of the TEVM where exogenous decorin was 
added, but due to an increase in strength of the controls. Results in Figure 74 are for 
porcine TEVMs cultured for 4 weeks in medium containing 10% BGS. The increase in 
strength was seen regardless of cell type (rat or pig) or serum (BGS or FBS).   
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Figure 74: Effects of Decorin and Biglycan on TEVM Strength Before and After 2006. After 2006 no 
significant differences in strength are seen with the addition of decorin. This is mainly due to the 
significant increase in the strength of the control TEVMs. 
It is unknown what exactly changed to elicit this effect. The current collagen lots 
are not pure. Transmission electron microscopy (TEM) was completed on TEVM without 
added decorin. Cupromeronic blue was used to stain GAG, see Figure 75. There is 
significant staining of GAG in these sections, most appears to be associated with the 
collagen fibrils. Unfortunately, no collagen from previous lots was available for 
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comparison. The difference may also be related to the endogenously synthesized decorin. 
As seen in Chapter 5, the SMCs produce significantly more decorin when placed in the 
collagen gels. Once again it is unknown how this compares to SMC encapsulated in the 
previous lot of collagen.  
 
 
 
Figure 75: TEM of Collagen Layer of TEVM. Acellular Collagen Gel (Left) and Collagen Layer of 2 
Week Old Rat TEVM (Right). GAG Staining is Visible in Both Pictures.  
Western blots were completed to look at collagen and biglycan in the collagen 
hydrogels, see Figure 76. There is some slight banding at 40 kDa for both decorin and 
biglycan; this is the expected location of the core protein. A large band of biglycan is 
seen around 20 kDa. 
 
Figure 76: Western Blots for Decorin and Biglycan in Collagen Hydrogels. There is staining for 
decorin and biglycan in the collagen hydrogels. 
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Even though there weren’t significant differences anymore, it was hypothesized 
that exogenous decorin or biglycan might affect collagen synthesis and degradation. The 
addition was expected to have an impact on decorin and biglycan synthesis as well. The 
synthesis of collagen I, decorin and biglycan were determined by PCR. Rat SMC were 
cultured in 2D or 3D as described in Chapter 5. Preliminary studies looked at different 
concentrations and denatured decorin and biglycan. No statistically significant 
differences were seen for concentration. Denatured proteoglycan resulted in reduced or 
similar gene expression (data not shown). Exogenous decorin or biglycan were added to 
the collagen hydrogels for 25 ng/ml concentrations; results are shown in Figure 77. 
There are some statistically significant differences found with monolayer culture. 
Exogenous decorin increases decorin and biglycan gene expression. Biglycan increases 
collagen gene expression. Once in 3D culture, biglycan continues to up-regulate collagen, 
but only for a short time frame. By 14 weeks in culture collagen gene expression is the 
same between all culture groups. 
Discussion 
From this data it is clear that there are certain conditions in which the addition of 
exogenous decorin could lead to an increase in tissue strength. This increase in strength is 
not due to changes in gel compaction. This is consistent with the literature which showed 
significant differences in gel compaction with changes in endogenously synthesized 
decorin but not with exogenous decorin [19-21]. There appears to be an increase in 
collagen synthesis, but it is not as much as was seen with the addition of cyclic strain. In 
4 weeks of static culture there was an almost 5 fold increase in strength, but only a 2 fold 
increase in collagen content which was fairly variable. With cyclic strain, 5 days of strain 
led to a 1.2 fold increase in strength with a 1.2 fold increase in collagen content. There 
are other mechanisms involved that are of interest.  
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Figure 77: Effects of Decorin and Biglycan on Gene Expression. Shows Results of Exogenous Decorin 
or Biglycan with Monolayers or Disks. Results are shown for Collagen (Top), Decorin (Middle), and 
Biglycan (Bottom) Gene Expression. There are some differences in gene expression. All is lost by 14 
days of hydrogel culture. 
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After the collagen lot change, exogenously added proteoglycan became less 
interesting. While both exogenous decorin and biglycan influenced gene synthesis of 
monolayer culture, neither significantly affected gene expression of collagen hydrogels. 
Biglycan leads to up-regulation of collagen, but the effect does not last. It is possible that 
with continued dosage it might be retained. 
If additional work is done with exogenous decorin or biglycan, it is recommended 
that these proteoglycans be obtained by isolating them from cells that are transfected to 
overexpress them. Isolating decorin and biglycan from tissue can damage the 
proteoglycan and lead to inconsistent and incorrect results [23]. The decorin and biglycan 
in this study were purchased from Sigma and were isolated from bovine collagen. The 
source of these proteoglycans does not appear to be the cause of the change. Multiple lots 
were used in both sets of experiments, and the shift in results appears to be affecting the 
controls. 
Proteoglycans are an important part of the extracellular matrix and are often 
overlooked, especially in tissue engineering. Decorin and biglycan play important roles in 
collagen fibrillogenesis. They also influence cell mediated collagen gel compaction. Both 
of these roles are important for tissue strength.  
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Antibodies 
The following is a list of antibodies that have been successfully used for 
immunostaining, western blotting, or flow cytometry. Note that the LiCor antibodies can 
also be purchased through VWR from Rockwell Immunochemical (different product #s). 
Table 12: Primary Antibodies 
Antigen Description Uses Supplier Product 
Number 
α-smooth muscle actin Mouse monoclonal  IHC Sigma F 3777 
β-actin Mouse monoclonal WB abcam ab8226 
BRDU Mouse monoclonal FC, IHC Sigma B 2531 
Biglycan, mouse Polyclonal antisera IHC, WB NIH, Larry Fisher LF-113 
Biglycan, bovine Polyclonal antisera WB NIH, Larry Fisher LF-96 
Calponin Goat polyclonal IHC, FC Santa Cruz sc-16604 
Decorin, mouse Polyclonal antisera IHC, WB NIH, Larry Fisher LF-159 
Decorin, bovine Polyclonal antisera WB NIH, Larry Fisher LF-94 
Myosin heavy chain Monoclonal to full 
length MHC 
IHC, FC Santa Cruz sc-6956 
Table 13: Secondary Antibodies 
Antigen Description Supplier Product 
Number 
Notes 
Donkey anti-goat 800CW LiCor 926-32213 1:30,000 
Donkey anti-mouse 680 Alexa Fluor A10043 Cross reacts with 
rabbit 
Donkey anti-mouse 680 LiCor 926-32222 1:30,000 
Donkey anti-rabbit Cy5 Jackson Immuno Research 711-175-152  
Donkey anti-rabbit Rhodamine Jackson Immuno Research 711-025-152  
Donkey anti-rabbit 800CW LiCor 926-32213 1:30,000 
Goat anti-mouse FITC Jackson Immuno Research 115-095-062  
Goat anti-mouse Rhodamine Jackson Immuno Research 115-025-062  
 
218 
Western Blotting And Zymography Products 
The following are the products used for gelatin zymography and SDS-PAGE. 
Table 14: Products for Zymography and SDS PAGE. 
Description Supplier Part Number 
Lysis 
 RIPA Buffer Sigma R 0278 
 Proteinase Inhibitor Cocktail Sigma P 2714 
Enzymatic Digestion 
 Proteinase K Sigma P 2308 
 Chondroitinase ABC Sigma C 2905 
Protein Quantification 
 Modified Lowry Kit Pierce 23240 
Pre-cast Gels 
 10% Tris-Glycine Gel Invitrogen EC60752BOX 
 10% Zymography Gelatin Gel Invitrogen EC6175BOX 
Standards 
 Kaleidoscope Prestained Standards BioRad 161-0375 
 Precision Plus All Blue Standards BioRad 161-0373 
 MMP-2/9 Standard Chemicon CC073 
Buffers 
 Tris-Glycine-SDS BioRad 161-0732 
 Tris-Glycine BioRad 161-0734 
 Renaturing Buffer Invitrogen LC2670 
 Developing Buffer Invitrogen LC2671 
Staining 
 Colloidal Blue Staining Kit Invitrogen LC6025 
Blocking  
 Near IR Blocking Buffer VWR/Rockwell RLMB-070 
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TEVM Fabrication and Culture Products 
The following is a list of the products used for creation and culture of TEVM. 
Table 15: Products for Construct Fabrication and Culture. 
Description Supplier Part Number 
Serum 
 Bovine Growth Serum Hyclone SH3-542 
Cells 
 Aortic SMC, Human Lonza CC-2571 
 SMGM-2 Bullet Kit Lonza CC-3181 
Scaffolds 
 Collagen I VWR/MP Biomedical IC15002683 
 Fibronectin Sigma F1141 
 Thrombin Sigma T 7513 
Biochemical Stimulation 
 Biglycan Sigma B 8041 
 Decorin Sigma D 8428 
 TGF-β1 Sigma T 7039 
 TNF-α R&D Systems 210-TS-010 
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PCR Products 
Products for performing qRT-PCR. 
Table 16: Products for qRT-PCR. 
Description Supplier Part Number 
RNA Isolation 
 Qiashredder Qiagen 79654 
 RNeasy Mini Kit Qiagen 74106 
 RNeasy Lipid Kit Qiagen 74804 
 DNase kit Qiagen 79254 
cDNA synthesis 
 Superscript III First Strand Invitrogen 18080-051 
Primers 
 Custom Primers Invitrogen  
Master Mix 
 Power SYBR Green Applied Biosystems 4367659 
 
Miscellaneous Products and Reagents 
The following are other miscellaneous products and reagents that have been used 
for other biochemical assays or staining. 
Table 17: Miscellaneous Products. 
Description Supplier Product Number 
BRDU Boehringer Mannheim 1296 736 
Cupromeronic Blue USBio C8210 
DNA, Calf Thymus Sigma D 4522 
Proline, 3H Perkin Elmer Life Net483250UC 
 
 
